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ABSTRACT 
Nephrotic syndrome is clinically characterized by massive proteinuria, and 
hypoalbuminemia. It represents a heterogeneous group of glomerular disorders 
characterized by distinct causes and histopathologic lesions. The present thesis 
evaluates the contribution of genetics in conditions commonly associated with NS: the 
immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), the 
C3 glomerulopathy (C3G) and the podocytopathies, usually characterized by steroid-
resistant nephrotic syndrome (SRNS). 
The first part of the thesis focused on IC-MPGN and C3G. We found likely pathogenic 
(LP) variants in complement alternative pathway genes in 18% of patients and describe, 
for the first time, thrombomodulin rare pathogenic variants in C3G patients. 
Interestingly, mutations alone did not increase the risk of developing IC-MPGN or 
C3G, but they did so when combined with common susceptibility variants. 
The prevalence of alternative pathway abnormalities (mutations and/or C3 Nephritic 
Factors, C3NeFs) was similar in IC-MPGN (53-56%) and C3G (64-65%). To 
investigate for more homogeneous subgroups within IC-MPGN/C3G, an operator-
independent approach was applied using genetic, biochemical, histological and clinical 
data. Four different groups emerged showing distinct pathogenesis, and histological and 
clinical features.  
In the second part, the genetic causes of podocytopathies were investigated. LP variants 
in podocytopathy-associated genes are found in 23% of SRNS patients, prevalently in 
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COL4A3-5 genes. Moreover, 8% of patients carried LP variants in Congenital 
Anomalies of the Kidney and the Urinary Tract (CAKUT)-associated genes, which were 
not previously associated with podocytopathies. LP variants in CAKUT-associated and 
podocytopathy-associated genes frequently combined together. 
Finally, possibly pathogenic variants in EPB41L45, a candidate gene for 
podocytopathies, were identified in 3 unrelated patients. 
In conclusion, this thesis contributes to understand the complex genetic basis of both 
IC-MPGN/C3G and podocytopathies. It introduces new players in the pathogenesis of 
these diseases. Finally, it provides evidence of the presence of subgroups within IC-
MPGN/C3G with distinct underlying mechanisms, and clinical and histopathologic 
features. 
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1. INTRODUCTION 
1.1 The glomerular anatomy, physiology and molecular biology 
1.1.1 The glomerulus 
The kidney’s key function is to filter waste products of metabolism out of the blood and 
pass them out of the body as urine. The functional units of the kidney are nephrons, 
which are further divided into filtration units, called renal corpuscles, and reabsorption 
units, called renal tubules. In the renal corpuscle, the afferent arteriole splits into a 
network of capillaries (glomerulus) that form tortuous loops and then drain to the 
efferent arteriole close to the afferent (vascular pole). The glomerular tuft of capillaries 
is enclosed in a globular sac, called Bowman’s capsule, and the space that separates the 
capillaries and Bowman’s capsule is called urinary space or Bowman’s space.1 
The blood enters in the glomerulus through the afferent arteriole, it flows into the 
glomerular capillaries where part of the plasma water and small solutes are forced out 
into the Bowman’s space, then it leaves the glomerulus through the efferent arteriole. 
This process is called ultrafiltration and is promoted by the efferent arteriole resistance 
that results in high hydrostatic pressure inside the glomerular capillary. The ultrafiltrate 
flows into the proximal tubule at the opposite of the vascular pole (urinary pole). The 
majority of the ultrafiltrate is reabsorbed back to the blood stream as it flows through 
the tubules and the collecting ducts. The remaining is eliminated as urine.
1, 2
 
The capillary wall where the filtration takes place is called the glomerular filtration 
barrier (GFB). It is composed of three layers: the endothelial cells that constitute the 
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intricately tortuous inner capillary tuft; the glomerular basement membrane (GBM), an 
extracellular cell matrix; and the podocytes, visceral epithelial cells that tightly wrap 
around the exterior of glomerular capillaries.
2
 
In the glomerulus are also present the mesangial cells that support the capillary loops, 
regulate blood flow and glomerular filtration rate, and have endocrine functions. 
Another cell population are the parietal epithelial cells at the Bowman’s capsule side.2 
 
 
Figure 1.1 
Figure 1.1. Graphical representation of the kidney, the nephron and the renal 
glomerulus (modified from Kurts, Nat Rev Immunol 2013, and Leeuwis, Adv Drug 
Deliv Rev 2010).
3, 4
 
 
 
1.1.2 The glomerular endothelial cells 
The endothelium constitutes the innermost layer of the GFB. Glomerular endothelial 
cell have two peculiarities: they are unusually flatten (height 50-150 nm) and they 
present the fenestrae, which are 60-100 nm wide transcellular pores comprising 
approximately 20-50% of the endothelium surface. These pores allow a more efficient 
and rapid passage of high volumes of fluid.
1, 2, 5
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Endothelial cells and the fenestrae are covered by the glycocalyx, a network of 
negatively charged glycoproteins, glycosaminoglycans and membrane-bound 
proteoglycans that cover the luminal face of glomerular capillaries constituting charge 
selective barrier.
6
 Plasma proteins are absorbed within the glycocalyx through binding 
to glycosaminoglycans. This layer is the first size and charge selective barrier with a 
thickness of 500 nm that restricts the passage of large molecules (more than 200 kDa) 
and/or negatively charged proteins (such as albumin). Evidence on the glycocalyx 
function comes from many proteinuric animal models in which the reduction of 
glomerular endothelial cell glycocalyx is associated with proteinuria.
2
 
In addition to the permeability barrier function, the endothelium contributes to the 
regulation of vasomotor tone inducing vascular smooth muscle contraction through the 
secretion of endothelin and platelet derived growth factor, and relaxation through the 
secretion of nitric oxide and prostacyclin.
7
 Another important function is to maintain the 
fluidity of the blood and to control coagulation through multiple mechanisms including 
surface expression of thrombomodulin and anticoagulant heparan sulfate, secretion of 
protein S and prostacyclin, and the ability to catalyze the activation of plasminogen to 
plasmin.
7
 
Moreover, endothelial cells are active participants in immune response both through 
vasodilator effects and by leukocyte recruitment. Cytokines or other inflammatory 
mediators activate the endothelial cells inducing the expression of adhesion molecules, 
such as E-selectin, Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Cell 
Adhesion Molecule 1 (VCAM-1) and P-selectin, that promote contacts between the 
endothelium and circulating leukocytes, thus leading to leukocyte recruitment at sites of 
inflammation and migration into the tissues. These processes explain the presence of 
leukocytes within the glomerulus in diseases with an inflammatory or immune basis.
7, 8
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The endothelium has a major role in the regulation of the complement system during 
immune response by expressing on its surface a set of regulators including membrane 
cofactor protein (MCP), thrombomodulin, decay accelerating factor (DAF) and CD59.
9
 
Since complement system dysregulation causes membranoproliferative 
glomerulonephritis and C3 glomerulopathy, which are widely studied in this thesis, and 
is also involved in the pathogenesis of other glomerulopathies that present nephrotic 
syndrome, a more detailed description of the complement system is provided in section 
2 of this chapter. 
 
1.1.3 The glomerular basement membrane 
The GBM is a 250 to 400 nm thin grid of extracellular matrix proteins located between 
the glomerular endothelial cells and the podocytes. The GBM supplies structural 
support for the glomerular capillaries and presents ligands for receptors of the adjacent 
endothelial cells, podocytes, and mesangial cells.
10, 11
 In addition, it acts as a size and 
charge selective filtration barrier.
12
 
The GBM is composed by three layers: lamina rara externa (adjacent to podocyte 
processes and mostly composed of heparan sulfate proteoglycans), lamina densa 
(constituting the large central zone and prevalently composed of type IV collagens, 
laminins and nidogens) and lamina rara interna (adjacent to endothelial cells, containing 
heparan sulfate proteoglycan). These molecules are synthesized and secreted by the 
podocytes and the glomerular endothelial cells.
13
 
Heparan sulfate proteoglycans (HSPGs) are composed of a core protein to which 
negatively charged glycosaminoglycan side chains are bound. The HSPG found in 
GBM is prevalently agrin, but also perlecan, and collagen XVIII are present.
14, 15
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HSPGs contribute to the charge-selectivity of the filtration barrier. Indeed, the 
elimination of their anionic charges after intravenous heparanases administration in 
animal models results in increased ferritin permeability and collagen XVIII deficient 
mice show mesangial expansion and mild renal insufficiency suggesting that this HSPG 
may play a role in the filter barrier structure and function.
15, 16
 In addition, 
glycosaminoglycans sequester and regulate availability of growth factors, such as 
vascular endothelial growth factor (VEGF), during their passage from podocytes to the 
fenestrated endothelium.
17
 
Laminins are large heterotrimeric glycoproteins composed by three chains: α, β, and γ. 
The different chains are stabilized together through interchain disulfide bonds. 
Typically, laminin heterotrimer has a cross-like shape structure in which the laminin 
coiled-coil domains of each chain wrap around to form the longer arm of the cross. At 
the end of this arm there is the C-terminal laminin globular (LG) domain of the α chain 
through which laminin interacts with cell surface receptors such as integrins and 
dystroglycan. The three short arms are formed by alternating globular and rod-like 
domains and contain the globular laminin N-terminal (LN) domain. The LN domain 
mediates the laminin trimer-trimer interactions that lead to the formation of the laminin 
polymer in the GBM.
10
 There are five different α chains, four β and three γ. The major 
laminin found in the mature GBM is the laminin α5β2γ1 also called laminin-521; 
however, during the GBM development there are transitions of the laminin trimers from 
laminin-111 to laminin-511 to laminin-521.
10
 The importance of laminins is underlined 
by the massive proteinuria observed in laminin β2 chain deficient mice and in patients 
with Pierson syndrome that carry mutations in the laminin β2 gene. Interestingly, 
proteinuria preceded alterations in podocyte foot process morphology and slit-
diaphragms in laminin β2 knockout mice, supporting the active role of the GBM as a 
size-selective filter.
10, 18
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Type IV collagens represent 50% of the all mature GBM proteins. Type IV collagen is a 
trimeric protein consisting of α chains rich in Gly-X-Y amino acid triplet repeats that 
wrap around one another to form the collagen triple helix. The Glycine at every third 
residue is the only amino acid small enough to fit at the center of the helix. Unlike most 
other collagen types, type IV collagens have interruption of the Gly-X-Y repeats that 
confer more flexibility to the molecules and to the GBM. Each type IV collagen has 
also a globular domain at the C-terminal (non collagen 1, NC1) and a 7S domain at the 
N-terminal.
10, 19
 There are 6 collagen IV genes that encode α1-6 chains assembled to 
form three different trimers (α1α1α2, α3α4α5 and α5α5α6) called protomers. Maturation 
of the GBM involves the transition of the α1α1α2 collagen to the α3α4α5. Protomers are 
secreted in the extracellular matrix and then self-polymerize through NC1-NC1 and 7S-
7S interactions to form a network distinct from that of the laminins.
10
 Of note, 
mutations in type IV collagen encoding genes cause the Alport syndrome, a disease 
characterized by hematuria and progressive renal disease.
20
 These patients usually 
present only mild proteinuria suggesting that type IV collagens probably have a minor 
role in the filtration selectivity of the glomerular barrier.
20, 21
 
Nidogen-1 and nidogen-2 are two homologous glycoproteins that make also part of the 
GBM. They contain three globular-like domains with two rod-like domains that 
separate the globular-like domains providing to nidogen a dumbbell-shape. Nidogen-1 
binds both laminin and type IV collagen and is supposed to link the corresponding 
distinct network and to provide extra stability to GBM under situations of unusual 
stress. However, double deficient mice for nidogen-1 and nidogen-2 show normal GBM 
and almost no renal abnormality.
10
 
Recently, a new model to explain the charge-selective nature of the GFB was proposed. 
Micropuncture studies on animal models showed that there is an electrical field across 
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the GFB, which is generated by filtration and is directly proportional to filtration 
hydrostatic pressures. During the passage of plasma through the negatively charged gel-
like GBM, due to a phenomenon called streaming potential, small anions such as Cl- 
and HCO3- pass the filter slightly faster than small cations such as Na+ and K+. This 
results in a potential difference that is negative in Bowman’s space. It is estimated that 
it is created a field with strength of 1600 V/m. The electrical field across the GFB 
would drive albumin and the other plasma proteins, which are negatively charged, 
toward the capillary lumen by electrophoresis.
22
 
 
1.1.4 The podocytes 
The podocytes are highly specialized epithelial cells that cover the urinary face of the 
glomerular capillaries. Podocytes have multiple functions including size and charge 
barrier to plasma proteins, counteraction of the intraglomerular pressure and 
maintenance of the capillary loop shape, synthesis and maintenance of the GBM, and 
production and signal transduction.
23, 24
 
The podocyte can be divided in cell body, major processes, secondary processes and 
foot processes. The foot processes interdigitate with neighboring foot processes, and 
adjacent foot processes are directly linked by specialized cell-cell junctions called slit-
diaphragms. In proteinuric diseases, the retractions of foot processes are often reported, 
a phenomenon named effacement, but how this effacement is involved in the 
development of proteinuria is not fully understood.
25
 
The slit-diaphragm divides the plasma membrane of foot processes into three different 
compartments: the basal, the apical, and the lateral (slit-diaphragm) surfaces. All these 
compartments are interconnected with the actin cytoskeleton of the foot processes; they 
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participate in signaling pathways and regulate podocyte shape and motility.
23, 26, 27
 
 
The basal compartment anchors the podocyte to the GBM though several types of 
integrins, tetraspanins and dystroglycans.
28, 29
 Integrins are heterodimeric α/β 
transmembrane proteins. The most common podocyte integrin is α3β1, which is an 
important receptor for the GBM component laminin-521. On the cytoplasmic surface of 
the podocyte membrane, α3β1 integrin associates with paxillin, talin, and vinculin, 
which mediate its connection to the actin cytoskeleton, and with integrin-linked kinase 
(ILK).
30, 31
 ILK forms a complex with nephrin (NPHS1), a slit-diaphragm protein, and 
actinin-4 (ACTN4), a protein of the cytoskeleton. Mouse and humans α3-mutants 
present glomerular abnormalities and early-onset massive proteinuria.
28, 32, 33
 Podocyte-
specific deletion of ILK in mice results in glomerular abnormalities and proteinuria.
31, 34
 
Moreover, absence of ILK results in the redistribution of NPHS1 and ACTN4.
31
 
Another integrin of the foot process basal surface, αvβ3, interacts with the urokinase 
plasminogen activator receptor and with vitronectin, a component of the extracellular 
matrix. Genetically modified mice with constitutively active beta3 integrin show 
proteinuria. Conversely, mice lacking b3 integrin or the avb3 integrin ligand vitronectin 
are protected from LPS-induced proteinuria.
35
 
Among tetraspanins, CD151 is located to the base of the foot processes and interacts 
with cell-matrix adhesion complexes such as α3β1 integrin. CD151-deficient mice 
develop proteinuria with GBM alterations that seem to precede podocyte abnormalities 
suggesting that CD151 is involved in the maturation and/or maintenance of the GBM 
structure.
32
 
Finally, αβ dystroglycan, a component of the basal membrane, binds laminin and agrin 
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on extracellular side, and is connected to the actin cytoskeleton on cytoplasm side via 
utrophin.
36
 
 
The apical side is negatively charged due to the presence of the anionic proteins 
podocalyxin, podoplanin, and podoendin, which form the podocyte glycocalyx and 
thereby contribute as a charge filter of the GFB. Podocalyxin is a type 1 transmembrane 
sialoprotein with an N-terminal mucin-like domain. It has anti-adhesive function that 
maintains an open filtration pathway between neighboring foot processes in the 
podocyte by charge repulsion.
37
 On the cytoplasmic side, podocalyxin is connected to 
the actin cytoskeleton via ezrin and Na+/H+ exchanger regulatory factor 2 (NHERF2). 
Podocalyxin-deficient mice lack foot processes and slit-diaphragms and are unable to 
filter primary urine.
38
 Disruption in animal models of the podocalyxin/ezrin/NHERF 
complex leads to foot process effacement and proteinuria.
39
 
Glomerular epithelial protein 1 (GLEPP1) is a transmembrane tyrosine phosphatase 
receptor type O exclusively present on the apical podocyte surface.
40
 GLEPP1 seems to 
be involved in the regulation of podocyte structure and function by phosphorylation of 
podocyte proteins.
40
 Glepp1 mutation cause proteinuria both in mice and in humans.
41
 
 
The podocyte slit-diaphragm is a specialized cell-cell junction of the GFB with zipper-
like structure and constant width of 40 nm.
42
 The main function of the slit-diaphragm is 
to form a size and probably charge selective barrier for plasma proteins. The slit-
diaphragm was first considered as a modified adherens junction, due to common 
morphologic features and proteins (P-cadherin, Fatty Acid Transporter tumor 
suppressor homolog-1 and -2, FAT1 and FAT2, and α-, β- and γ- catenins), together 
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with podocyte-specific proteins.
43
 Later the presence of tight junction proteins, such as 
junction adhesion molecule A, occludin and cingulin, were observed in the slit 
diaphragm complexes.
44
 Altogether these make the slit-diaphragm a specialized multi-
protein junction for carrying out the renal ultrafiltration function. These specific 
proteins interact with the actin cytoskeleton, triggering signalling pathways and 
regulating podocyte motility.
26, 45-47
 
Many proteins constitute the slit-diaphragm such as NPHS1, podocin (NPHS2), 
Nephrin-Like proteins 1, 2 and 3 (NEPH1, NEPH2 and NEPH3), FAT1, FAT2 and 
Calcium channel Transient Receptor Potential cation Channel 6 (TRPC6). CD2-
Associated Protein (CD2AP) and Non-Catalytic Region of Tyrosine Kinase) Adaptor 
Proteins (NCKs) connect the slit-diaphragm to the actin cytoskeleton. Furthermore, 
other proteins that are not included in the slit-diaphragm, are also involved in 
cytoskeleton regulation including synaptopodin, dynamin and cytoplasmic cathepsin L 
(CATL).
27
 
NPHS1 is a transmembrane adhesion protein that belong to the immunoglobulins 
superfamily and the first transmembrane protein identified in the slit-diaphragm.
48
 Its 
extracellular domain forms homodimers and heterodimers with NEPH1 contributing to 
the formation of the zipper-like structure.
46
 NPHS1 is recruited at the slit diaphragm by 
NPHS2. This is a U-shaped membrane protein of the slit-diaphragm that accumulates in 
oligomeric form in lipid rafts. NPHS2 is also associated with CD2AP and NEPH1 
suggesting that it may have a crucial role in the assembly of the slit-diaphragm 
complex, as a scaffolding protein.
49-51
 The transmembrane proteins NEPH1, NEPH2 
and NEPH3 are also located to the slit-diaphragm and share certain homology with 
NPHS1.
52
 NEPH1 seems to be involved with NPHS1 in actin recruitment via NCK 
proteins.
53
 The importance of NEPH1 is underlined by the fact that Neph1 deficient 
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mice die perinatally due to massive proteinuria.
54
 
TRPC6 is a transient non-selective cation channel that belongs to the Transient 
Receptor Potential Cation Channel (TRPC) family and interacts with the slit-diaphragm. 
It is involved in mechanosensation, regulates intracellular calcium concentration in 
response to the G-protein-coupled receptor activation and to tyrosine kinase receptors, 
and regulation of gene transcription.
55-57
 TRPC6 interacts both with NPHS1 and 
NPHS2. TRPC6 is phosphorylated by Fyn, a member of the Src protein kinase family, 
thus enhancing TRPC6 channel conductivity, and it is dephosphorylated by 
calcineurin.
58, 59
 Similar to TRPC6, NPHS1 is also phosphorylated by Fyn. Of note, 
Fyn-deficient mice develop proteinuria and foot process effacement.
60
 
P-cadherin, vascular endothelial cadherin (VE-cadherin) and the two protocadherins 
FAT1 and FAT2, are also located to the slit-diaphragm.
42
 FAT1 is involved in the 
formation of new intercellular junctions both during podocyte development and as a 
response to injury.
61
 Fat1 deficient mice lack slit-diaphragms and show proteinuria and 
mutations in humans cause mixed glomerulo-tubular proteinuria.
62, 63
 P-cadherin is 
associated with signaling proteins α-, β-, γ- catenins and colocalizes with the scaffold 
protein, zona occludens associated protein (ZO-1, a member of the membrane 
associated guanylate kinase family), but does not seem to be necessary for the renal 
filtration barrier, while the role of VE-cadherin in the podocyte is still unknown.
52
 
NPHS1 is linked to the actin cytoskeleton through CD2AP and NCK intracellular 
proteins.
64-66
 The NPHS1/CD2AP connection is critical for the functional renal filtration 
demonstrated by the observation that Cd2ap deficient mice die due to massive 
proteinuria and show foot process effacement.
66
 Phosphorylation of NPHS1 also 
promotes NCK-dependent actin rearrangements, suggesting a critical role for NPHS1 in 
preventing foot process effacement.
64, 67, 68
 NCK1 and NCK2 interact with tyrosine 
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phosphorylated NPHS1. Mice lacking both Nck proteins in podocytes develop massive 
proteinuria.
64, 65
 
The cell polarity complex is localized at the cytoplasmic side of the slit-diaphragm and 
include partitioning defective 3 (Par3), partitioning defective 6 (Par6) and atypical 
protein kinase C (aPKC).
69
 Par3 can bind directly to NPHS1 and NEPH1, and recruit 
Par6/aPKC to the slit-diaphragm area.
70
 The deficiency of an aPKC isoform in 
podocytes results in altered distribution of the slit-diaphragm molecules and proteinuria 
suggesting that this cell polarity complex is essential for the GFB.
69
 
Dendrin, the junctional adhesion molecule A (JAMA), densin, MAGI-1/2, 
Calcium/Calmodulin dependent Serine protein Kinase (CASK), αII spectrin, and βII 
spectrin have also been reported to be associated with the slit-diaphragm despite the role 
of these molecules in podocytes still needs to be clarified.
42
 
 
1.1.5 The mesangial cells 
The mesangial cells are specialized pericytes important for the keeping of the 
glomerular tuft integrity and forming the stalk that supports the capillary loops.
71
 
Mesangial cells are in direct contact with glomerular endothelial cells and are separated 
from podocytes by the GBM. They show contractile properties and they can regulate the 
distensibility of the glomerulus and the capillary blood flow in response to systemic 
arterial pressure.
72, 73
 In this way, mesangial cells regulate the glomerular filtration rate 
of single nephrons. 
Mesangial cells produce extracellular matrix, which provides support for glomerular 
capillaries. The mesangial matrix is composed of collagens (type I, III, IV, and V), 
laminin, fibronectin, heparan sulfate proteoglycans and chondroitin sulfate 
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proteoglycans.
74, 75
 In addition, mesangial cells produce many growth factors including 
insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), transforming 
growth factor β (TGF-β), interleukin (IL-1) and other factors that are essential for the 
homeostasis of podocytes and glomerular endothelial cells.
76-78
 
Mesangial cell proliferation and matrix expansion have been reported in several 
diseases, such as membranoproliferative glomerulonephritis and IgA nephropathy. As 
the mesangial matrix expands, it affects the glomerular capillaries by reducing the area 
available for filtration and may eventually even occlude the capillary lumen.
79-81
 
 
1.1.6 The Bowman's Capsule and the Parietal Epithelial Cells 
Bowman's capsule surrounds the glomerular capillary tuft and is formed by a basement 
membrane associated to the parietal epithelial cells (PECs) that are flat cells linked by 
tight junctions.
82
 PECs are involved in the reduction of permeability, contractility and 
mechanosensation of Bowman’s capsule.82 Recently, studies in both mice and humans 
showed that PECs migrate to replace lost podocytes, and perhaps tubular cells.
83, 84
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1.2 The complement system 
1.2.1 The three pathways of complement activation 
Complement system is a network of proteins that make part of the innate immune 
system, it acts as a bridge between innate and adaptive antibody-mediated immunity, 
and plays a fundamental role in the clearance of immune complexes and cell debris.
85
 
The complement system is activated through three different main pathways, namely the 
alternative, the classical and the lectin pathway, that converge to the formation of the C3 
convertases, enzymatic complexes that cleave Complement component 3 (C3) into C3a 
and C3b. C3b may opsonize foreign and non-self surfaces such as bacteria or bind to C3 
convertases to form the C5 convertases and initiate the terminal complement pathway 
(Figure 1.2).
85
 
C3 is constantly spontaneously hydrolyzed at low level (“tick over”). In the alternative 
pathway (AP), factor B binds to hydrolyzed C3 [C3(H2O)] or to C3b followed by Factor 
D that cleaves Factor B to form the AP C3 convertases [C3(H2O)Bb and C3bBb]. This 
C3 convertase cleaves further C3 molecules to form C3b. A local increase of the C3b 
concentration leads to a rapid amplification of the AP positive loop.
85, 86
 
The classical pathway (CP) is triggered by the binding of the Complement complex 1 
(C1) to immunoglobulins G (IgGs) or immunoglobulins M (IgMs) bound to antigen. 
The C1 complex is composed of C1q, C1r and C1s molecules. C1 recognizes and binds 
to the Fc portion of the IgG or IgM in the immune complex. C1s then cleaves 
Complement components 4 (C4) and 2 (C2) to form the CP C3 convertase, C4bC2a. In 
addition pentraxin can recognize pathogens and eliminate them by direct binding to 
C1q.
85, 86
 
The lectin pathway is activated when either mannose-binding lectin or ficolin bind to 
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carbohydrate moieties on surfaces of pathogens including yeast, bacteria, parasites and 
viruses. Both mannose-binding lectin and ficolin circulate in the serum as complexes 
with other associated proteins (Mannan-binding lectin Serine Proteases, MASPs). 
Binding to the pathogens induces conformational changes resulting in autoactivation of 
MASP2 (also known as MAP19) which cleaves C4 to form C4a and C4b. C4b attaches 
to the surface of the pathogens inducing C2 to bind, which is in turn cleaved by MASP2 
to form C2b and C2a. C4b together with the attached C2a has enzymatic activity and 
forms the lectin pathway C3 convertase C4bC2a.
85, 86
 
C3 convertases C3bBb of the alternative pathway, C4bC2a of the classical and lectin 
pathways, cleave the C3 to C3a and C3b. The newly generated C3b acts as an opsonin 
promoting phagocytosis and helps to amplify complement activation. The addition of a 
C3b molecule to the C3 convertases leads to the formation of the C5 convertases: 
C3bBbC3b and C4bC2aC3b. The C5 convertases cleave Complement component 5 
(C5) to form C5a and C5b. The membrane attack complex (C5b-9, MAC), also called 
terminal complement complex (TCC), is then initiated by Complement components 6 
(C6) and 7 (C7) binding to C5b followed by Complement component 8 (C8) and 
multiple molecules of Complement component 9 (C9) that bind to the C5bC6C7 
complex. The C5b-9 complex forms a pore by inserting itself into cell membranes, 
resulting in cell lysis.
85, 86
 
In addition to the three pathways, proteases released by neutrophils and macrophages, 
such as kallikrein, plasmin and factor XIIa (Hageman) can generate complement 
activation products. Studies in C3 deficient mice, which are unable to generate the 
conventional C5 convertase, showed that thrombin, a member of the coagulation 
pathway, can generate C5a in vivo.
87
 
The anaphylatoxins C3a and C5a are small octapeptides that act as potent 
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chemoattractants for neutrophils and monocytes to sites of inflammation, act as 
vasodilators, induce smooth muscle contraction, histamine release from mast cells and 
oxidative bursts from neutrophils. They are implicated in the cytokine production and 
exert pleiotropic effects binding their receptors, C3aR and C5aR (CD88).
88, 89
 
 
 
Figure 1.2 
Figure 1.2. Graphical representation of the three pathways of activation of the 
complement system (based on Noris, N Engl J Med. 2009, and Noris, Semin Nephrol. 
2013).
88, 95
 
 
 
1.2.2 Regulation of the complement system 
The inflammation generated by C3a and C5a is quickly reduced by plasma 
carboxypeptidases that cleave the C-terminal Arginine, resulting in C3a des-Arg and 
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C5a des-Arg, each of which has less than 10% of their original biological activity.
86
 
C3b and C4b are also quickly inactivated by proteolytic cleavage into fragments iC3b, 
C3dg, C3c, and into C4c, C4d, respectively. This occurs by the serine protease Factor I 
(FI) in the presence of cofactors, which are present at the cell membrane (membrane 
cofactor protein, MCP/CD46, and complement receptor 1, CR1/CD35) or in plasma 
(Factor H, FH). The thrombomodulin (THBD) transmembrane protein also binds to C3b 
accelerating its FI-mediated inactivation in the presence of FH. Complement activation 
is also regulated by either preventing the assembly of the C3 convertase or, once it is 
formed, by inhibiting its activity through the decay acceleration factor (DAF/CD55), 
and C4 binding protein (C4BP). Finally, the C1 inhibitor (C1-INH) inactivates C1r, C1s 
and MASP2.
9
 
The five FH-related proteins (FHR1 to 5), together with FH, comprise a family of 
structurally related proteins. Due to the high homology of FHR to FH, it is believed that 
the genes encoding for CFHRs derive from CFH duplication and subsequent 
chromosomal rearrangments.
90, 91
 Similar to FH, the FHRs are involved in the 
alternative pathway of complement system. FHR1, FHR2 and FHR5 proteins form 
homodimers or heterodimers that compete with FH for binding to surface-fixed C3b, 
thus reducing the negative control of FH and enhancing complement activity.
91
 
Properdin is a positive regulator of the complement system. It is released by activated 
neutrophils, stabilizes the AP C3 convertase by binding to C3b and preventing its 
cleavage by FI and FH.
86
 
Finally, the TCC formation is controlled both before the integration into the membrane 
and the pore formation, by a set of different membrane and plasma regulators. The 
abundant S-protein (also called vitronectin), clusterin (also called SP-40), lipoproteins, 
anti-thrombin III, proteoglycans, such as heparin, and protamine, are all able to bind to 
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nascent C5b-7, preventing its membrane insertion. Vitronectin and clusterin bind to the 
nascent amphiphilic C5b-9 complex rendering it water soluble and lytically inactive. 
These water soluble complexes dissociate from the membrane and accumulate in 
solution (SC5b-9).
92, 93
 In the final steps of TCC assembly, subsequent to C5b-7 
insertion, host cells are protected from lysis due to autologous complement attack by 
CD59, a glycolipid-anchored membrane molecule, which interferes with the particular 
C9 interaction site on the C8α-chain that is needed for membrane insertion and 
subsequent polymerization of C9.
94
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1.3 Nephrotic syndrome 
1.3.1 Epidemiology and clinical features 
Nephrotic syndrome (NS) is a disorder clinically defined by massive proteinuria, and 
hypoalbuminemia. Edema and hyperlipidemia are also frequently present. The 70% of 
cases occur in children under 6 years of age. The annual incidence is around 2-7 cases 
per 100,000 children, with a prevalence of 16 cases per 100,000 children. The incidence 
in adults is 3 new cases per 100,000 individuals/year.
96
 
The proteinuria is considered in the nephrotic-range when the protein excretion is >3.5 
g/24h in adults and >40 mg/h/m2 in children (despite the definition is more difficult in 
the young patients because of the large body size range). Hypoalbuminemia, a low level 
of albumin in blood, is defined as albuminemia <3.0 g/dl, although some authors use a 
2.5 or a 3.5 cut-offs.
96, 97
 
Edema is observed in the majority of patients with NS. Edema is defined as an 
abnormal accumulation of fluid in the interstitial compartment. Edemas are mainly 
localized in slope regions like foot or sacrum, and in regions with low tissue pressure 
such as periorbital region. In more severe cases, edema is generalized and may involve 
lungs leading to life-threatening conditions.
96
 
The NS patients are also characterized by hyperlipidemia, high concentrations of lipids 
in blood, including total cholesterol, low density lipoprotein (LDL) and triglycerides. 
The hypercholesterolemia is the most frequent abnormality present in the 85% of 
patients. The less frequent is the hypertriglyceridemia showed only when the serum 
albumin is below 1-2 g/dl. Lipiduria, the excretion of fatty casts in urine, is also 
reported.
96, 98
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Some complications are frequent in patients with NS. In these patient thromboembolic 
events such as renal-vein thrombosis may occur. Development of cardiovascular disease 
is another important complication of NS in patients with prolonged clinical courses. 
There is a 5-fold increase of the risk for myocardial infarction in NS patients compared 
controls.
99
 The risk of infections is also increased, especially in children. Primary 
bacterial peritonitis is the most common of infection with an incidence of 25-5% in NS 
children.
100
 Due to loss of proteins other than albumin, other disorders may manifest 
including endocrine abnormalities (hypothyroidism), microcytic anemia and vitamin D 
deficiency.
98
 
 
1.3.2 Pathophysiology of Nephrotic Syndrome 
Independently of the underlying cause of NS, the abnormally increased permeability of 
the GFB leads to loss of proteins mainly with a molecular weight between 40-150 kDa, 
such as albumin, IgG, transferrin, ceruloplasmin and α1-acid glycoprotein. Small 
amounts of higher molecular weight proteins (200 kDa), such as the small forms of high 
density lipoprotein (HDL), can also be lost. However, proteins higher than 200 kDa 
such as IgM, macroglobulins, fibrinogen, XIII factor, fibronectin and large lipoproteins 
are not lost even in case of severe proteinuria.
101
 
Albumin is the most abundant plasma protein and represents 70-90% of the proteins 
detected in the urine of NS patients. A fraction of the filtrated albumin is catabolized by 
the renal tubule increasing its catabolic rate. To compensate the albumin loss in urine, 
albumin synthesis in liver increases up to 300%. Hypoalbuminemia appears when the 
proteinuria and the renal albumin catabolism exceed its hepatic synthesis. The severity 
of the hypoalbuminemia is well correlated with the amount of proteinuria although 
other factors such as the age, the nutritional state and the type of renal lesion also 
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contribute.
98
 
To explain edema in NS, there are two different hypotheses: the underfilling hypothesis 
and the overfilling hypothesis. In the underfilling hypothesis, the hypoalbuminemia 
determines a decrease in the intravascular oncotic pressure leading to fluid 
extravasation. The response to the hypovolemia is the activation of the renin angiotensin 
aldosterone system, the sympathetic nervous system and the release of anti-diuretic 
hormone. Finally, the plasma volume normalizes as a result of the increase of the 
extracellular space and the edema formation. On the other hand, according to the 
overfilling hypothesis, patients with nephrotic syndrome have a primary defect that 
enhances distal tubular sodium and water reabsorption, independently of the 
hemodynamic situation. The consequences of this defect are intravascular volume 
expansion that causes increased intravascular hydrostatic pressure and subsequent fluid 
extravasation leading to edema formation. This hypothesis is based on the observation 
that NS patients show resistance to Atrial Natriuretic Peptide (ANP), a peptide that is 
able to reduce the blood pressure by decreasing the amount of water, sodium and fat in 
the circulation. Another explanation is that the intrarenal sodium retention is due to 
activation of the epithelial sodium channel in the collecting duct. The precise cause of 
the edema and its persistence is still uncertain. The finding that most NS patients have 
normal or elevated intravascular volume suggests that the overfilling hypothesis is 
probably the most reliable. Nonetheless, the two hypotheses are not mutually exclusive 
and the volume status may depend on the stage of disease.
98
 
Several factors could determine the hypercholesterolemia in NS. Early studies 
suggested that the reduction of the intravascular oncotic pressure may stimulate the 
synthesis of lipids and apolipoproteins by the liver, however the high cholesterol and 
LDL levels are rather caused by a decrease in lipoprotein due to the low level of tissue 
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low density lipoprotein receptors.
98
 The predominant mechanism responsible for 
hypertriglyceridemia is a delayed triglyceride catabolism. The reduced catabolic rate is 
likely secondary to diminished lipoprotein lipase activity due to downregulation of the 
enzyme gene expression and to the presence of lipase inhibitors.
102
 
Hyperlipidemia and hypertension observed in patients with NS are factor that promote 
atheromatosis. In addition, NS may lead to proteins involved in the coagulation and the 
immune response favoring a pro-inflammation and pro-coagulant state. This may 
explain the high risk of cardiovascular events in NS patients.
98, 103
 
The susceptibility to infections is associated to the low serum levels of IgG due to 
urinary IgG loss. Other factors that may be involved are a dysregulation of T 
lymphocytes and decreased levels of complement factors B and D, resulting in a 
decreased ability to opsonize encapsulated bacteria. In addition, NS treatment widely 
use immunosuppressive drugs including steroids, cyclosporine, mycophenolate and 
others that further increases the risk of infection.
98
 
 
1.3.3 Classification of disorders associated with NS based on pathogenesis 
NS may be caused by a variety of glomerular or systemic diseases that determine the 
alteration of the size or the charge selectivity of the GFB. The forms that are associated 
with glomerular diseases intrinsic to the kidney and not related to systemic causes are 
defined as primary, also called idiopathic, because the disease cause is usually 
unknown. The NS is instead defined secondary, if the etiology is extrinsic to the kidney. 
In all cases, injury to glomeruli is an essential feature. 
The patients can be classified based on the pattern of glomerular injury. There are 
several glomerular lesions including Focal Segmental Glomerulosclerosis (FSGS), 
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Minimal Change disease (MC), Congenital Nephrotic syndrome (CNS) of Finnish Type, 
Diffuse Mesangial Sclerosis (DMS), Membranoproliferative Glomerulonephritis 
(MPGN), Membranous Nephropathy (MN), Immunoglobulin A nephropathy (IgAN), 
and others. 
MCD, DMS, FSGS are also defined as podocytopathies
104
 because patient podocytes 
show foot process effacement, with a structural disorganization of the glomerular 
filtration barrier leading to proteinuria. The most common primary 
glomerulonephritides that can be associated with NS are described in section 1.4 of this 
chapter. 
Secondary NS is due to systemic diseases that affect other organs (such as diabetes 
mellitus, hypertension and amyloidosis), malignancies (including colon or lung cancer), 
autoimmune diseases (including systemic lupus erythematosus, monoclonal 
gammopathy, Henoch-Schönlein Purpura), infections (including Human 
Immunodeficiency Virus, hepatitis B and C virus, Treponema pallidum), drug exposure 
(including heroin, mercury), and many others.
105
 
Noteworthy, complex syndromes with extra-renal involvement have been associated 
with NS, such as Denys-Drash syndrome, Pierson syndrome, Nail-Patella syndrome, 
Alport syndrome and Schimke immuno-osseous dysplasia. These diseases are usually 
associated to genetic defects that may also be found in not syndromic NS patients (see 
section 4 of this chapter). 
 
1.3.4 Classification of primary forms of NS based on therapy 
The therapy of idiopathic NS aims to counteract the causes leading to glomerular injury 
and also the derived systemic complications. 
Introduction 
 
24 
 
Glucocorticoids (prednisone or prednisolone) are first-line treatment in NS. They show 
anti-inflammatory and immunosuppressive properties, acting on lymphocytes and 
inflammatory cells through the inhibition of the NF-κB transcription factor pathway.106 
The rationale for immunosuppressive therapy relies on the evidence that immune 
alterations have been identified among affected patients.
107
 Specifically, it appears that 
in some patients T cells promote the production of a circulating factor that alters the 
glomerular permeability of the filtration barrier.
108
 It is estimated that about 80% of 
patients with idiopathic NS will respond to corticosteroids with complete resolution of 
proteinuria and edema. Among this steroid-responsive group, the clinical course is 
variable, with up to 60% having frequent relapses or becoming dependent on steroid 
therapy to maintain them in remission. Based on these findings, it became important to 
establish some clinically relevant definitions for the diagnosis of NS and to clarify 
various patient responses to treatment. Patients who enter remission in response to 
corticosteroid treatment alone are referred to as having steroid-sensitive NS (SSNS), 
while patients who fail to enter remission after corticosteroid treatment are referred to as 
having steroid-resistant NS (SRNS). Some patients respond to initial corticosteroid 
treatment by entering complete remission but develop a relapse either while still 
receiving steroids or within 2 weeks of discontinuation of treatment following a steroid 
taper. Such patients typically require continued low-dose treatment with steroids to 
prevent development of relapse, and are therefore referred to as having steroid-
dependent NS (SDNS). Patients who enter complete remission in response to steroids, 
remain in remission for several weeks following discontinuation of treatment but 
develop frequent relapses are defined as frequently relapsing NS (FRNS) if relapses 
occur 4 or more times in any 12-month period.
109
 
Some patients with SRNS, FRNS or SDNS might benefit from other 
immunosuppressive treatments, such as alkylating agents, calcineurin inhibitors or 
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Rituximab, which however have significant toxicity profiles.
110
 Cyclosporin A (CsA) 
and Tacrolimus are calcineurin inhibitors typically used in NS patients and both 
determine a proteinuria reduction in NS patients.
111, 112
 Calcineurin inhibitors inhibit 
cytokine production from T-helper cells (Th1 and Th2) and have an inhibitory effect on 
antigen-presenting cells.
113
 CsA may also reduce proteinuria through stabilization of the 
actin cytoskeleton in kidney podocytes through the inhibition of the calcineurin 
mediated dephosphorylation of synaptopodin.
59
 Alkylating agents, such as 
Cyclophosphamide, cause a depletion of immune competent cells but the exact 
mechanisms of action are still unknown.
114, 115
 Among the antiproliferative agents, 
Mycophenolate Mofetil has the minor nephrotoxic potential.
116
 
Rituximab is an anti-CD20 chimeric murine/human antibody. CD20 is largely expressed 
on B-lymphocytes thus treatment with Rituximab cause a depletion of circulating B-
lymphocytes, but had no effect on B-cell precursors or differentiated B-cell (plasma 
cell) populations 
117
. Rituximab showed an unexpected efficacy in SDNS, inducing 
rapid and long-term remission even in multi-relapsing patients who did not respond to 
treatments primarily active on T-cells (including CsA, Cyclophosphamide and 
Tacrolimus). 
Proteinuria is treated with renin-angiotensin-aldosterone system (RAAS) blockers 
including both, angiotensin-converting-enzyme inhibitors (ACEi) and angiotensin II 
receptor antagonists (AII-RA) which lower blood pressure, prevent worsening of kidney 
disease, and reduce the amount of protein excreted in the urine. The antiproteinuric 
effects of ACEis are determined to their ability to reduce glomerular capillary plasma 
flow rate, decrease transcapillary hydraulic pressure, and alter the permselectivity of the 
GFB.
118-120
 
General measures to control edema include salt restriction, lying in supine position, and 
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use of diuretics drugs. Moderate exercise, a low cholesterol diet, 
hydroxymethylglutaryl-CoA reductase inhibitors, and weight lost in obese patients are 
recommended to reduce hyperlipidemia. Hygienic, dietetic and pharmacological 
measures are needed to counteract the high morbidity and mortality associated with NS 
and its complications. 
 
1.3.5 Prognosis 
The introduction of immunosuppressive therapies has contributed to decrease the NS 
mortality to 9%.
121
 Nowadays, the single most important prognostic indicator for 
maintenance of long-term normal renal function in idiopathic NS is the patient’s initial 
response to corticosteroids. Overall, close to 80% of newly diagnosed children treated 
with corticosteroids will achieve complete remission.
122
 Among patients with SSNS, 
relapse is common. Risk factors for frequent relapses or a steroid-dependent course may 
be age of less than 5 years at onset and a prolonged time to initial remission.
123, 124
 
It is estimated that 40% to 50% of patients with SRNS will progress to End Stage Renal 
Disease (ESRD) within 5-10 years of diagnosis, despite aggressive immunosuppression. 
For this subgroup, the ultimate treatment goal is renal transplantation, which can also 
pose serious challenges. NS recurs in the allograft in up to 30% of children with FSGS 
and leads to graft loss in about 50% of such patients.
125, 126
 Patients who have familial 
forms of SRNS usually do not respond to immunosuppressive treatment and often 
progress to ESRD requiring renal transplantation. In most of these patients the genetic 
disease does not recur in the renal allograft, although the overall risk for disease 
recurrence is controversial: NS has been noted in a subset of patients because of 
immunological attack on a new antigen encountered for the first time in the transplanted 
kidney.
127-129
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1.4 Common primary glomerulonephritides associated to nephrotic 
syndrome 
Idiopathic nephrotic syndrome can be associated with a variety of histological lesions 
and their frequency depends on the age at disease onset (Table 1.1). These histological 
types reflect distinct underlying mechanisms, although overlapping of both clinical 
features and pathogenesis may occur. 
 
Table 1.1. Frequency of Primary Glomerulopathies in patients with Nephrotic 
Syndrome 
Type of Primary Glomerulopathy  
Frequency (%) 
Childhood Adults 
Minimal change nephropathy 55 to 76% 15 to 20% 
Focal segmental glomerulosclerosis  8 to 31% 23 to 35% 
Membranous nephropathy  <1 to 7%  33 to 36% 
IgA nephropathy 1 to <5%  8 to 9% 
Membranoproliferative glomerulonephritis  4 to 5% 2 to 6% 
Mesangial proliferative (other than IgAN) <5 to 22% na 
Other 1 to 5% <7% 
Data obtained from Orth (1998)
130
 and Bonilla-Felix (1999)
131
 for children, and from 
Korbet (1996)
132
 and Haas (1997)
133
 for adults. 
 
 
1.4.1 Podocytopathies 
1.4.1.1 Minimal change disease (MC) 
Histopathological features 
On light microscopy (LM), MC is characterized by minimal or no glomerular 
alterations. The “minimal” findings include podocyte swelling and mild mesangial 
expansion. MC was also known in the past as lipoid nephrosis due to the lipids found in 
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the renal tubular cells, as well as to the presence of lipid-laden proximal tubular cells 
and macrophages in the urine. 
Commonly no glomerular immune deposits are detected on immunofluorescence (IF). 
In a minority of patients, there may be weak mesangial positivity for IgM, IgA and/or 
C3. 
Electron microscopy (EM) shows extensive effacement of foot processes in the absence 
of other abnormalities of the capillary walls. Slit-diaphragms are almost always 
obliterated. 
 
Clinical features 
Annual incidence of primary MC is 2.0 per 100,000 individuals in children and 0.6 per 
100,000 individuals in adults.
134, 135
 MC is the most common histopathological pattern 
in children with idiopathic NS accounting for 55-76% of cases (Table 1.1). Patients with 
MC usually manifest the diseases at age 2-6 years. MC also accounts for 15-20% of 
idiopathic NS in adults. The incidence of MC is a higher in elderly than middle-aged 
adults. More than 90% of children and 77-96% of adults go to remission after 
appropriate steroid treatment. The long term outcome is excellent for steroid sensitive 
patients. The risk of ESRD is <3% in patients with initial response to corticosteroid, 
while up to 50% steroid non responders develop ESRD within 10 year.
133, 136
 
 
1.4.1.2 Focal Segmental Glomerulosclerosis (FSGS) 
Histopathological features 
The term FSGS describes a histological pattern of injury characterized on LM by 
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scarring (sclerosis) in some portions of the glomerular capillary tuft (segmental) and 
only in some glomeruli (focal). As the disease progresses, a more diffuse and global 
pattern of sclerosis evolves and tubular atrophy and interstitial fibrosis develop. 
FSGS can be further divided in the following subtypes: i) collapsing; ii) tip-lesion; iii) 
cellular variant; iv) perihilar variant; v) FSGS not otherwise specified (NOS).
137
 The 
order from i to v is important because the assignment to one subtype presumes that all 
the previous have been excluded. The collapsing variant is characterized by implosive 
glomerulus tuft collapse. The tip variant is characterized by the adhesion of the tuft’s 
most peripheral portion with the Bowman’s capsule at the urinary pole. This occurs by 
extracellular matrix adhesion and/or confluence of podocytes with parietal or tubular 
epithelial cells.
137
 In the cellular variant there is segmental endocapillary 
hypercellularity associated with variable glomerular epithelial cell proliferation. The 
perihilar variant is defined as perihilar hyalinosis and sclerosis involving the majority of 
glomeruli with segmental lesions.
137
 FSGS is defined as not otherwise specified when it 
cannot be assigned to any other variant.
137
 It is the most common histological 
subtype
138
. Repeated biopsies have shown that other variants may evolve into FSGS-
NOS over time. 
On IF, FSGS typically shows IgM and C3 coarse segmental deposits entrapped in areas 
of sclerosis. 
On EM, an extensive effacement of the foot processes is observed without other 
abnormalities in the GBM. 
 
Clinical features 
Annual incidence of primary FSGS is about 0.1 per 100,000 individuals in children and 
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0.8 per 100,000 individuals in adults.
134, 135
 Approximately 75-90% of children and 50-
60% of adults with focal segmental glomerulosclerosis have the nephrotic syndrome at 
presentation.
139
 Hematuria may also be present. The renal outcome of FSGS is similar 
in children and in adults, although children may sometimes show a better response to 
therapy. Forty to 69% of nephrotic patients treated for appropriately long period with 
steroids attain complete remission. More than 90% of the responders show stable renal 
function after 10 years after the clinical onset, while more than 60% of patients who do 
not enter remission progress to ESRD.
140-142
 
 
1.4.1.3 Diffuse mesangial sclerosis (DMS) 
Histopathological features 
On LM, DMS is characterized by mesangial matrix expansion, with no mesangial 
hypercellularity, and sclerosis that conduces to the obliteration of the capillary lumen 
and to the contraction of the glomerular tuft. 
No glomerular immune deposits are found on IF, although nonspecific staining for IgM, 
C3, and C1q may be identified in the mesangium of some glomeruli. 
On EM, effacement of foot processes is present. 
 
Clinical features 
DMS is characterized by early onset of NS (in the first year of life) and rapid 
progression to end stage renal disease. This entity has been described as an isolated 
disorder or also a symptom of syndromes with renal and extrarenal abnormalities such 
as Denys-Drash or Pierson Syndrome. 
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1.4.1.4 Congenital Nephrotic syndrome of Finnish Type 
Histopathological features 
On LM, the first signs of the disease are increased mesangial cellularity and matrix, and 
the characteristic focal cystic dilatations of proximal tubules, followed by radial 
dilatations of the proximal tubules, mesangial proliferation and focal segmental 
sclerosis. 
Immunofluorescence does not detect immune deposits, although, IgM and C3 staining 
can be observed as the disease progresses. 
EM shows effacement of podocyte foot processes and disappearance of the slit 
diaphragm. 
 
Clinical features 
Nephrotic syndrome is defined as congenital (CNS) when it is manifested in the first 3 
months of life. CNS of Finnish type (CNF) represents the most severe form of NS. 
The disease is manifested in the fetus and can be suspected around 16-18 weeks of 
gestation by elevated α-fetoprotein levels in the maternal serum. The placenta is 
abnormally large, while the fetus is small for gestational age in 25% of cases. 
Proteinuria at birth and it is very high ranging from 1 to 6 g/day. Microhematuria and 
signs of tubular dysfunction, such as aminoaciduria and glycosuria, may also be present. 
Renal function is usually normal at birth but it progress to ESRD within the first three 
years of life. The mortality is high due to the complications of NS, especially infections 
and sepsis. 
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1.4.1.5 Genetic causes of Podocytopathies 
The first gene identified as a cause of SRNS was NPHS1 that underline the importance 
of the slit-diaphragm and the podocyte in the pathogenesis of the disease.
143
 
To date more than 30 genes have been described to carry disease-causing mutations for 
SRNS that encode for proteins involved in different aspects of the podocyte and the 
glomerular basement membrane. These proteins are involved in the slit diaphragm, the 
podocyte cytoskeleton, the podocyte development and regulation of homeostasis, 
mitochondrial energy metabolism, the nuclear pore complex, and the glomerular 
basement membrane and the cell-matrix interactions.
144
 Interestingly, defects in these 
proteins can cause isolated glomerulopathy, complex syndromes, where the 
nephropathy is associated with extra-renal manifestations, or both. 
 
 
Figure 1.3 
Figure 1.3. Graphical representation of the glomerular filtration barrier and of some 
genes associated with podocytopathies. In grey genes that are not associated with 
nephropathy in humans. 
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Slit diaphragm 
There is evidence that mutations affecting proteins that make part of the podocyte slit 
diaphragm, such as nephrin (NPHS1), podocin (NPHS2), calcium channel Transient 
Receptor Potential cation Channel 6 (TRPC6) and CD2-Associated Protein (CD2AP), 
cause SRNS.
145, 146
 
The NPHS1 encodes for nephrin, a major component of the slit diaphragm (see chapter 
1.1.4). Mutations in NPHS1 are characterized by an autosomal recessive inheritance and 
are the major cause of CNS in Finland (causing the CNF) due to a founder effect of two 
mutations (L41fs*91 and R1109*) that account for more than 94% of all mutations.
143
 
Both mutations lead to truncated protein products causing the absence of nephrin from 
the podocyte slit diaphragm.
143
 These mutations are rare in non-Finnish populations. 
The frequency of NPHS1 mutations in CNS patients is lower worldwide than in Finnish 
patients, accounting for 39% to 80% of cases.
147-150
 Less frequently, NPHS1 mutations 
are also found in SRNS patients with age of disease onset between 6 months and 12 
years that show a pattern of MC or FSGS on renal biopsy.
151, 152
 In addition, a case with 
adult-onset SRNS carrying two compound heterozygous NPHS1 mutations has been 
described.
153
 In at least one patient with later-onset NPHS1-associated SRNS a milder 
effect of the mutation on the nephrin function has been demonstrated.
151
 
NPHS2 encodes for podocin that physically interacts with nephrin at the slit diaphragm. 
Mutations in NPHS2 are characterized by autosomal recessive inheritance and are 
identified more frequent in familial cases (30-40% of cases) compared to sporadic cases 
(10-30% of cases).
128, 147, 154-157
 NPHS2 mutations are the main cause of SRNS in 
patients with age of onset between 4 months and 12 years, and are also found in 
congenital (15-39%), adolescent (3-11%) and adult forms (5-16%).
150, 152, 158, 159
 
Interestingly, in adults the presence of two mutated alleles is rare, while it is frequently 
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observed the combination of one mutation with the R229Q variant in trans. R229Q is a 
common polymorphism with an allele frequency of 2.7% in the general population and 
leads to a disease phenotype only when it is associated specifically with certain 
mutations affecting the C-terminal portion of the podocin because of an altered 
heterodimerization and entrapment of the 229Q-podocin in the endoplasmic 
reticulum.
160
 NPHS2 mutations are associated with a FSGS diagnosis in kidney biopsy 
in approximately 80-96% of cases and the remaining patients show a pattern of MC.
128, 
150, 156
 NPHS2 pathogenic mutations include missense, nonsense, frameshift, and 
splicing variants. The most prevalent mutation in European patients is the NPHS2 
R138Q that accounts for 32-44% of all affected NPHS2 alleles and has an allelic 
frequency of 0.16% in the European non-Finnish general population of the Exome 
Aggregation Consortium (ExAC) database (v0.3).
128, 156
 In congenital and infantile 
SRNS, the 94% of patients with NPHS2 mutations carry at least one truncating 
mutation or homozygous R138Q mutations.
147
 Missense mutations such as the p.R138Q 
or the p.R168H characterized by retention of the mutant protein in the endoplasmic 
reticulum result in an earlier onset and a more severe phenotype compared to mutations 
that do not disrupt the mutant protein trafficking to the plasma membrane, such as 
G92C, V180M and R238S.
128, 161
 
TRPC6 encodes for the short transient receptor potential canonical 6. TRPC6 co-
localizes and physically interacts with podocin and nephrin. It is critical in adjusting the 
calcium influx close to the slit diaphragm and is functionally connected to the actin 
cytoskeleton.
162, 163
 Mutations in TRPC6 are characterized by autosomal dominant 
inheritance and are found in 0.5-3% of patients both in children and adults.
150, 152, 162
 
Mutation in this gene are characterized by high phenotypic variability, even within 
members of the same family, and incomplete penetrance with healthy mutation 
carriers.
162, 164, 165
 Histopathological findings typically show FSGS and occasionally 
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MC.
164-167
 The majority of TRPC6 mutations are gain-of-function mutations leading to 
increased channel activity by increasing calcium current amplitudes or by delaying 
channel inactivation, whereas some loss-of-function mutations have been described.
162, 
168
 
PLCE1 encodes for the phospholipase C epsilon 1 protein, which catalyzes the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate to generate inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG), thus opening DAG-sensitive classical 
transient receptor channels including TRPC6.
168
 Mutations in PLCE1 show an 
autosomal recessive pattern of inheritance.
169
 On renal biopsy, DMS is the most 
frequently finding but FSGS can also be observed. Most patients carrying PLCE1 
mutations show severe phenotype with early-onset of the disease and rapid progression 
to ESRD.
169
 In four different families with patients carrying PLCE1 mutation, four 
unaffected individuals carrying homozygous truncating mutations have been reported 
suggesting that modifiers modifier genes or environmental factors are required to 
manifest the disease.
170, 171
 
CD2AP encodes for the CD2-Associated Protein, a cell adhesion molecule found on the 
surface of T lymphocytes and natural killer cells that is implicated in T-cell adhesion to 
antigen-presenting cells. In podocytes, CD2AP interacts with nephrin, podocin and F-
actin suggesting its role in anchoring the slit diaphragm to the actin cytoskeleton.
50, 172, 
173
 CD2AP mutations cause FSGS with both autosomal recessive and autosomal 
dominant mode of inheritance. Accordingly to a recessive mode, two compound 
heterozygous CD2AP mutations in a congenital form and one homozygous mutation in 
an infantile form have described.
174, 175
 Both parents of the homozygous patient carried 
a heterozygous mutation and were asymptomatic.
175
 Accordingly to a dominant mode, 5 
patients carrying heterozygous mutations have been reported with prevalently adult-
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onset.
176-178
 Similar to humans, Cd2ap deficient mice present congenital NS with rapid 
progression to ESRD, while Cd2ap haploinsufficient mice show only mild glomerular 
abnormalities in more advanced age.
176
 CD2AP mutations were not identified in a large 
international cohort, suggesting a low contribution of this gene to SRNS.
152
 
 
Podocyte Cytoskeleton 
SRNS can also be caused by mutations in proteins involved in the organization of the 
podocyte cytoskeleton such as inverted formin 2 (INF2), α-actinin-4 (ACTN4), myosin 
1E (MYO1E), Rho GDP dissociation inhibitor-α (ARHGDIA), RhoA-activated Rac1 
GTPase-activating protein (ARHGAP24), and anillin (ANLN).
145, 146, 179, 180
 
The INF2 protein has the unique ability to accelerate both polymerization and 
depolymerization of actin.
181
 The α-actinin-4 protein belonging to the spectrin gene 
superfamily that binds actin and interconnects actin filaments.
182
 MYO1E is localized at 
the plasma membrane of foot processes in podocytes, and is involved in podocyte 
cytoskeleton organization and motility.
179, 183
 ARHGAP24 is upregulated in podocytes 
during their differentiation and inhibits RAC1and CDC42 activity thus suppressing 
lamellipodia formation and cell spreading.
180
. ARHGDIA interacts with RHO GTPases, 
including Ras Homolog Family Member A (RHOA), Ras-Related C3 Botulinum Toxin 
Substrate 1(RAC1), and Cell Division Cycle 42 (CDC42), and sequester them in an 
inactive state in the cytosol.
184
 Finally, ANLN is an F-actin binding protein that is 
enriched in the cytoskeleton.
185
 
The inheritance is autosomal dominant for INF2, ACTN4, ARHGAP24 and ANLN, 
while it is autosomal recessive for MYO1E and ARHGDIA. 
Typically, patients with INF2 mutations present FSGS with moderate proteinuria and 
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adolescent or early-adult onset. However, there is high phenotypic variability. Nephrotic 
range proteinuria and NS at onset have been described. The age of clinical presentation 
ranges from 5 years to 72 years, while the age of progression to ESRD ranges from 13 
to 70 years.
186-188
 Intra-familial variability is also widely present in INF2-assocaited 
FSFS and incomplete penetrance of the disease is also common.
187, 189, 190
 Interestingly, 
INF2 mutations are also frequently detected in patients with Charcot-Marie-Tooth 
disease associated with FSGS.
191
 Mutations INF2 account for about 9-17% of familial 
cases and less than 1% of sporadic cases.
152, 187-189
 To date dozen of mutations have 
been reported and all of them are located within the diaphanous inhibitory domain 
(DID) of INF2. Mutations in exons 2 to 4, which encode for the DID domain, account 
for more than 90% of all mutations.
187-189, 192
 Some reported mutations are recurrent 
with certain codons appearing to be hotspots. The R218Q, R218W, R214H and R214C 
mutations were described in 6, 2, 4 and 4 independent families, respectively.
187-189
 A 
possible founder effect of these mutations has been excluded, since no common 
ancestral disease-associated haplotype was found.
187
 
Patients carrying ACTN4 mutations present FSGS with adolescent or adult onset, 
although childhood onset cases have been described. Like other dominant FSGS-
causing genes the disease presents incomplete penetrance.
193-196
 Mutations in the 
ACTN4 gene were reported to account for approximately 2% of autosomal dominant 
FSGS.
188
 However, no mutations were identified in a large cohort, suggesting a low 
contribution of ACTN4 in the pathogenesis of FSGS.
152
 Animal models and in vitro 
studies suggest both gain-of-function and loss-of-function mechanisms for ACTN4 
mutations.
197
 Most of the described ACTN4 mutations are missense involving residues 
within or next to the actin binding site of α-actinin-4.182, 188, 193, 194, 198 Some of these 
mutations increase the affinity of α-actinin-4 to F-actin and/or lead to protein 
mislocalization followed by formation of α-actinin-4/F-actin aggregates around the 
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nucleus with subsequent impairment of podocyte spreading and motility.
193, 194, 197, 199, 
200
 
MYO1E mutations cause a rare autosomal recessive form of SRNS that is commonly 
manifested in the first decade of life. On renal biopsy FSGS is mainly observed, 
although a case with MC has been described.
174, 179
 Mutations in the MYO1E gene 
account for the 0.3% of SRNS cases, but may involved in the pathogenesis of a 
significant number of families that have some degree of consanguinity.
152, 174, 179
 The 
available functional studies show that at least in some mutations lead to impaired 
function or loss of important MYO1E domains thus causing abnormal subcellular 
localization of the protein and reduction of podocyte motility.
179
 
ARHGAP24 mutations are associated with severe, early-onset FSGS.
180
 In a large 
cohort, mutations in this gene accounted for 0.06% of mutations.
152
 Functional studies 
showed that mutated ARHGAP24 results in a marked increase in the level of active 
Rac1causing dysregulation of the RhoA-Rac1 signaling.
180
 
All reported patients with homozygous or compound heterozygous ARHGDIA 
mutations showed an early onset of the disease (3 months to 2.4 years), rapid 
progression to ESRD and DMS on renal biopsy.
201, 202
 In some patients, extra-renal 
features such as intellectual disability, sensorineural hearing loss, seizures or cortical 
blindness were present. ARHGDIA mutations account for 0.06% of mutations in SRNS 
patients.
152
 Functional studies showed that all three described mutant GDIα proteins 
present impaired actin polymerization, smaller cell size, increased cellular projections 
and slow podocyte motility.
201-203
 
Heterozygous missense mutations in ANLN have recently been described in two 
families with FSGS. The age at proteinuria onset ranged from 9 to 69 years and ESRD 
occurred between 35 and 75 years.
185
 The mutant anillin displays reduced binding to the 
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slit diaphragm-associated CD2AP. Knockdown of ANLN in zebrafish causes a loss of 
glomerular filtration barrier integrity, podocyte foot process effacement, and an 
edematous phenotype.
185
 
 
Glomerular Basement Membrane and GBM-Podocyte Interactions 
Another group of genes associated with SRNS are those encoding proteins involved in 
focal adhesions that tether basal surface of the podocytes to the underlying glomerular 
basement membrane including integrins ITGA3 and ITGB4, EMP2, LAMB2, and 
collagens COL4A3, COL4A4 and COL4A5. 
The diseases associated with mutations in LAMB2 gene, encoding for the β2 chain of 
laminin-521, show an autosomal recessive inheritance. Mutations in LAMB2 are 
associated with Pierson syndrome, which is characterized by congenital NS with 
histological lesions of DMS and ocular malformations (microcoria, abnormal lens with 
cataracts, and retinal abnormalities).
204
 Childhood onset of Pierson syndrome has also 
been reported with progressive visual impairment leading to blindness at approximately 
2 years of age, and NS and ESRD between 5 and 10 years of age.
205
 Interestingly, 
missense LAMB2 mutations are also found in patients with congenital NS with no or 
only minor ocular changes.
206-208
 Complete loss-of-function mutations, such as 
truncating mutations, seem be associated with the complete Pierson syndrome, whereas 
missense mutations may display variable phenotypes ranging from a milder variant of 
Pierson syndrome to isolated congenital NS.
147, 206-208
 
Mutations in the genes encoding for the components of the collagen IV α3α4α5 
protomer are also associated with NS. COL4A5 is characterized by X-linked recessive 
inheritance, although affected females can also be observed usually with a milder 
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phenotype. In the COL4A3 and COL4A4 genes, both an autosomal dominant and 
recessive mode of inheritance have been described. Traditionally, mutations in these 
genes are associated with Alport syndrome, a glomerulopathy associated with variable 
ocular anomalies and sensorineural hearing loss. Typical renal features in Alport 
syndrome are microscopic hematuria with progressive proteinuria and, eventually, renal 
failure.
21
 The allelic disease thin basement membrane nephropathy (TBMN) is 
characterized by persistent microscopic hematuria, but progressive proteinuria and 
ESRD are rarely reported. Finally, mutations in COL4A3–5 genes have been found in 
patients who had a primary diagnosis of FSGS with or without NS, even though on in-
depth clinical evaluation at least some of them presented features of Alport syndrome, 
such as characteristic findings on electron microscopy and hearing loss.
21, 209
 
Remarkably, also Alport syndrome and TBMN show FSGS on LM. Inheritance of 
Alport syndrome is X-linked in 65% of cases (in patients with COL4A5 mutations) and 
dominant (20%) or recessive (15%) in other cases (that is, in patients with COL4A3 and 
COL4A4 mutations).23
21
 In adult-onset FSGS mutations in COL4A3–5 may be found in 
up to 20% patients, mainly in the COL4A4 gene.
210
 
The EMP2 gene encodes for Epithelial Membrane Protein 2, a transmembrane protein 
that regulates cell-membrane localization of integrins, caveolins, and 
glycosylphosphatidyl-inositol-linked proteins. In podocytes and endothelial cells, EMP2 
deficiency results in an increased caveolin-1 levels and decreased cell proliferation. It is 
characterized by autosomal recessive inheritance. Patients with EMP2 mutations may 
present SRNS or SSNS.
211
 Patients describe to date presented a disease onset in the first 
3 years of life.
211
 
The ITGA3 encodes for the integrin alpha-3 subunit. Integrin alpha-3 is present in 
different tissues. In podocytes, it makes part of the integrin α3β1 heterodimer that it is 
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localized at the basal membrane interacts with the GBM component laminin-521.
10
 
Mutations in this gene are characterized by autosomal recessive inheritance and are 
found in syndromic cases with congenital nephrotic syndrome, interstitial lung disease 
and epidermolysis bullosa.
212
 In a large SRNS cohort, ITGA3 mutations were found in 
0.3% of patients.
152
 
 
Mitochondrial dysfunction 
NS is also observed in patients carrying mutations in genes encoding for proteins 
involved in the biosynthesis of Coenzyme Q10 (CoQ10), such as Prenyl Decaprenyl 
Diphosphate Synthase Subunit 2 (PDSS2), Coenzyme Q6 FAD-dependent 
Monooxygenase (COQ6), Coenzyme Q2 Polyprenyltransferase (COQ2) and AarF 
Domain Containing Kinase-4 (ADCK4).
213-216
 CoQ10 is a lipophilic molecule composed 
of a benzoquinone and a decaprenyl side chain. It is present in all cell membranes and 
acts as an electron carrier in the mitochondrial respiratory chain transporting electrons 
from complexes I and II to complex III. In addition, CoQ10 is an antioxidant, a 
membrane stabilizer, a regulator of mitochondrial permeability transition pores and a 
cofactor for uncoupling proteins in brown adipose tissue.
213
 The PDSS2 protein is the 
first enzyme of the CoQ10 biosynthetic pathway and synthesizes the prenyl side-chain 
of coenzyme Q10. Coenzyme Q6 FAD-dependent Monooxygenase is required for the 
C5-ring hydroxylation. Coenzyme Q2 Polyprenyltransferase acts in the final steps in the 
CoQ10biosynthesis. The ADCK4 protein resides both to podocyte foot processes and to 
the mitochondria interacts COQ6 and COQ7 of the CoQ10 biosynthesis pathway.
214
 
PDSS2, COQ6, COQ2 and ADCK4 abnormalities are all characterized by autosomal 
recessive inheritance and account for approximately 0.1%, 0.5%, 0.2% and 0.2-2% of 
SRNS patients, respectively.
152, 214
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Mutations in PDSS2 cause Leigh syndrome, a congenital disease characterized by 
encephalomyopathy and nephrotic syndrome; however, isolated nephropathy may also 
be present.
213
 
Mutations in COQ6 cause a syndrome characterized by nephrotic syndrome with 
sensorineural deafness.
216
 In the reported patients, the age of onset ranges from 0.2 to 6 
years. The main histopathologic feature is FSGS but also DMS may be observed.
216
 
Patients carrying the CoQ2 mutations manifest the disease within the first two years of 
life. Inherited COQ2 mutations cause a primary glomerular disease with renal lesions 
that vary in severity and are not necessarily associated with neurological signs.
215
 On 
kidney biopsy focal segmental glomerular sclerosis, crescentic glomerulonephritis is 
observed.
215, 217
 
The ADCK4 gene is associated with a nephropathy that is typically manifested in 
adolescence with mild to moderate proteinuria and occasionally hematuria. On kidney 
biopsy, patients show a FSGS pattern of injury.
214, 218
 In most patients the disease is 
limited in the kidney, however some patients show features compatible with neurologic 
dysfunction.
214, 218
 
 
Podocyte Development 
Mutations are also found in genes involved in the regulation podocyte development and 
homeostasis including transcription factors WT1, PAX2 and LMX1B, and the Crumbs 
complex component CRB2.
110
 
PAX2 regulates the levels of GDNF and c-Ret that mediate the ureteric bud induction in 
early kidney development.
219
 PAX2 represses WT1 expression in the presence of 
groucho and transducin-like enhancer proteins, while it induces WT1 expression in the 
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absence of these proteins. Following the expression of WT1, PAX2 is down-regulated in 
the podocyte.
220
 LMX1B in podocytes binds to the promoters NPHS2, CD2AP, 
COL4A3 and COL4A4 inducing their expression.
220
 Mutations in PAX2, WT1 and 
LMX1B show an autosomal dominant inheritance. WT1 and LMX1B mutations account 
for 5% and 0.2% of SRNS patients, respectively.
152
 Mutations in PAX2 account for 
approximately 4% of families with FSGS.
221
 
The WT1 gene encodes the Wilms Tumor protein 1. Abnormalities in this gene are 
associated with a wide phenotypic spectrum of diseases ranging from Wilms tumor to 
syndromic forms of glomerular disease and genitourinary abnormalities including 
Denys-Drash, Frasier Syndromes and WAGR syndrome (Wilms tumor, Aniridia, 
Genitourinary abnormalities, and mental Retardation).
222-225
 Patients with WT1 
mutations may also manifest isolated SRNS.
226-230
 The type and localization of the 
mutations correlate with the renal and extra-renal phenotypes.
230
 Nephropathy 
secondary to WT1 mutations is usually manifested in the first decade of life but it may 
also occur in adolescents and adults. Histological findings show DMS in most patients 
and FSGS in a minority.
230
 
PAX2 mutations have been first associated with congenital abnormalities of the kidney 
and urinary tract (CAKUT) as part of a syndrome known as renal coloboma syndrome 
(also called papillorenal syndrome).
231
 Renal coloboma syndrome is highly variable 
even in patients carrying the same mutation within the same family and some affected 
individuals may show only renal features.
232
 Moreover, PAX2 mutations have been 
found in a significant portion of patients with primary FSGS. The disease is commonly 
manifested from the second to the fourth decade but it may be observed from children to 
elderly individuals.
221
 
Mutations in LMX1B cause Nail-Patella syndrome, a disorder characterized by dysplasia 
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of the patellae, nails and elbows associated to iliac horns, glaucoma and in 50% of cases 
glomerulopathy. On renal biopsy a pattern of FSGS is observed. LMX1B mutations are 
also identified in patients with primary FSGS and no extra-renal manifestations.
233, 234
 
The age of onset is highly variable and ranges from 5 to 70 years of age, and some of 
them reached ESRD between 26 and 70 years of age.
233, 234
 
The CRB2 gene encodes the transmembrane Crumbs homolog 2 protein that is required 
for podocyte foot process arborization, slit diaphragm formation, and proper nephrin 
trafficking.
235
 Following an autosomal recessive inheritance, homozygous or compound 
heterozygous CRB2 mutations are identified in patients with childhood-onset isolated 
SRNS with age of onset ranging from 9 months to 6 years. FSGS is observed on kidney 
biopsy.
235
 Of note, CRB2 mutations may also be detected in fetuses and infants with 
cerebral ventriculomegaly and echogenic kidneys, in which histopathological features of 
congenital nephrosis are found.
236
 CRB2 mutations very rare in SRNS patients.
152
 
 
Nucleoporins 
Recently, mutations in nucleoporin genes, such as nucleoporin 93 (NUP93), 107 
(NUP107), 205 (NUP205), and exportin 5 gene (XPO5), have been described as a cause 
of autosomal recessive SRNS. Nucleoporins make part of the nuclear pore complex 
(NPC), a huge protein complex embedded in the nuclear envelope, which mediates the 
transport of proteins, RNAs and ribonucleoprotein particles between the nuclear interior 
and the cytoplasm, Nucleoporins exert their function by interacting with transport 
receptors such as exportins and importins that shuttle their cargo through the NPC. 
NUP93, NUP107, NUP205 encode for nucleoporins 93, 107 and 205, respectively, 
while XPO5 encodes for exportin 5. NUP93 physically interacts with NUP205 within 
the inner ring of NPC. NUP93, NUP205 and exportin 5 are expressed in developing 
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podocytes. In addition, exportin 5 colocalizes with synaptopodin in foot processes of rat 
podocytes.
237, 238
 Mutations in NUP93, NUP107, NUP205 and XPO5 have been 
described in SRNS patients with age of onset between 1 and 12 years. On kidney biopsy 
most of the patients showed a pattern of FSGS, while in a minority MC and MDS was 
observed. Noteworthy, in addition to the glomerular phenotype, tubular abnormalities 
were commonly observed.
237, 238
 
 
Apical membrane 
The PTPRO gene encodes for the transmembrane podocyte protein Glepp1, which is 
localized in the apical membrane of podocytes and is involved in the regulation of the 
glomerular pressure and filtration rate.
239, 240
 PTPRO has also been associated to SRNS 
in two Turkish consanguineous families (five individuals) with autosomal recessive 
inheritance.
239
 Patients with PTPRO mutations had a disease onset between 5 and 14 
years of age. On kidney biopsy FSGS or MCD with severe foot process effacement was 
observed. Studies on animal models showed that Ptpro-deficient mice present 
modification of podocyte structure, hypertension and glomerular filtration rate but no 
proteinuria.
240
 Screening in a large cohort of 1783 unrelated, international families 
found no mutations in PTPRO.
152
 
 
Primary Cilium 
The TTC21B gene encodes the retrograde intraflagellar transport protein 139 (IFT139). 
IFT139 is a component of the intraflagellar transport-A complex that associates with the 
motor protein dynein2 to regulate retrograde trafficking in the primary cilium.
241
 The 
primary cilium is a microtubule-based organelle with an antenna-like structure that is 
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present on the surface of most cells and plays a crucial role during development in 
sensing flow changes and mediating signaling pathways involved in the establishment 
of cell polarity.
242
 The TTC21B gene is characterized by autosomal recessive 
inheritance. Mutations in TTC21B gene have been identified in nine individuals with 
different ciliopathies including isolated nephronophthisis, nephronophthisis with extra-
renal manifestations and Jeune Asphyxiating Thoracic Dystrophy.
243-245
 Ttc21b-null 
mice are characterized by embryonic lethality and ciliopathy-like features.
246
 Recently, 
TTC21B mutations have been identified in patients from seven unrelated families with 
FSGS and tubulointerstitial lesions. Clinically these patients were characterized by late-
onset proteinuria (9-23 years), high blood pressure and ESRD at ages 15-32 years. 
Renal biopsies show FSGS together with typical alterations of nephronophthisis 
including tubular basement membrane thickening.
247
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1.4.2 Immune-complex-mediated Membranoproliferative glomerulonephritis and C3 
glomerulopathy 
Histopathological features 
Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury 
observed in light microscopy characterized by mesangial hypercellularity, endocapillary 
proliferation, and capillary-wall remodeling with double contour formation.
248
 On 
immunofluorescence (IF), C3 staining is observed. Immunoglobulin deposits are also 
frequently detected. These are usually IgG and/or IgM deposits but also IgA and C1q 
can be found.
249
 
Traditionally, through electron microscopy (EM), MPGN was divided into type I, with 
subendothelial deposits, type II or Dense-Deposit Disease (DDD), with 
intramembranous electron-dense deposits, and type III, with subendothelial and 
subepithelial deposits.
248
 A better understanding of MPGN’s pathogenesis has led to 
reclassification into immune-complex-mediated MPGN (IC-MPGN, also called 
immunoglobulin-associated MPGN, Ig-MPGN) and complement-mediated MPGN.
248, 
250, 251
 IC-MPGN shows immunoglobulin and C3 positive staining on IF, supporting 
glomerular immune-complex deposition as the trigger of classical complement pathway. 
Complement-mediated MPGN, named C3 glomerulopathy (C3G), presents predominant 
C3 staining resulting from alternative complement pathway dysregulation.
250-253
 
Predominant C3 glomerular staining is defined as C3 intensity ≥2 orders of magnitude 
more than any other immune-reactant on a 0 to 3 scale.
253
 C3G is further divided into 
DDD and C3 glomerulonephritis (C3GN), the latter lacking the characteristic linear or 
ribbon-like intramembranous highly electron-dense deposits. Notably, the term C3G is 
also used to define other proliferative patterns (mesangial and endocapillary) or even 
nonspecific alterations sharing C3-dominant glomerular staining.
253
 In all subtypes, 
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mesangial, subendothelial and subepithelial deposits may be found on EM. 
 
Clinical features 
MPGN commonly presents with the nephritic syndrome (microscopic hematuria, non-
nephrotic proteinuria, and renal insufficiency). However, up to one third of the patients 
show relatively preserved renal function and nephrotic syndrome at onset.
254
 Following 
the historical classification, types I and III MPGN are more common in children. The 
majority of patients have microscopic hematuria, and some have macroscopic 
hematuria. Hypertension may be present at the diagnosis and is less common in 
children. MPGN type II/Dense deposit disease commonly presents in children between 
the ages of 5 and 15 years. Clinically is similar to type I and III, although nephrotic 
range proteinuria is observed in approximately 50% of patients.
254
 
According to the current IC-MPGN/C3G classification, microhematuria rate is similar 
between the subtypes and is present in 51-76% of patients. On the other hand, nephrotic 
syndrome is more frequently observed in IC-MPGN (65%) compared to DDD (38%) 
and C3GN (27%). Age of onset is higher in C3GN (median age 26 years) than in DDD 
(median 12 years).
255, 256
 Finally, the prevalence of patients with low serum C3 levels is 
higher in DDD compared to C3GN.
255, 256
 The risk to progress to ESRD within ten years 
from onset is 25-50%.
255, 256
 
 
Pathogenesis 
The presence of glomerular C3 deposits in IC-MPGN and C3G underline the 
importance of the complement system activation in these disorders. The association of 
significant immunoglobulin and C1q deposits suggested an activation of the 
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complement system through the classical pathway. Indeed, immunoglobulin deposits 
are frequently observed in the secondary forms of MPGN. Thereby, the presence of 
idiopathic IC-MPGN was questioned, and it is believed that only few IC-MPGN 
patients remain idiopathic after extensive evaluation.
248, 253, 257, 258
 On the other hand, the 
presence of glomerular C3 deposits with no or scanty immunoglobulins implicate 
complement activation through the alternative (or the lectin) pathway.
248, 252
 
Both acquired and genetic abnormalities are found in IC-MPGN and C3G. The most 
frequently involved is C3NeF. It is an IgG auto-antibody that binds and stabilizes the 
alternative pathway C3 convertase C3bBb leading to over-production of activated C3b. 
C3NeF is found in approximately 80% of DDD patients but also in about 40% of C3G 
and 40% of IC-MPGN patients.
256
 Other less frequently observed acquired 
abnormalities include autoantibodies against complement factors H (FH) or B (FB).
259, 
260
 
Genetic abnormalities also account for a smaller portion of IC-MPGN and C3G 
patients. Mutations are found in the two components of the alternative pathway C3 
convertase, C3 and Factor B.
261-263
 Mutations are also identified in complement 
regulator proteins such as FH, factor H-related 5, factor I (FI) and CD46/MCP.
256, 262
 In 
a study where both IC-MPGN and C3G patients were screened for the CFH, CFI and 
CD46/MCP genes, genetic abnormalities were identified in 17% of IC-MPGN patients, 
in 17% of DDD and in 20% of C3GN patients (19% in all C3G patients).
256
 In a 
successive study in which the C3, CFB, CFH, CFI, CFHR5, and CD46/MCP were 
analyzed a positive genetic diagnosis was provided in 43% of patients carrying the 
clinical diagnosis of C3G.
262
 
Together with rare pathogenic genetic variants, common genetic variants increase the 
risk to present DDD. Indeed, DDD patients segregate a complotype given by the 
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combination of the risk alleles 102G and 314L in C3, and 402H and V62 in FH. This 
complotype is associated with higher AP activity in healthy control subjects, which is 
consistent with the interaction of these two proteins.
264
 These data are supported by in 
vitro studies showing that C3(102G) activates complement alternative pathway more 
efficiently than C3(R102). The C3 convertase negative regulator FH binds more 
strongly to C3(R102) than the C3(102G). FH cofactor activity in CFI-mediated C3 
inactivation is reduced for C3b(102G) compared to C3b(R102), favoring alternative 
pathway amplification. Finally, C3 102G and FH V62 combined with the CFB R32 
common variant have a 6-fold higher hemolytic activity compared to the combination of 
the variants C3 R102, FH 62I and CFB 32Q.
265
 Altogether, these data show that DDD is 
a complex genetic disease. 
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1.4.3 Membranous glomerulonephritis 
Pathological features 
The hallmark in MN is the uniform thickening of the glomerular basement membrane 
caused by granular subepithelial IgG deposits.
266
 The pathological evolution of the 
glomerular lesions has been divided in four stages. 
In stage 1, light microscopy may show a normal or slightly thickened GBM. In stage 2, 
the GBM is prominent, GBM projections toward urinary space, called spikes, may be 
seen with appropriate staining. In stage 3, the deposits are incorporated within the 
GBM. In stage 4, there is an irregular thickening of the GBM due to reabsorbed 
deposits. In patients showing complete remission, the GBM deposits may disappear; the 
GBM turns normal but some lucent areas may remain. In patients with progressive 
disease, segmental sclerosis and tubule-interstitial fibrosis may arise.
266, 267
 
On immunofluorescence microscopy, granular polyclonal IgG deposits (often IgG4) are 
observed along the subendothelial portion of glomerular basement membrane. 
Complement C3 can also be associated with the IgG deposits.
266, 267
 
Electron microscopy shows subepithelial deposits with increasing matrix spike reaction 
during disease progression. Foot process effacement is also extensively present. In stage 
3, the GBM can envelop the deposits though matrix reaction, thus resulting in a 
laddering appearance. The deposits may become rarefied as the disease becomes 
chronic (stage 4). Mesangial deposits are absent or rare in primary MN.
266, 267
 
 
Clinical features 
Membranous nephropathy primarily affects middle-aged and elder adults. The disease 
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may be idiopathic or secondary to infections (e.g., hepatitis B and C), tumors (e.g. lung 
and colon cancer), systemic autoimmune diseases (lupus erythematosus) or drugs (e.g., 
gold and penicillamine). 
Annual incidence of primary membranous nephropathy has been estimated as 1.2 per 
100,000.
134, 135
 It is clinically characterized by proteinuria, which is usually 
nonselective. Microscopic hematuria is also commonly present. About 60%-80% of MN 
patients show nephrotic syndrome at disease presentation and 60% of the remaining 
patients develop nephrotic syndrome during disease course. Arterial hypertension and 
renal impairment at clinical onset is observed in approximately 20% of patients.
266, 268
 
Clinical outcome is variable and difficult to predict individually. Spontaneous remission 
occurs in about one third of the patients, usually within the first 2 years after onset. The 
remaining patients can be divided equally into those with persistent proteinuria that 
maintain renal function long term and those patients who will progress to ESRD despite 
immunosuppressive therapy. Predictors of spontaneous remission are baseline 
proteinuria <8 g/day, female sex, age younger than 50 years, and preserved renal 
function at presentation.
268
 
Detection of circulating anti-PLA2R antibodies is useful for diagnosis, since they seem 
to be specific for MN, even though they can also be detected in secondary forms. The 
finding of PLA2R on podocytes on renal biopsy can also aid in the diagnosis of 
membranous glomerulonephritis. Circulating anti-PLA2R1 titer correlates with disease 
activity, prognosis and response to treatment, as well as recurrences in kidney graft. 
During treatment, a decrease in antibody titers often precedes proteinuria response and 
can identify responders from patients refractory to treatment. 
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Pathogenesis 
MN is an autoimmune disease caused by antibody formation against podocyte antigens. 
So far, the role of three different antibodies has been established that recognize human 
endogenous antigens such as neutral endopeptidase (NEP), M-type phospholipase A2 
receptor 1 (PLA2R1) and thrombospondin type-1 domain-containing 7A (THSD7A). 
Antibodies against an exogenous antigen, the cationic bovine serum albumin (BSA), 
have been described in children younger than 5 years affected by MN, however the 
source of the cationic BSA remains obscure.
268
 
The anti-NEP autoantibodies were the first to be discovered and explain some cases 
with congenital onset. Anti-NEPs are produced in mothers with neutral endopeptidase 
deficiency that become alloimmunised to the paternally inherited NEP antigen 
expressed in the placenta. Maternal anti-NEP antibodies cross the placenta and bind to 
NEP expressed on fetal glomerular podocytes. Therefore the disease is manifested in the 
newborn. 
Beck et al. showed that in white people 70% of primary MN cases represent 
autoimmune responses against the M-type PLA2R, a type I transmembrane glycoprotein 
expressed on glomerular podocytes.
269
 These anti-PLA2R1 can be detected in 
glomerular subepithelial immune deposits on kidney biopsy and on podocytes. These 
findings have been widely confirmed and circulating anti-PLA2R autoantibodies are 
found in 52–82% of MN patients.270 
Auto-antibodies against THSD7A are another cause of MN. THSD7A is a large 250kDa 
protein that is located at the basal surface of the podocyte. Anti-THSD7As are found in 
5-10% of MN patients that are negative for anti-PLA2R1.
271
 
IgG4 autoantibodies against aldose reductase (AR), SOD2, and α-enolase (αENO) have 
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been described in 34%, 26% and 43% of MN patients. Such levels were significantly 
higher in MN compared to controls and patients with other glomerulopathies. In this 
study, 60% of patients carried anti-PLA2R1, while no patient had anti-NEP antibodies. 
Coexistence of more types of auto-antibodies was observed with 10% of patients being 
positive for all three anti-AR, anti-SOD2 and anti-αENO.272 However, these findings 
are reported only by one group, and anti-AR and anti-SOD2 may be found in other 
diseases; therefore further validation for these autoantibodies is required. 
Subsequently, a genome-wide association study in white patients of European ancestry 
showed that the rs4664308 polymorphisms of the PLA2R gene combined with the 
rs2187668 polymorphisms in the HLA-DQA1 locus increase the risk for primary MN. 
The risk alleles of these two genes have an additive effect; individuals carrying all four 
risk alleles have an odds ratio of 78 for developing MN compared to those carrying all 
four protective alleles.
273
 These findings were confirmed in an independent Spanish 
cohort (Table 1.2).
274
 
 
Table 1.2. Summary of GWAS results from membranous nephropathy cohorts. 
Study Cohort 
dbSNP 
locus 
Locus 
 P value 
Odds ratio 
(95% CI) per 
allele Chr Minor 
allele 
Nearest 
gene 
Stanescu et 
al. (2011)  
556 white European 
MN patients and 
2,338 controls 
rs4664308 2 A PLA2R1 8.6×10
-29
 2.28 (1.96–2.64) 
rs2187668 6 G HLA-DQA1 8.0×10
-93
 4.32 (3.73–5.01) 
 
Bullich et 
al. (2014)  
89 white European 
MN patients and 
286 controls 
rs4664308 2 A PLA2R1 0.03 1.53 (1.05–2.23) 
rs2187668 6 G HLA-DQA1 2.5×10
-6
 2.58 (1.72–3.87) 
Modified from Jiang (2013).
275
 MN: membranous nephropathy; Chr: chromosome. 
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1.4.4 IgA nephropathy 
Pathological features 
The diagnosis of IgA nephropathy (IgAN) is based on a histopathologic evaluation of 
renal biopsy, which shows mesangial hypercellularity and predominant immunoglobulin 
A (IgA) deposition in the glomeruli.
276
 Nonetheless, histopathologic findings in IgAN 
are highly heterogeneous.
276
 
On light microscopy, the features may vary greatly among patients and within the 
individual biopsy sample. Increased mesangial matrix and mesangial hypercellularity 
are commonly observed. Other glomerular lesions may include focal necrosis, 
segmental scarring, and crescents in Bowman's space.
276
 
Immunofluorescence microscopy shows a predominant IgA deposition in the 
glomerular mesangium, which can be either alone or associated with IgG and/or IgM. 
The frequency of IgA deposits alone varies across centers from 0 to >85%. In addition 
to immunoglobulin deposits, complement C3 and properdin are almost always 
observed. C4 or C4d, mannose-binding lectin, and terminal complement complex (C5b–
9) are frequently present, whereas C1q is usually absent.
276
 
On electron microscopy, it is usually observed electron-dense material corresponding to 
immune deposits on immunofluorescence. These deposits are generally located in 
mesangial and paramesangial areas but they can be occasionally also present in 
subepithelial and subendothelial portions of glomerular basement membranes.
276
 
An international consensus working group developed the Oxford classification of IgA 
nephropathy based on four pathological features: mesangial hypercellularity, segmental 
glomerulosclerosis, endocapillary hypercellularity, and tubular atrophy/interstitial 
fibrosis. These features have prognostic significance and the classification predicts more 
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accurately the risk of progression of renal disease.
277
 
 
Clinical features 
IgAN is a major cause of kidney failure worldwide. The incidence of IgAN is estimated 
as 2.5 cases per 100,000 adults.
135
 The prevalence of this disease is highest in Asia, 
intermediate in Europe and USA, and lowest in Africa.
134
 
IgAN is a highly heterogeneous disorder, in which the clinical presentation ranges from 
asymptomatic hematuria to rapidly progressive glomerulonephritis evolving in ESRD. 
The typical presentation is hypertension or mild edema in young oligosymptomatic 
adults.
134
 Microscopic hematuria (persistent or intermittent), episodic gross hematuria 
and chronic kidney disease are the main characteristic, while NS is observed in 10% of 
patients.
278
 Among patients with NS, 48% show complete remission, 32% partial 
remission and 20% no response to treatment.
278
 Up to 50% of IgAN patients show a 
progressive loss of glomerular filtration rate, while most of the remaining patients 
present persistent hematuria and/or proteinuria. Only in a minority of patients sustained 
clinical remission occurs (spontaneously or after treatment).
134, 279
 
The prognosis in IgAN patients is highly variable. At least half of the patients have a 
benign disease course or remit spontaneously, while about 30%–50% progress to ESRD 
within 20 years of the first biopsy. Kidney transplantation is the treatment of choice for 
ESRD, but the disease recurs in up to 50% of patients.
280
 
To predict individual outcome, a three-point score was established in a French cohort, 
based on proteinuria >1 g/day, presence of hypertension, and histological changes in the 
biopsy sample. This score efficiently predicted the risk of death or ESRD (ranging from 
4% to 64% after 20 years in those with a score of 0 or 3, respectively). Moreover, the 
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current Oxford-MEST classification of IgAN has been developed to better reflect 
outcome. It is based on four histological features associated with a progressive course: 
glomerular mesangial hypercellularity; endocapillary hypercellularity; segmental 
glomerulosclerosis and/or tuft adhesions; and tubular atrophy and/or interstitial fibrosis 
in more than 25% of the section. 
 
Pathogenesis 
IgA nephropathy is likely a systemic disease with extrarenal causes in which the 
kidneys are damaged as innocent bystanders. This is suggested by the fact that IgA 
nephropathy frequently recurs in renal allografts. Conversely, IgA deposits in a kidney 
from a donor with subclinical IgA nephropathy disappeared within several weeks after 
transplantation in a patient with a different kidney disease.
281
 
IgAN is an immune-mediated disease caused by abnormal deposition of deficient O-
linked glycan IgA1 antibodies. Type 1 IgA heavy chains are composed of one variable 
(VH) and 3 constants regions (Cα1-3). Between Cα1 and Cα2 there is a hinge region 
with Serine and Threonine residues that can be subject to O-glycosylation (Figure 
1.1A). Three to six of the 9 potential glycosylation sites are usually glycosylated. The 
carbohydrate composition of the O-linked glycans on normal human circulatory IgA1 is 
variable, with the prevailing glycan being a tetrasaccharide consisting of one N-
acetylgalactosamine (GalNAc), one galactose (Gal), and two sialic acid molecules (one 
linked to GalNAc and one to Gal) (Figure 1.1B). In patients affected by IgAN, a greater 
fraction of circulatory IgA1 with hinge-region O-linked glycans without galactose is 
observed. These O-linked glycans consist of only a terminal GalNAc or a sialylated 
GalNAc (Figure 1.1B) and the corresponding IgA1s are as defined galactose-deficient 
O-linked glycan (Gd-IgA1).
279, 282
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The IgAN patients have elevated serum Gd-IgA1 levels compared to controls and 50-
78% of patients have serum Gd-IgA1 levels above the 95
th
 percentile of healthy 
controls. Family studies have shown that elevated Gd-IgA1 levels are heritable, with 
25-33% of asymptomatic family members displaying levels that are just as elevated as 
those of patients. The heritability of Gd-IgA1 has been estimated at >50%. 
The presence of high Gd-IgA1levels is not sufficient to cause the disease. A multi-hit 
pathogenetic model has been proposed in which genetic and environmental factors are 
involved. According to this model, individuals with high Gd-IgA1 levels are prone to 
auto-sensitization and production of anti–Gd-IgA1 IgG or IgA antibodies results in the 
formation of immune complexes. These pathogenic immune complexes deposit in the 
glomerular mesangium activating mesangial cells that produce cytokines, proliferate 
and excessively produce extracellular matrix leading to renal injury.
279, 283
 Interestingly, 
both the circulating concentrations of Gd-IgA1 and of anti-Gd-IgA1 autoantibodies are 
associated with IgAN progression.
134
 
Four different GWAS studies are available in IgAN that have identified fifteen 
independent risk loci with genome-wide significance. These loci cumulatively explain 
about 6-8% of the genetic risk.
279
 The susceptibility loci for IgAN implicate defects in 
adaptive immunity (MHC region), mucosal barrier innate immunity (VAV3, DEFA gene 
cluster, TNFSF , CARD9, ITGAM, ITGAX and HORMAD2) and alternative pathway of 
complement (CFHR1).
279, 282
 A IgAN genetic risk score was created as the weighted 
sum of the number of risk alleles. Subjects carrying all the risk alleles have a 3.71-fold 
higher risk to develop IgAN than the worldwide average, while subjects carrying all the 
protective alleles have a 5.03-fold less risk to develop the disease. Therefore, the two 
extremes show an 18.66-fold difference in IgAN risk.
279
 
Six independent susceptibility loci have been identified in the MHC region that involve 
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prevalently HLA-DR/HLA-DQ but also HLA-DP and TAP1/TAP2/PSMB8/PSMB9. 
Imputation of classical HLA alleles using the data from SNP arrays identified a role for 
HLA-DQA1*0101, HLA-DQA1*0102, HLA-DQB1*0201 and HLA-DQB1*0301.
279
 
However, it must be considered that imputation of classic HLA alleles by SNP data may 
miss or impute with low confidence rare alleles due to the limited size of the reference 
database given the highly polymorphic HLA locus.
284, 285
 The HLA genes are 
responsible for antigen processing and presentation, and it is hypothesized that they are 
involved in the genesis of the anti-Gd-IgA1 autoantibodies. One of the MHC region 
susceptibility loci contains the TAP1, TAP2, PSMB8, and PSMB9 genes.
279
 These are 
interferon-regulated genes that are involved in antigen processing for presentation by 
MHC-I molecules and in modulation of cytokine production and cytotoxic T cell 
response.
280
 Interestingly, IgAN patients present increased mRNA levels of PSMB8.
286
 
Another group of genes involved in the IgAN pathogenesis includes genes that 
participate in the innate immune defense of the mucosal barrier. The TNFSF13 gene, 
encoding APRIL, is a powerful B cell–stimulating cytokine that promotes IgA1 to IgA2 
class switching. The fact that APRIL levels are elevated in the serum of some IgAN 
patients further supports the role of TNFSF13 in IgAN.
287
 Moreover, TNFSF13 
mutations cause partial IgA deficiency and reduced IgA antibody responses to mucosal 
immunization both in mice and humans.
288
 Another susceptibility locus contains the 
DEFA cluster that includes genes encoding the α-defensin antimicrobial peptides. The 
α-defensin peptides are released at mucosal surfaces and have microbiocidal and 
chemoattractant properties.
279
 Mammalian α-defensins exert their bactericidal effects 
through the conserved triple-stranded β-sheet that creates pores in the target membranes 
and permeabilizes the target cell envelope.
289
 DEFA1, DEFA3 and DEFA4 peptides are 
synthesized in neutrophils, while (DEFA5 and DEFA6 are constitutively secreted by the 
intestinal Paneth cells into the gut lumen.
280
 GWAS suggest the involvement in the 
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IgAN pathogenesis also for ITGAM and ITGAX, which encode for integrins αM and αX, 
respectively. These integrins mark intestinal dendritic cells that maintain the balance 
between inflammation and tolerance, and combine with the integrin β2 chain to form 
leukocyte-specific complement receptors 3 and 4 (CR3 and CR4, respectively). Studies 
in mice show that ITGAM regulates the IgA-producing plasma cells in the bowel.
290
 
CARD9, encoding for Caspase Recruitment Domain Family Member 9, and VAV3, 
encoding for Vav Guanine Nucleotide Exchange Factor 3, are involved in NF-κB 
activation and are essential for maintenance of the intestinal epithelial barrier and 
control of the local inflammatory response to infection. CARD9 mediates intestinal 
repair and control of bacterial infection after intestinal epithelial injury in mice. 
Moreover, CARD9 deficiency results in susceptibility to invasive fungal infections. 
VAV proteins are required for the proper enterocyte differentiation in colon and the 
prevention of spontaneous ulcerations of intestinal mucosa.
279
 The role of HORMAD2 is 
not clear, however the same gene was associated with inflammatory bowel disease.
291
 
A common deletion involving the two CFH-related genes CFHR3 and CFHR1 is 
protective against IgAN. The CFH gene and CFHR1-R5, encoding factor H (FH) and 
five FH-related (FHR) proteins, are located in tandem in the cluster of complement 
activation regulators at chromosome 1q32 and present a high level of sequence identity. 
The presence of repeated sequences favors genomic rearrangements through non-allelic 
homologous recombination and the most frequently observed recombination is the 
deletion of CFHR3-CFHR1 (allele frequency of 20% in Europeans), which is strongly 
associated with anti-FH autoantibodies development in atypical hemolytic uremic 
syndrome and has a protective role in age-related macular degeneration.
90, 292
 FH and 
FHRs are involved in the alternative pathway of complement system. FHR1 forms 
homodimers or heterodimers with FHR2 and FHR5 that compete with FH for binding to 
surface-fixed C3b, thus reducing the negative control of FH and enhancing complement 
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activity.
91
 FHR1 deficiency should lead to reduced complement activation at GBM. The 
presence of complement C3 and properdin deposits in the glomeruli of IgAN patients, 
which are frequently associated with the presence of the terminal complement complex 
(C5b–9) and the absence of C1q,276 underlines the role of the complement alternative 
pathway in IgAN and supports a possible involvement of FHR1. The role of FHR3 is 
unknown. 
Environmental factors may also play a role in IgAN pathogenesis. The increased 
incidence of IgAN in some geographical areas might represent an untoward 
consequence of protective adaptation to mucosal invasion by local pathogens. 
Bioinformatic analyses showed a very strong positive association of the IgAN genetic 
risk score with local pathogen diversity from different geographical regions and in 
particular with the helminth diversity. Furthermore, some secondary IgAN forms are 
caused by schistosomiasis, which is a helminth infection. In addition, the ability of 
ITGAM-positive dendritic cells to stimulate CD4+ T cells is specifically impaired 
during schistosome infection. The enhanced immune response conferred by risk alleles 
in IgAN would be multi-locus adaptation response to mucosal infections.
279
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Figure 1.4 
Figure 1.4. A) Graphical representation of an IgA1 antibody with the presence of O-
glycans in the hinge region. B) Representation of normal and galactose-deficient O-
glycans. 
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Table 1.3. Summary of GWAS results from IgA nephropathy cohorts. 
Study Cohort 
dbSNP 
locus 
Locus 
 
P value 
Odds ratio (95% 
CI) per allele Chr Minor 
allele 
Nearest gene 
Yu et al. 
(2012)
27
 
4,137 Han 
Chinese IgAN 
patients and 7,734 
controls 
rs2738048 8 A DEFAs 3.18×10
-14
 0.79 (0.74–0.84) 
rs3803800 17 G TNFSF13 9.40×10
-11
 1.21 (1.14–1.28) 
rs4227 17 T MPDU1 4.31×10
-10
 1.23 (1.16–1.32) 
rs12537 22 C MTMR3 1.17×10
-11
 0.78 (0.72–0.84) 
rs2523946 6 T HLA-A 1.74×10
-11
 1.21 (1.15–1.28) 
rs660895 6 A HLA-DRB1 4.13×10
-20
 1.34 (1.26–1.42) 
rs1794275 6 G HLA-DQA/B 3.43×10
-13
 1.30 (1.21–1.39) 
 
Feehally 
et al. 
(2010)
25
 
244 European 
IgAN patients and 
4,980 controls 
rs3115573 6 A NLNHP4 2.00×10
-6
 1.55 (1.29–1.85) 
rs3130315 6 G NLNHP4 2.00×10
-6
 1.55 (1.29–1.85) 
 
Gharavi 
et al. 
(2011)
26
 
3,144 Han 
Chinese IgAN 
patients and 2,822 
controls
*
 
rs3766404 1 C CFHR1,3 4.24×10
-5
 0.77 
rs6677604 1 A CFHR1,3 2.96×10
-10
 0.68 
rs2856717 6 T HLA-DQB1 8.44×10
-16
 0.73 
rs9275596 6 C HLA-DQB1 1.59×10
-26
 0.63 
rs9357155 6 A PSMB8 2.11×10
-12
 0.71 
rs2071543 6 A PSMB8 5.77×10
-12
 0.73 
rs1883414 6 T HLA-DPB2 4.84×10
-9
 0.78 
rs3129269 6 T HLA-DPB2 8.54×10
-9
 0.79 
rs2412971 22 A HORMAD2 1.86×10
-9
 0.80 
rs2412973 22 A HORMAD2 4.46×10
-9
 0.80 
 
Kiryluk et 
al. (2014) 
4,418 European 
and 3,240 Han 
Chinese IgAN 
patients and 
10,229 European 
and 2,287 Han 
Chinese controls 
rs17019602 1 G VAV3 6.8×10
-9
 1.17 
rs6677604 1 A CFHR1,3 4.8×10
-14
 0.74 
rs7763262 6 T HLA-DR/DQ 1.8×10
-38
 0.71 
rs9275224 6 A HLA-DR/DQ 5.9×10
-30
 0.74 
rs2856717 6 T HLA-DR/DQ 1.1×10
-15
 0.79 
rs9275596 6 C HLA-DR/DQ 2.5×10
-31
 0.69 
  
rs2071543 6 A TAP2-PSMB9 1.5×10
-4
 0.87 
  
rs1883414 6 T HLA-DP 1.5×10
-11
 0.82 
  
rs2738048 8 C DEFA 1.6×10
-4
 0.91 
  
rs10086568 8 A DEFA 1.0×10
-9
 1.16 
  
rs4077515 9 T CARD9 1.2×10
-9
 1.16 
  
rs11150612 16 A ITGAM-ITGAX 1.3×10
-11
 1.18 
  
rs11574637 16 C ITGAM-ITGAX 8.1×10
-13
 0.76 
  
rs3803800 17 A TNFSF13 9.3×10
-6
 1.12 
  
rs2412971 22 A HORMAD2 4.8×10
-12
 0.83 
Modified from Jiang (2013).
275
 
*
All values are given for all cohorts combined (the Beijing discovery 
cohort, plus both the Shanghai and European replication cohorts). 
dbSNP: database of single nucleotide polymorphisms; GWAS: genome-wide association study; IgAN, 
IgA nephropathy. 
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2. AIMS 
The global aim of the present thesis was to evaluate the contribution of genetics to the 
pathogenesis and clinical outcome of two kidney disorders characterized by the 
presence of nephrotic syndrome: the immune complex-mediated membranoproliferative 
glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), and the steroid-resistant 
nephrotic syndrome (SRNS). 
 
The first part of this thesis was focused on IC-MPGN/C3G. Specific aims of this part 
were: 
To evaluate the prevalence of complement genetic and acquired abnormalities in a large 
cohort of patients with idiopathic IC-MPGN/C3G. 
To investigate whether specific patterns of complement abnormalities and genetic 
variants correlate with disease manifestations and whether they can predict the long-
term evolution of these complex diseases. 
To evaluate whether the current IF-based C3G/IC-MPGN classification captures all 
patients with complement-mediated pathogenesis. 
To explore whether cluster analysis based on histologic findings, clinical features, 
serum complement profile and genetic data could be a tool for better understanding the 
disease etiology. 
 
Aims  
 
66 
 
The second part of this thesis aimed to analyze the genetic causes of SRNS and to 
develop a genetic test based on NGS able to screen the coding regions and the 
polymorphisms associated with the most common primary proteinuric glomerular 
disorders. Specific aims of this part were: 
To create a NGS based genetic test containing genes associated with the most common 
primary proteinuric glomerular disorders. 
To create a strategy and a score that allows to distinguish true from false variant during 
NGS in order to increase the sensitivity and reduce the false positive error detection rate 
of the Ion Torrent Personal Genome Machine (PGM) platform. 
To search for mutations in known SRNS-associated genes in patients with the sporadic 
and the familial form of SRNS, in order to evaluate the prevalence of mutations in 
patients. 
To evaluate whether SRNS patients carry mutations in genes associated with other 
primary proteinuric glomerular disorders. 
To search for new gene/s involved in the pathogenesis of SRNS by screening selected 
candidate genes in the entire cohort. 
To search for new gene/s involved in the pathogenesis of SRNS in familial cases 
without mutations in the known genes using autozygosity and linkage studies all along 
the genome and whole exome studies. 
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3. COMPLEMENT GENE VARIANTS DETERMINE 
THE RISK OF IMMUNOGLOBULIN-ASSOCIATED 
MPGN AND C3 GLOMERULOPATHY AND 
PREDICT LONG-TERM RENAL OUTCOME 
3.1. Introduction 
Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of chronic 
proteinuric nephropathy diagnosed based on a glomerular injury pattern characterized 
by mesangial hypercellularity, endocapillary proliferation, and capillary-wall 
remodeling with double contour formation.
248
 The onset varies widely with patients 
presenting with asymptomatic hematuria and proteinuria, nephritic or nephrotic 
syndrome, or rapidly progressive glomerulonephritis. MPGN may be secondary to 
infections, autoimmune diseases and malignancies, or idiopathic, when a clear 
underlying etiology cannot be identified. Traditionally, through electron microscopy 
(EM), MPGN was divided into type I, with subendothelial deposits, type II or Dense-
Deposit Disease (DDD), with intramembranous electron-dense deposits, and type III, 
with subendothelial and subepithelial deposits.
248
 A better understanding of MPGN’s 
pathogenesis has led to reclassification into immunoglobulin-associated (Ig-MPGN; 
also called immune complex-mediated MPGN, IC-MPGN) and complement-mediated 
MPGN.
248, 250, 251
 Ig-MPGN shows immunoglobulin- and complement-positive staining 
by immunofluorescence (IF), supporting glomerular immune-complex deposition as the 
trigger of classical complement pathway. Complement-mediated MPGN, named C3 
glomerulopathy (C3G), presents predominant C3 staining resulting from alternative 
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complement pathway dysregulation.
250-253
 C3G is further divided into DDD and C3 
glomerulonephritis (C3GN), the latter lacking the intramembranous electron-dense 
deposits. The term C3G is also used to define other proliferative patterns (mesangial 
and endocapillary) or even nonspecific alterations sharing C3-dominant glomerular 
staining.
253
 
Although Ig-MPGN is considered an immune-complex mediated disease with 
complement activation through the classical pathway, the presence of mutations 
affecting alternative pathway regulatory proteins in a few cases, and C3 nephritic 
factors (C3NeFs) - autoantibodies that stabilize the alternative pathway C3 convertase - 
in about 50% of patients, suggests the alternative pathway plays a role.
256
 
Alternative pathway dysregulation is well documented in C3G: low serum C3 levels 
associated with C3NeFs are observed in most patients and few carry autoantibodies 
against complement factors H (FH) or B (FB), or mutations in genes encoding C3 and 
the regulatory proteins FH, factor H-related 5, factor I (FI) and CD46.
256, 259, 260, 293-295
 
In this study we evaluated the complement genetic and biochemical profile in a large 
cohort of patients with idiopathic Ig-MPGN/C3G. We also investigated whether specific 
patterns of complement abnormalities and genetic variants correlate with disease 
manifestations and whether they can predict the long-term evolution of these complex 
diseases. 
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Figure 3.1 
Figure 3.1. Examples of immunofluorescence studies for C3 (A), C4d (B), IgG (C) and 
C1q (D) in renal biopsy specimens from patients with IC-MPGN. Modified from Sethi, 
J Am Soc Nephrol 2015,
296
, Sethi, Semin Nephrol 2011
250
 and Yabuuchi, Case Rep 
Nephrol Dial 2016.
297
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3.2 Specific aims 
1. To evaluate the prevalence of complement genetic and acquired abnormalities in a 
large cohort of patients with idiopathic Ig-MPGN/C3G. 
2. To investigate whether specific patterns of complement abnormalities and genetic 
variants correlate with disease manifestations and whether they can predict the long-
term evolution of these complex diseases. 
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3.3. Patients and Methods 
Patients 
Patients (n=227) were consecutively recruited through the Registry of MPGN 
established at the Mario Negri Institute (Figure 3.2). All kidney biopsy reports were 
centrally reviewed, adopting the recent classification.
250, 253
 MPGN diagnosis was based 
on the typical light microscopy pattern.
250
 Patients with glomerular immunoglobulin and 
C3 deposits at IF were considered Ig-MPGN. C3G was diagnosed based on the presence 
of MPGN or mesangial proliferative patterns under light microscopy with “dominant 
C3” glomerular staining (intensity≥2 orders of magnitude more than any other immune-
reactant on a 0 to 3scale).
253
 Based on EM, C3G was further classified as DDD or 
C3GN.
253
 Even though only patients with idiopathic MPGN are recruited through our 
Registry, after a deeper evaluation we excluded 87 patients: 11 did not meet diagnostic 
criteria, 18 were affected by secondary MPGN following a comprehensive diagnostic 
work-up, 7 received an MPGN diagnosis years after atypical hemolytic uremic 
syndrome (aHUS), 4 received an MPGN diagnosis on allograft but the native kidney 
biopsy was not available, 23 had no IF studies, 15 had no EM, and for 9 DNA samples 
were not available. 
All participants provided informed written consent. The study adheres to the 
Declaration of Helsinki and was approved by the Ethics Committee of the Azienda 
Sanitaria Locale of Bergamo (Italy). 
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Figure 3.2 
Figure 3.2. Histopathologic classification of the patients recruited through the Registry 
of Idiopathic Membranoproliferative Glomerulonephritis (MPGN). Ig-MPGN: 
immunoglobulin-associated MPGN; C3G: C3 glomerulopathy; DDD: Dense Deposit 
Disease; C3GN: C3 glomerulonephritis; IF immunofluorescence microscopy; EM: 
electron microscopy. 
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Complement component assays 
Serum C3 and C4 levels were assessed by kinetic nephelometry.
294
 To assess plasma 
SC5b-9 levels and C3NeF activity, blood was collected in ice-cold EDTA tubes, 
immediately centrifuged at 4° C to avoid ex-vivo complement activation, and frozen at -
80°C until assay. SC5b-9 levels were measured using the MicroVue SC5b-9 Plus EIA 
commercial kit (SC5b-9 Plus, Quidel). Serum C3, C4 and plasma SC5b-9 were assessed 
at Mario Negri Institute. C3NeF activity was determined at the Cordelier Research 
Center by purifying IgG from plasma and assessing their ability to stabilize cell-bound 
C3bBb convertase as previously described.
298
 
 
DNA Sequencing 
Genomic DNA was extracted from peripheral blood using the Nucleon
TM
 BACC2 
Genomic DNA extraction kit (GE Healthcare, Little Chalfont, UK). 
Through next-generation sequencing, genetic screening of all exons and flanking 
regions of CFH (NG_007259.1), CD46 (NG_009296.1), CFI (NG_007569.1), CFB 
(NG_008191.1), C3 (NG_009557.1) and THBD (NG_012027.1) genes was performed 
by highly multiplex PCR using the Ion AmpliSeq™ Library Kit 2.0 and 311 primer 
pairs (subdivided into two pools), designed using the Ion AmpliSeq Designer tool. After 
clonal amplification using the Ion PGM™ Template OT2 200 Kit, sequencing was 
performed on Ion PGM Sequencer. Variants were identified using TorrentSuite 
Software 3.6, and putative mutations were validated by Sanger sequencing. Regions 
with a depth of amplicon coverage ≥40x reads were considered appropriately analyzed. 
Regions with low coverage or regions not covered by the Ion AmpliSeq Designer were 
sequenced by Sanger method. In 9 patients, screening of CFH, CD46 and CFI coding 
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exons was performed by Sanger sequencing as previously described.
294
 
 
Genetic variant annotation 
Genetic variants were functionally annotated using the ANNOVAR software. Missense 
variants, insertions/deletions in the coding regions, splicing variants affecting the first 
two nucleotides flanking exons, or variants lying within the Kozak consensus sequence 
were considered functional. Variants that did not exceed an allelic frequency of 0.01 in 
none of the ESP or the 1000 Genomes Project subpopulations were considered rare. 
Likely pathogenic variants were defined as the variants with minor allele frequency in 
the ExAC database <0.001 and with Combined Annotation Dependent Depletion 
(CADD)
299
 phred score ≥10. 
The Combined Annotation Dependent Depletion is a method that integrates different 
annotation in a general framework to estimate the relative pathogenicity of human 
genetic variants.
299
 It was implemented as a support vector machine trained to 
differentiate 14.7 million fixed or nearly fixed derived alleles in humans from 14.7 
million simulated variants. The fixed or nearly fixed human-derived alleles are those 
alleles that differ from the inferred human-chimpanzee ancestral genome and have an 
allele frequency of at least 95% in the human population (according to the 1000 
Genomes Project variant catalog). Deleterious variants that reduce organism fitness are 
depleted by natural selection in fixed but not simulated variation. The support vector 
machine uses 63 distinct annotations that span a range of data types including species 
conservation metrics like GERP, phastCons, and phyloP; regulatory information like 
genomic regions of DNase hypersensitivity and transcription factor binding; transcript 
information like distance to exon-intron boundaries or expression levels in commonly 
studied cell lines; and protein-level scores like Grantham, SIFT, and PolyPhen. CADD 
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objectively integrates the diverse annotations into a single, quantitative score (C-score).  
“C-scores” were pre-computed for all 8.6 billion possible human single nucleotide 
variants and enable scoring of short insertions/deletions. C-scores were also scaled to a 
Phred-like scale ranging from 1 to 99 on the basis of their ranking relative to all 
possible substitutions in the human reference genome [−10log10 (rank/total number of 
substitutions)]. A Phred-scaled C-score of greater or equal 10 indicates that these are 
predicted to be the 10% most deleterious substitutions that may occur to the human 
genome, a score of greater or equal 20 indicates the 1% most deleterious and so on. The 
authors state that the choice of a cutoff on deleteriousness to identify potentially 
pathogenic variants is always arbitrary and there is no natural choice. They suggest a 
cutoff of Phred-scaled C-score somewhere between 10 and 20. Since C3G and Ig-
MPGN are considered complex diseases that may derive by adding up the small effect 
of multiple hits, the less stringent cutoff of 10 was adopted for these diseases. For 
steroid-resistant nephrotic syndrome, which is believed a monogenic disease, we 
adopted a more stringent cutoff of 15 (http://cadd.gs.washington.edu/).
299
 
The ExAC database, containing 60,706 subjects, was adopted as reference to assess 
allelic frequencies. To perform association studies, we used as a control group the 286 
unphenotyped subjects of European origin from the 1000 Genomes Project (CEU, TSI, 
GBR and IBS subpopulations), for whom individual genotypes were available. 
 
Statistical analyses 
Categorical data were analyzed with χ2 test or Fisher exact test, where appropriate. One-
way ANOVA, Kruskal-Wallis and multivariate regression tests were used for 
continuous variables. 
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Degree of mesangial proliferation, endocapillary proliferation, interstitial inflammation, 
interstitial fibrosis, and arteriolar sclerosis, as well as IF findings were graded using a 
scale of 0 to 3, including 0, trace, 1+, 2+ and 3+. These findings were considered as 
quantitative variables after substituting 'trace' with 0.5, and analyzed with one-way 
ANOVA. EM findings were considered as dichotomous variables and were analyzed 
with χ2 test or Fisher exact test where appropriate. 
Survival analyses considered as cumulative fractions of patients free of events were 
estimated using Kaplan-Meier survival curves and with Cox proportional-hazard 
regression. Multivariate analyses included all the covariates that reached statistical 
significance at the univariate analysis. To perform multivariate analyses with genetic 
variants, homozygous genotypes for the reference allele were codified as 0, 
heterozygous as 1 and homozygous for the alternative allele as 2. In the dominant model 
the group with at least one alternative allele was compared with the group with no 
alternative alleles. In the recessive model the group homozygous for the alternative 
allele was compared with the group with no or one alternative allele. P-values <0.05 
were considered statistically significant. Analyses were performed with the MedCalc 
software and with the R software (https://cran.r-project.org/). 
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3.4. Results 
3.4.1 Pathologic Features 
Among 140 patients from 135 families studied, 52% had C3G (DDD: 21, C3GN: 52) 
and 48% Ig-MPGN (Figure 3.2), a distribution comparable with that of a previously 
reported large cohort of idiopathic MPGN.
300
 Kidney biopsy was performed a median of 
0.3 and 0.4 years after disease onset for Ig-MPGN and C3G, respectively (DDD: 0.6 
years, C3GN: 0.4 years), without significant differences between histology groups 
(Table 3.1). Glomerular C3 staining was intense in all three histology groups. As 
expected, immunohistology showed stronger immunoglobulin and C1q staining in Ig-
MPGN, while EM showed the presence of intramembranous highly electron-dense 
ribbon-like deposits in DDD and higher prevalence of subendothelial and subepithelial 
deposits in Ig-MPGN and C3GN. Interestingly, two patients with intramembranous 
highly electron-dense ribbon-like deposits by EM were classified as Ig-MPGN (C3 3+, 
IgA 0, IgG 3+, IgM 0, C1q 2+ and fibrinogen 0 in one patients, and C3 3+, IgA 1+, IgG 
2+, IgM traces, C1q 1+ and fibrinogen 1+ in the other patients) confirming that some 
DDD cases would not be classified as C3G even with the criterion of dominant C3 (C3 
of ≥2 orders of magnitude of intensity by IF greater than any other immune reactant).253, 
300
 Additionally, we observed a higher degree of mesangial proliferation, endocapillary 
proliferation, and interstitial inflammation in Ig-MPGN compared with C3G (Table 
3.1). 
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Table 3.1. Light microscopy, immunofluorescence and electron microscopy features of 
kidney biopsies in patients classified according to the recent Ig-MPGN and C3G 
classification. 
  Ig-MPGN C3G     
      DDD C3GN 
N 67 73 21 52 
Time Onset to Biopsy (yr) - median 
(IQR) 
0.3 (0.1-2.3) 0.4 (0.1-3.6) 0.6 (0.1-3.9) 0.4 (0.1-3.1) 
Light microscopy     
N. of glomeruli 17.7 (±9.1) 17.3 (±9.8) 16.6 (±9.1) 17.6 (±10.2) 
Sclerotic glomeruli 9% (±15%) 5% (±15%) 2% (±7%) 7% (±16%) 
Crescents 6% (±18%) 4% (±14%) 8% (±22%) 2% (±1%) 
Degree of mesangial proliferation* 1.98 (±0.95)
a
 1.61 (±0.95)
a
 1.82 (±0.78) 1.53 (±1.01) 
Degree of endocapillary 
proliferation* 
1.33 (±1.03)
b
 0.93 (±1.13)
b
 0.97 (±1.18) 0.92 (±1.12) 
Degree of interstitial inflammation* 0.9 (±0.78)
c
 0.6 (±0.86)
c
 0.69 (±0.84) 0.57 (±0.87) 
Degree of interstitial fibrosis* 0.6 (±0.85) 0.37 (±0.72) 0.17 (±0.38) 0.44 (±0.79) 
Degree of arteriolar sclerosis* 0.27 (±0.63) 0.28 (±0.75) 0.03 (±0.12) 0.37 (±0.85) 
Immunofluorescence     
C3* 2.61 (±0.59) 2.71 (±0.46) 2.87 (±0.23) 2.65 (±0.51) 
IgA* 0.55 (±0.85)
d,e1,e2
 0.04 (±0.18)
d
 0.11 (±0.32)
e1
 0.02 (±0.1)
e2
 
IgG* 1.7 (±1.16)
f,g1,g2
 0.18 (±0.4)
f
 0.13 (±0.28)
g1
 0.2 (±0.43)
g2
 
IgM* 1.25 (±0.94)
h,i1,i2
 0.34 (±0.55)
h
 0.58 (±0.55)
i1
 0.22 (±0.42)
i2
 
C1q* 1.16 (±1.04)
k,l1,l2
 0.15 (±0.33)
k
 0.16 (±0.34)
l1
 0.15 (±0.34)
l2
 
Fibrinogen* 0.34 (±0.71) 0.38 (±0.81) 0.35 (±0.84) 0.39 (±0.81) 
Electron microscopy     
Mesangial deposits 51% 63% 53% 68% 
Subepithelial deposits 37%
m,n 48% 10%m,o 63%n,o 
Subendothelial deposits 81%
p 53% 19%p,q 67%q 
Intramembranous granular 
deposits 
37%r 37% 0%r,s 52%s 
Intramembranous highly electron-
dense ribbon-like deposits 
3%t 29% 100%t,u 0%u 
a
p=0.029; 
b
p=0.041; 
c
p=0.043; 
d
p=2x10
-6
; 
e1
p=0.026;
 e2
p=1x10
-5
;
 f
p=1x10
-18
; 
g1
p=2x10
-7
;
 g2
 p=1x10
-17
; 
h
p=1x10
-10
; 
i1
p=0.013; 
i2
p=4x10
-11
; 
k
p=3x10
-11
; 
l1
p=1x10
-4
; 
l2
p=1x10
-9
; 
m
p=0.016; 
n
p=0.005; 
o
p=3x10
-5
; 
p
p=2x10
-7
; 
q
p=0.0002; 
r
p=0.001; 
s
p=3x10
-5
; 
t
p<2x10
-16
; 
u
p<2x10
-16
 
*Degree of mesangial proliferation, endocapillary proliferation, interstitial inflammation, interstitial 
fibrosis, and arteriolar sclerosis, as well as IF findings were graded using a scale of 0 to 3, including 0, 
trace, 1+, 2+ and 3+. 
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Table 3.2. Clinical and laboratory findings in different histology groups. 
  Ig-MPGN C3G     
      DDD C3GN 
N 67 73 21 52 
Gender (% males) 51% 41% 38% 42% 
Data at onset     
Age (y) - Mean (SD) 20.1 (±15.2)
a 15.0 (±11.9)a 15.9 (±11.4) 14.6 (±12.1) 
Microhematuria 86% 86% 90% 84% 
Gross hematuria 35% 38% 38% 38% 
Proteinuria 88% 90% 86% 92% 
Nephrotic syndrome 43% 29% 29% 29% 
Renal impairment 27%
b 14% 5%b 17% 
Trigger event 31% 42% 41% 42% 
     
C3NeFs positive 44%
e 54% 78%e,f 44%f 
Serum C3 (mg/dl) - Median (IQR) 45 (13-77)
c 38 (15-73) 20 (9-46)c,d 44 (17-87)d 
Serum C4  (mg/dl) - Median (IQR) 21 (12-29) 21 (17-27) 26 (20-29) 21 (17-25) 
Low Serum C3 & normal C4 67% 74% 86% 69% 
Plasma SC5b-9 (ng/ml) - Median (IQR) 
515 
(286-1860) 
417 
(228-1033) 
353 
(252-623) 
486 
(215-1140) 
     
Mutation carriers* 17% 18% 14% 20% 
Mutation carriers and/or C3NeFs* 56% 65% 83% 58% 
Familiarity for nephropathy* 11% 14% 10% 16% 
a
p=0.028; 
b
p=0.035;
 c
p=0.047;
 d
p=0.028; 
e
p=0.012;
 f
p=0.016. 
*calculated in unrelated patients (64 Ig-MPGN, 21 DDD and 50 C3GN). 
Nephrotic syndrome was defined as: 24-hour proteinuria exceeding 3.5g in adults or 40mg/h/m2 in 
children together with albuminemia ≤3 g/L. Renal impairment was defined as abnormal serum creatinine 
levels. Familiarity for nephropathy was defined as the presence of at least one relative (up to 3
rd
 degree) 
with biopsy-proven Ig-MPGN/C3G, or proteinuria and/or renal impairment without other apparent cause. 
Quantitative variables are expressed as mean (±S.D.) unless otherwise specified. 
Serum C3: reference 90-180 mg/dl; serum C4: reference 10-40 mg/dl; plasma SC5b-9: reference ≤303 
ng/ml.  
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3.4.2 Genetic screening 
Likely pathogenic variants, defined as genetic variants with Minor Allelic Frequency 
(MAF) ≤0.001, and Combined Annotation Dependent Depletion (CADD) pathogenic 
score ≥10, were detected in 24/135 (18%) unrelated patients, and their prevalence was 
comparable between Ig-MPGN and C3G (17 and 18%) and did not differ between the 
three histology groups (Ig-MPGN, DDD and C3GN, Table 3.2). 
We compared the cumulative allelic frequency of the likely pathogenic variants between 
our cohort and 286 ethnically matched controls from the 1000 Genome Project. The 
patient group is significantly enriched in likely pathogenic variants in all six genes 
(p=1.9x10
-7
) compared to controls, and significant differences were also observed 
between CFB (p=0.032) and C3 (p=1.8x10
-4
) variants separately (Table 3.3). The 
screening of the available affected family members of three unrelated patients showed 
segregation of the variants with the disease, further supporting their involvement in 
disease pathogenesis. 
 
Table 3.3. Cumulative frequency of patients and controls carrying variants with MAF 
<0.001 and CADD pathogenic score ≥10. 
  MAF≤0.001 & CADD≥10 
  Pt Ctr p 
All 0.18 0.03 1.9x10
-07
 
CFH 0.04 0.01 0.118* 
CD46 0.01 0.00 0.321* 
CFI 0.01 0.00 0.242* 
CFB 0.02 0.00 0.032* 
C3 0.09 0.01 1.8x10
-04
 
THBD 0.01 0.00 0.539* 
*Fisher exact test. For this analysis we considered as controls the 286 
European subjects from the 1000 Genome Project for whom the individual 
genotypes were available. Ig-MPGN, n=64; DDD, n=21; C3GN, n=50. 
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Of the likely pathogenic variants (herein defined as mutations), 5 have already been 
described in patients with Ig-MPGN, C3G or aHUS, while 19 are novel (Figure 3.3 and 
Table 3.4).
294, 295, 301-306
 We identified seven additional variants that have previously 
been reported in Ig-MPGN, C3G or aHUS patients, but we did not include these 
variants among the mutations, because they were relatively common in the control 
population or because they were not predicted as damaging by CADD (Table 3.4). 
  
Complement gene variants in Ig-MPGN/C3G  
 
82 
 
 
 
Figure 3.3 
Figure 3.3 Graphical representation of CFH, CD46, CFI, CFB, C3, THBD genes and 
location of the mutations identified in Ig-MPGN (red), DDD (green) and C3GN (blue) 
patients. 
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Table 3.4. Likely pathogenic variants and other variants previously reported in Ig-
MPGN, C3G or aHUS patients. 
Mutation 
Zygo-
sity 
Histology 
group 
ExAC Global 
Frequency 
ExAC NFE 
Frequency 
CADD 
New/ 
known 
Likely pathogenic variants 
    
CFH R78G Hom C3GN 0 0 10 (306-308) 
CFH P88T Hom Ig-MPGN 0 0 19 New 
CFH R127C Het C3GN 0 0 18 New 
CFH Y1008X Hom C3GN 0 0 37 New 
CFH R1210C Het DDD 0.0002 0.0003 16 (256, 294, 301) 
CD46 K66N Het Ig-MPGN 0.0005 0.0009 13 New 
CFI c.1-4C>T Het C3GN 8.2E-06 1.5E-05 18 New 
CFI G57D Het DDD 8.2E-06 0 16 New 
CFB G161R Het Ig-MPGN 6.8E-05 7.9E-05 18 New 
CFB H451R Het Ig-MPGN 0 0 24 New 
CFB R679W Hom Ig-MPGN 0 0 17 New 
C3 V86I Het Ig-MPGN 0 0 12 New 
C3 R505C Het Ig-MPGN 8.2E-06 1.5E-05 16 New 
C3 V619M Het C3GN 0.0003 0.0004 14 New 
C3 G637R Het Ig-MPGN 0.0002 0.0004 11 New 
C3 R1042Q* Het C3GN 0 0 21 (301) 
C3 K1051M Het Ig-MPGN 1.6E-05 3.0E-05 15 (304) 
C3 S1063N Het Ig-MPGN 9.1E-05 0 12 New 
C3 R1303H Het C3GN 8.2E-06 8.2E-06 17 New 
C3 R1320Q Het C3GN 0 0 19 New 
C3 D1362N Het Ig-MPGN 4.9E-05 6.0E-05 10 New 
C3 C1518R Het C3GN 0 0 15 New 
C3 D1625H Het C3GN 0 0 10 New 
THBD P495S Het DDD 0.0004 0.0010 12 (309) 
       
Variants previously reported in Ig-MPGN, C3G or aHUS patients 
 
CFH I216T Het Ig-MPGN 8.2E-05 0 6 (293) 
CFH Q950H Het Ig-MPGN 0.0036 0.0061 13 (307) 
CFH T956M Het C3GN 0.0012 0.0013 17 (302, 303) 
CFI R317W* Het C3GN 9.9E-05 9.0E-05 8 (310) 
CFB E566A
§
 Het 5 patients
$
 0.011 0.010 0 (303, 311) 
C3 K633R
§
 Het C3GN 0.0004 0.0007 2 (306) 
THBD D486Y Het C3GN 0.0065 0.0004 12 (309) 
*One patient carried both C3 R1042Q and CFI R317W; 
$
found in 3 I-MPGN, 1 DDD and 1 C3GN 
patients, 5/135 (0.04) patients with CFB E566A vs. 5/286 (0.02) controls, p=0.302; 
§
one patient 
carried both C3 K633R and CFB E566A variant. 
ExAC Global Frequency: variant frequency in all subjects of the ExAC database; ExAC NFE 
Frequency: variant frequency in non-Finnish European subjects of the ExAC database. In brackets 
the reference of the variants already described in MPGN, C3G or aHUS patients. 
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Mutations were homozygous in four patients, all with parental consanguinity, and 
heterozygous in twenty. Three out of the 4 homozygous mutations affected CFH and 
the fourth CFB. The highest frequency of genetic abnormalities was found in C3 (12 
patients, 50%), followed by CFH (5 patients, 21%), CFB (3 patients, 13%), CFI (2 
patients, 8%), CD46 (1 patient, 4%) and THBD (1 patient, 4%). 
C3 mutations were found only in Ig-MPGN and C3GN but not in DDD (Figure 3.3 and 
Table 3.4). The mutations affected domains involved in C3 convertase formation, such 
as the C345C domain, which binds FB, and the MG5 domain, which participates in the 
C3bBb-C3 interaction, or in domains (MG1, TED and CUBf) involved in the binding of 
C3 with the complement regulators FH and FI.
312-314
 Mutations of CFB, the counterpart 
of C3 in the formation of the alternative pathway C3 convertase, were found in three Ig-
MPGN patients and occurred in functional domains that are involved in C3-FB 
interactions (Figure 3.3).
315
 
Mutations in complement regulatory genes were found both in Ig-MPGN and C3G, 
regardless histologic pattern (Figure 3.3 and Table 3.4). All CFH mutations affected 
domains involved in the C3-FH interaction. Three of the 5 mutations occurred in the N-
terminal short consensus repeat (SCR) 2, at variance with aHUS-associated mutations 
that mainly clustered in SCRs 18-20.
294
 The CFI G57D is in the FIMAC domain, 
critical for FI-mediated C3b degradation,
316
 while the c.-4C>T in the Kozak sequence 
should affect protein translation (Figure 3.3). The CD46 K66N is located within SCR1, 
whose function is unclear.
317
 The THBD P495S has previously been reported in patients 
with aHUS and results in less effective C3b inactivation.
309
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3.4.3 Susceptibility genetic variants 
We then investigated whether common genetic variants causing amino-acid change, and 
non-coding CFH and CD46 variants previously associated with MPGN, promote 
susceptibility to Ig-MPGN or C3G (Table 3.5).
256
 We observed a higher frequency of 
the c.-366A (OR=1.7, 95%CI 1.1-2.6, p=0.015) and the c.*783T (OR=1.6, 95%CI 1.1-
2.5, p=0.023) CD46 alleles in Ig-MPGN patients compared with 286 ethnically matched 
controls from the 1000 Genomes Project. Fifty-nine out of 64 Ig-MPGN patients (92%) 
carried at least one CD46 c.-366A allele. We also observed a higher frequency of the 
CFB R32 allele in Ig-MPGN patients compared to controls (OR=1.8, 95%CI 1.1-2.8, 
p=0.020) and significance fitted with a recessive inheritance mode (OR=1.8, 95%CI 
1.1-3.1, p=0.031). Considering a recessive mode of inheritance, there was a trend of 
association of CD46 c.-366A with C3G, which was significant when we considered 
DDD alone (OR=3.3, 95%CI 1.3-8.4, p=0.009). C3G patients had a higher frequency of 
the CFH V62 (OR=1.7, 95%CI 1.04-2.7, p=0.032) and THBD A473 (OR=2.1, 95%CI 
1.2-3.7, p=0.012) alleles compared with controls and significance fitted with a recessive 
inheritance mode. The CFH V62 also significantly conferred disease risk (recessive 
model) in DDD (OR=3.3, 95%CI 1.1-10.1, p=0.027). Among the 71 C3G patients, 41 
(58%) carried both the CFH V62 and THBD A473 alleles in homozygosity; 24 (34%) 
were homozygous for one susceptibility allele (CFH V62 n=9, THBD A473 n=15); only 
6 (8%) patients carried no homozygous susceptibility variants. 
Complement gene mutations were associated with a risk of Ig-MPGN (OR=6.4, 95%CI 
2.5-16.2, p=0.0001) and C3G (OR=6.9, 95%CI 2.8-16.9, p=3x10
-5
). We then evaluated 
whether mutations and the susceptibility genetic variants, namely homozygous or 
heterozygous CD46 c.-366A allele for Ig-MPGN and homozygous CFH V62 and 
THBD A473 for C3G, synergized to increase disease risk (Figure 3.4). For Ig-MPGN, 
mutations combined with the CD46 c.-366A susceptibility variant increased disease risk 
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(OR=19.2, 95%CI 4.6-80.8, compared with the reference group with subjects lacking 
both mutations and CD46 c.-366A). For C3G, disease risk was highest in subjects 
carrying mutations and both susceptibility variants (OR=23.9, 95%CI 4.0-143.2 
compared with. subjects lacking both mutations and susceptibility variants). The disease 
risk was intermediate (OR=8.2, 95%CI 1.9-35.4) for subjects with mutations and only 1 
susceptibility variant. 
 
  
Table 3.5. Association study between common polymorphic variants and histology groups. 
SNP-ID 
Risk 
Allele 
 
  Group 
Alleles   
Dominant model (homozygous or heterozygous 
for the risk allele)  
Recessive model (homozygous for the risk allele) 
Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
  Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
  Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
CFH c.-331C>T 
(rs3753394) 
T 
 
Ig-MPGN 0.36 1.36 (0.91-2.04) 0.134 0.389  0.56 1.32 (0.77-2.28) 0.315 0.750  0.16 1.85 (0.84-4.06) 0.120 0.198 
 
 
C3G 0.31 1.09 (0.73-1.62) 0.676   0.54 1.18 (0.7-1.99) 0.52   0.08 0.92 (0.36-2.34) 0.87  
 
 
DDD 0.26 0.86 (0.42-1.75) 0.679   0.43 0.77 (0.32-1.89) 0.57   0.10 1.05 (0.23-4.77) 1.00*  
  
 
C3GN 0.33 1.19 (0.76-1.88) 0.443   0.58 1.42 (0.77-2.61) 0.26   0.08 0.87 (0.29-2.61) 1.00*  
  
 
Ctr 0.29     0.49     0.09    
                  
CFH V62I 
(rs800292) 
V 
 
Ig-MPGN 0.80 1.35 (0.84-2.2) 0.218 0.474  0.95 1.20 (0.33-6.65) 1.00* 0.668*  0.66 1.48 (0.84-2.61) 0.172 0.550 
 
 
C3G 0.84 1.69 (1.04-2.7) 0.032   0.97 2.04 (0.46-18.7) 0.544*   0.70 1.85 (1.06-3.24) 0.030  
 
 
DDD 0.88 2.42 (0.93-6.3) 0.061   0.95 1.18 (0.17-52.2) 1.00*   0.81 3.3 (1.08-10.1) 0.027  
  
 
C3GN 0.82 1.49 (0.86-2.6) 0.149   0.98 2.90 (0.43-124.2) 0.485*   0.66 1.51 (0.8-2.83) 0.200  
  
 
Ctr 0.75     0.94     0.56    
                  
CFH Y402H 
(rs1061170) 
H 
 
Ig-MPGN 0.35 0.93 (0.63-1.4) 0.741 0.337  0.55 0.89 (0.51-1.53) 0.661 0.490  0.16 0.99 (0.47-2.09) 0.983 0.411 
 
 
C3G 0.41 1.19 (0.82-1.73) 0.363   0.61 1.13 (0.66-1.91) 0.661   0.21 1.43 (0.75-2.76) 0.277  
 
 
DDD 0.45 1.42 (0.76-2.68) 0.270   0.57 0.98 (0.40-2.39) 0.961   0.33 2.68 (1.02-7.00) 0.063*  
  
 
C3GN 0.39 1.1 (0.71-1.7) 0.662   0.62 1.20 (0.65-2.22) 0.569   0.16 1.02 (0.45-2.32) 0.962  
  
 
Ctr 0.37     0.58     0.16    
                  
CFH E936D 
(rs1065489) 
D 
 
Ig-MPGN 0.21 1.18 (0.73-1.89) 0.504 0.995  0.31 0.94 (0.53-1.69) 0.845 0.321  0.11 2.58 (0.99-6.75) 0.068* 0.084* 
 
 
C3G 0.21 1.18 (0.75-1.86) 0.481   0.39 1.35 (0.79-2.31) 0.270   0.03 0.61 (0.13-2.76) 0.744*  
 
 
DDD 0.14 0.73 (0.30-1.78) 0.492   0.29 0.83 (0.31-2.21) 0.709   0.00 nc 1.00*  
  
 
C3GN 0.24 1.39 (0.84-2.30) 0.202   0.44 1.63 (0.89-3.00) 0.114   0.04 0.88 (0.19-4.00) 1.00*  
  
 
Ctr 0.19     0.33     0.05    
Ig-MPGN, n=64; DDD, n=21; C3GN, n=50, controls, n=286. p: p-value assessed by chi-square test or with Fisher Exact test (*) where appropriate (p-values in bold are statistically significant); Freq: 
frequency; OR: Odds-ratio with 95% confidence interval in brackets; nc: not calculable. SNP: Simple Nucleotide Polymorphism. CD46 c.-366A>G and c.*783T>C are in strong linkage disequilibrium 
(r2=0.98). 
  
Table 3.5. continue 
SNP-ID 
Risk 
Allele 
 
  
Group 
Alleles   
Dominant model (homozygous or heterozygous 
for the risk allele) 
  Recessive model (homozygous for the risk allele) 
 Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
 
Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
 
Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
CD46 c.-652G>A 
(rs2796267) 
A 
 
Ig-MPGN 0.70 1.45 (0.95-2.21) 0.087 0.607  0.90 1.95 (0.80-4.79) 0.137 0.448  0.50 1.42 (0.81-2.49) 0.213 0.859 
 
 
C3G 0.67 1.26 (0.83-1.89) 0.276   0.85 1.28 (0.59-2.76) 0.531   0.48 1.33 (0.77-2.32) 0.303  
 
 
DDD 0.74 1.72 (0.79-3.76) 0.167   0.88 1.63 (0.36-7.34) 0.746*   0.59 2.03 (0.75-5.50) 0.154  
  
 
C3GN 0.64 1.12 (0.71-1.79) 0.620   0.84 1.18 (0.50-2.79) 0.709   0.44 1.14 (0.60-2.15) 0.687  
  
 
Ctr 0.62     0.82     0.41    
                  
CD46 c.-366A>G 
(rs2796268) 
A 
 
Ig-MPGN 0.72 1.68 (1.1-2.56) 0.015 0.555  0.92 2.44 (0.93-6.39) 0.062 0.235  0.52 1.75 (0.99-3.03) 0.056 0.988 
 
 
C3G 0.69 1.44 (0.97-2.13) 0.071   0.86 1.24 (0.59-2.59) 0.566   0.51 1.75 (1.00-2.95) 0.051  
 
 
DDD 0.76 2.11 (1.02-4.37) 0.041   0.86 1.24 (0.35-4.37) 1.00*   0.67 3.3 (1.29-8.42) 0.009  
  
 
C3GN 0.65 1.24 (0.79-1.94) 0.349   0.86 1.24 (0.53-2.92) 0.622   0.45 1.34 (0.73-2.48) 0.344  
  
 
Ctr 0.60     0.83     0.38    
                  
CD46 A309V 
(rs35366573) 
V 
 
Ig-MPGN 0.02 1.19 (0.12-6.09) 0.687* 0.229*  0.03 1.19 (0.12-6.09) 0.658* 0.228  0.00 nc   
 
 
C3G 0.00 nc 0.363*   0.00 nc 0.357*   0.00 nc   
 
 
DDD 0.00 nc 1.00*   0.00 nc 1.00*   0.00 nc   
  
 
C3GN 0.00 nc 0.607*   0.00 nc 0.6*   0.00 nc   
  
 
Ctr 0.01     0.02     0.00    
                  
CD46 c.*783T>C 
(rs7144) 
T 
 
Ig-MPGN 0.71 1.62 (1.07-2.46) 0.023 0.653  0.92 2.44 (0.93-6.39) 0.062 0.235  0.50 1.65 (0.96-2.84) 0.071 0.869 
 
 
C3G 0.69 1.44 (0.97-2.13) 0.071   0.86 1.24 (0.59-2.59) 0.566   0.51 1.75 (0.99-2.95) 0.051  
 
 
DDD 0.74 1.85 (0.91-3.76) 0.083   0.86 1.24 (0.34-6.82) 1.00*   0.62 2.68 (1.08-6.67) 0.029  
  
 
C3GN 0.66 1.3 (0.83-2.03) 0.259   0.86 1.24 (0.53-2.92) 0.622   0.47 1.46 (0.79-2.68) 0.224  
  
 
Ctr 0.60     0.83     0.38    
 
  
Table 3.5. continue 
SNP-ID 
Risk 
Allele 
 
Group 
Alleles   
Dominant model (homozygous or heterozygous for 
the risk allele) 
  
Recessive model (homozygous for the risk 
allele) 
Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-
MPGN 
vs. C3G) 
 
Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
 
Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
CFB L9H 
(rs4151667) 
H 
 
Ig-MPGN 0.03 0.59 (0.20-1.71) 0.328 1.00*  0.06 0.62 (0.21-1.85) 0.392 1.00*  0.00 nc 1.00* 1.00* 
 
 
C3G 0.03 0.55 (0.19-1.58) 0.259   0.06 0.58 (0.20-1.70) 0.312   0.00 nc 1.00*  
 
 
DDD 0.02 0.44 (0.01-2.8) 0.714*   0.05 0.46 (0.06-3.56) 0.705*   0.00 nc 1.00*  
  
 
C3GN 0.03 0.60 (0.11-1.98) 0.607*   0.06 0.63 (0.18-2.16) 0.594*   0.00 nc 1.00*  
  
 
Ctr 0.05     0.10     0.01    
                  
CFB R32W/Q 
(rs12614 & 
rs641153) 
R 
 
Ig-MPGN 0.86 1.75 (1.09-2.81) 0.020 0.104  0.99 4.10 (0.53-31.8) 0.203* 0.089*  0.74 1.79 (1.05-3.05) 0.031 0.286 
 
 
C3G 0.79 1.07 (0.68-1.69) 0.769   0.93 0.62(0.21-1.80) 0.366*   0.66 1.23 (0.71-2.13) 0.452  
 
 
DDD 0.74 0.79 (0.36-1.61) 0.514   0.86 0.29 (0.07-1.09) 0.087*   0.62 1.05 (0.42-2.60) 0.923  
  
 
C3GN 0.82 1.24 (0.72-2.15) 0.436   0.96 1.12 (0.25-5.12) 1.00*   0.67 1.33 (0.70-2.52) 0.386  
                  
CFB G252S 
(rs4151651 ) 
S 
 
Ig-MPGN 0.02 0.56 (0.06-2.43) 0.756* 0.609*  0.03 0.56 (0.06-2.43) 0.753* 0.607*  0.00 nc   
 
 
C3G 0.01 0.26 (0.01-1.67) 0.221*   0.02 0.26 (0.01-1.67) 0.215*   0.00 nc   
 
 
DDD 0.03 0.84 (0.02-5.63) 1.00*   0.05 0.84 (0.02-5.63) 1.00*   0.00 nc   
  
 
C3GN 0.00 nc 0.148*   0.00 nc 0.143*   0.00 nc   
  
 
Ctr 0.03     0.06     0.00 nc   
                  
CFB K565E 
(rs4151659) 
E 
 
Ig-MPGN 0.01 0.67 (0.01-5.27) 1.00* 1.00*  0.02 0.67 (0.01-5.27) 1.00* 1.00*  0.00 nc   
 
 
C3G 0.01 0.63 (0.01-4.94) 1.00*   0.02 0.63 (0.01-4.94) 1.00*   0.00 nc   
 
 
DDD 0.00 nc 1.00*   0.00 nc 1.00*   0.00 nc   
  
 
C3GN 0.01 0.91 (0.02-7.2) 1.00*   0.02 0.91 (0.02-7.2) 1.00*   0.00 nc   
  
 
Ctr 0.01     0.02     0.00 nc   
 
 
  
Table 3.5. continue 
SNP-ID 
Risk 
Allele 
 
Group 
Alleles   
Dominant model (homozygous or heterozygous 
for the risk allele) 
  Recessive model (homozygous for the risk allele) 
Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
 
Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
 
Freq OR (95%CI) 
p 
(vs. Ctr) 
p 
(Ig-MPGN 
vs. C3G) 
CFB E566A 
(rs45484591) 
A 
 
Ig-MPGN 0.02 2.72 (0.42-14.17) 0.166* 0.670*  0.05 2.72 (0.42-14.17) 0.164* 0.668*  0.00 nc   
 
 
C3G 0.01 1.62 (0.15-10.01) 0.631*   0.03 1.62 (0.15-10.01) 0.630*   0.00 nc   
  
 
DDD 0.02 2.76 (0.06-25.48) 0.347*   0.05 2.76 (0.06-25.48) 0.349*   0.00 nc   
  
 
C3GN 0.01 1.15 (0.02-10.39) 1.00*   0.02 1.15 (0.02-10.39) 1.00*   0.00 nc   
  
 
Ctr      0.02     0.00    
                  
C3 P314L 
(rs1047286) 
L  Ig-MPGN 0.16 0.76 (0.45-1.26) 0.279 0.642  0.27 0.60 (0.33-1.09) 0.091 0.426  0.06 1.84 (0.41-6.64) 0.297* 0.709* 
  C3G 0.19 0.88 (0.55-1.41) 0.587   0.33 0.81 (0.46-1.40) 0.446   0.04 1.24 (0.21-4.97) 0.725*  
  DDD 0.21 1.05 (0.49-2.25) 0.902   0.33 0.82 (0.32-2.11) 0.686   0.10 2.89 (0.29-15.07) 0.194*  
   C3GN 0.17 0.81 (0.46-1.41) 0.454   0.33 0.80 (0.42-1.52) 0.494   0.02 0.58 (0.01-4.22) 1.00*  
   Ctr 0.21     0.38     0.03    
                  
C3 R102G 
(rs2230199) 
G  Ig-MPGN 0.21 0.94 (0.59-1.5) 0.784 0.947  0.31 0.71 (0.4-1.26) 0.238 0.473  0.11 2.21 (0.73-6.09) 0.148* 0.271 
  C3G 0.21 0.96 (0.61-1.5) 0.843   0.37 0.92 (0.54-1.58) 0.756   0.06 1.09 (0.26-3.59) 0.774*  
  DDD 0.26 1.24 (0.61-2.54) 0.550   0.38 0.96 (0.38-2.38) 0.923   0.14 2.99 (0.51-12.1) 0.115*  
   C3GN 0.19 0.84 (0.49-1.44) 0.533   0.37 0.90 (0.48-1.69) 0.747   0.02 0.38 (0.01-2.56) 0.484*  
   Ctr 0.22     0.39     0.05    
                  
THBD A473V 
(rs1042579) 
A  Ig-MPGN 0.84 1.31 (0.78-2.21) 0.301 0.216  0.95 0.81 (0.21-4.68) 0.727* 0.104*  0.73 1.51 (0.82-2.77) 0.181 0.458 
  C3G 0.89 2.06 (1.16-3.66) 0.012   1.00 nc 0.131*   0.79 2.04 (1.10-3.79) 0.022  
  DDD 0.93 3.17 (0.96-10.4) 0.066   1.00 nc 1.00*   0.86 3.28 (0.94-11.4) 0.079  
   C3GN 0.88 1.79 (0.94-3.38) 0.071   1.00 nc 0.380*   0.76 1.73 (0.86-3.46) 0.118  
    Ctr 0.80     0.96     0.65    
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Figure 3.4 
Figure 3.4. Panel A. Graphical representation of the risk (expressed as odds-ratio, OR) 
of developing Ig-MPGN obtained through the combination of the mutations with the 
CD46 c.-366A susceptibility variant. The group lacking both mutations and CD46 c.-
366A was taken as reference. Panel B. Risk (expressed as OR) of developing C3G 
obtained through the combination of the mutations with the homozygous CFH V62 and 
homozygous THBD A473 (susceptibility variants). The group lacking both mutations 
and susceptibility variants was taken as reference. Histogram colors are scaled. Below 
each graph, the percentages of patients (Pt) or controls (Ctr) carrying mutations and/or 
susceptibility variants (SV) are reported.  
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3.4.4 Complement component assessment 
Serum C3NeFs, C3 and C4 and plasma SC5b-9 at first investigation are reported in 
Table 3.2. There were no differences in the interval between onset and first 
investigation between histology groups. C3NeFs were positive in 57/116 tested patients 
(49%) and their prevalence was comparable between Ig-MPGN and C3G. However, 
when we considered the DDD and C3GN subgroups separately, the prevalence of 
C3NeFs in DDD (78%) was significantly higher compared with Ig-MPGN (44%, 
p=0.012) and C3GN (44%, p=0.016). Similarly, C3 levels were lower in DDD 
compared with Ig-MPGN (20 vs. 45mg/dl, p=0.047) and C3GN (20 vs. 44mg/dl, 
p=0.028). However, the prevalence of subjects with low C3 and normal C4, and plasma 
SC5b-9 levels did not differ between Ig-MPGN and C3G and among the 3 histology 
groups. 
We then investigated whether genetic or acquired complement alternative pathway 
abnormalities were associated with a specific complement profile. Ig-MPGN and C3G 
patients carrying complement gene mutations, C3NeFs, or both, presented lower C3 and 
higher SC5b-9 levels (Figure 3.5) than patients without mutations or C3NeFs. However, 
in both groups intense C3 deposits in the kidney biopsy were observed (mutation and/or 
C3NeFs 2.8±0.4; no mutation or C3NeFs 2.5±0.7). Additionally, in C3G patients the 
homozygous THBD A473 allele was associated with lower C3 (p=0.026) and higher 
SC5b-9 levels (p=0.005) (Figure 3.6). 
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Figure 3.5 
Figure 3.5. A) Box plot shows that Ig-MPGN patients with mutations and/or C3NeFs 
have lower serum C3 levels than Ig-MPGN patients without mutations or C3NeFs 
(median 15 vs. 66, respectively). B) Box plot shows that C3G patients with mutations 
and/or C3NeFs have lower serum C3 levels than C3G patients without (median 18 vs. 
60, respectively). C) Box plot shows that Ig-MPGN patients with mutations and/or 
C3NeFs have higher plasma SCb-9 levels than Ig-MPGN patients without (median 1391 
vs. 857, respectively). D) Box plot shows that C3G patients with mutations and/or 
C3NeFs have higher plasma SCb-9 levels than C3G patients without (median 983 vs. 
463, respectively). 
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Figure 3.6 
Figure 3.6. A) Box plot shows that C3G patients homozygous for the THBD A473 risk 
allele (AA) have lower serum C3 levels than those heterozygous (AV) or homozygous 
for the 473V allele (VV) (median 27 vs. 62, respectively, p=0.026). B) Box plot shows 
that C3G patients homozygous for the THBD A473 risk allele (AA) have higher plasma 
SC5b-9 levels than heterozygous (AV) or homozygous for the 473V allele (VV) 
patients (median 561 vs. 347, respectively, p=0.005). 
 
 
3.4.5 Clinical parameters and predictors of long-term outcome 
The mean age of onset was higher in Ig-MPGN than in C3G patients (20.1 vs. 15.0 
years, p=0.028) (Table 3.2). The main clinical features at onset were proteinuria and 
microhematuria in all histology groups. Nephrotic syndrome at onset was present in 
43%, 29% and 29% of patients with Ig-MPGN, DDD and C3GN, respectively. Renal 
impairment at onset was observed in 27%, 5% and 14% of Ig-MPGN, DDD and C3GN 
patients, respectively, and the difference was statistically significant between Ig-MPGN 
and DDD (Table 3.2). 
 The median follow-up was 4.8 years (interquartile range, IQR: 1.8-9.5). Sixteen 
patients developed ESRD (time from onset median, IQR: 5.8 years, 1.7-10.6). Kaplan-
Meier survival analysis showed no differences in cumulative renal survival between 
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histologic groups (Figure 3.7). In order to evaluate whether the absence of correlation 
between renal survival and histology was influenced by clinical, therapeutic, 
biochemical or genetic confounders, we performed multivariate Cox proportional-
hazards regression. The results, shown in Tables 3.6 and 3.7, confirmed the absence of 
any significant difference in renal survival between histology groups. However, other 
factors independently predicted progression to ESRD. Indeed, patients without 
mutations or C3NeFs had a higher risk of progression to ESRD, while a higher 
proportion of sclerotic glomeruli or of crescents in the kidney biopsy, and nephrotic 
syndrome at onset, predisposed to ESRD. 
 
 
Figure 3.7 
Figure 3.7. Kaplan-Meier renal survival analysis according to histology groups. 
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Table 3.6. Univariate analysis of the association of long-term renal outcome with 
clinical, laboratory and genetic features. 
  
HR HR 95%CI p 
Gender (male=1, female=2) 1.02 0.38-2.72 0.974 
Familiarity for nephropathy 0.38 0.09-1.71 0.209 
Clinical data at onset 
   
Age of onset 1.01 0.98-1.04 0.588 
Age of onset≥16 1.71 0.64-4.6 0.288 
Gross hematuria 0.85 0.27-2.69 0.780 
Nephrotic syndrome 4.80 1.73-13.34 0.0027 
Renal impairment 4.74 1.76-12.77 0.0021 
High Blood Pressure 2.17 0.76-6.22 0.148 
Trigger 0.35 0.08-1.58 0.171 
Serum C3 1.00 0.99-1.01 0.697 
Serum C4 1.04 0.99-1.09 0.106 
Plasma SC5b-9 1.00 1.00-1.00 0.221 
Treatment 
   
Steroids 1.49 0.42-5.29 0.535 
ACEi/ARB 0.51 0.17-1.53 0.231 
Intensified immunosuppression 3.32 1.04-10.65 0.043 
    
Light microscopy 
   
Sclerotic glomeruli 14.70 1.83-117.91 0.011 
Crescents 22.03 3.27-148.42 0.0015 
Degree of Mesangial proliferation 1.06 0.66-1.71 0.815 
Degree of Endocapillary proliferation 1.15 0.73-1.8 0.546 
Degree of Interstitial inflammation 1.51 0.84-2.72 0.169 
Degree of Interstitial fibrosis 1.11 0.64-1.93 0.702 
Degree of Arteriolar sclerosis 1.35 0.76-2.39 0.308 
Immunofluorescence 
   
C3 0.98 0.38-2.52 0.969 
IgA 0.54 0.16-1.79 0.312 
IgG 1.20 0.81-1.79 0.369 
IgM 1.26 0.76-2.1 0.370 
C1q 1.35 0.85-2.14 0.199 
FBG 1.05 0.60-1.86 0.859 
Electron microscopy 
   
Mesangial deposits 0.66 0.23-1.88 0.440 
Subepithelial deposits 0.76 0.25-2.32 0.635 
Subendothelial deposits 1.28 0.41-3.95 0.672 
Intramembranous non DDD-like 
deposits 
0.50 0.15-1.75 0.281 
Intramembranous DDD-like deposits 0.82 0.22-3.04 0.771 
Diagnosis of C3GN* 0.93 0.33-2.68 0.900 
Diagnosis of DDD9* 0.63 0.13-2.94 0.557 
    
Absence of mutations or C3NeFs 3.20 1.2-9.1 0.025 
*Ig-MPGN was used as reference category. 
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Table 3.6. continue 
  HR HR 95%CI p 
Common genetic variants 
   
CFH c.-331C>T (additive model) 1.61 0.83-3.13 0.159 
CFH c.-331C>T (dominant model) 1.57 0.54-4.55 0.402 
CFH c.-331C>T (recessive model) 2.37 0.82-6.86 0.112 
CFH V62I (additive model) 0.35 0.08-1.46 0.147 
CFH V62I (dominant model) 0.34 0.08-1.49 0.152 
CFH V62I (recessive model) nc 
  
CFH H402Y (additive model) 0.98 0.5-1.92 0.959 
CFH H402Y (dominant model) 1.44 0.32-6.36 0.633 
CFH H402Y (recessive model) 0.80 0.29-2.2 0.661 
CFH E936D (additive model) 1.50 0.77-2.91 0.232 
CFH E936D (dominant model) 1.57 0.58-4.21 0.374 
CFH E936D (recessive model) 2.17 0.62-7.68 0.228 
CD46 c.-652G>A (additive model) 0.82 0.38-1.75 0.600 
CD46 c.-652G>A (dominant model) 0.37 0.1-1.33 0.129 
CD46 c.-652G>A (recessive model) 1.13 0.39-3.26 0.821 
CD46 c.-366A>G (additive model) 0.94 0.44-2 0.866 
CD46 c.-366A>G (dominant model) 0.68 0.15-3.05 0.616 
CD46 c.-366A>G (recessive model) 1.04 0.38-2.87 0.942 
CD46 A309V (additive model) 3.98 0.5-31.35 0.190 
CD46 A309V (dominant model) 3.98 0.5-31.35 0.190 
CD46 A309V (recessive model) nc 
  
CD46 c.*783T>C (additive model) 0.99 0.47-2.1 0.984 
CD46 c.*783T>C (dominant model) 0.87 0.32-2.34 0.781 
CD46 c.*783T>C (recessive model) 1.39 0.31-6.14 0.667 
CFB L9H (additive model) nc 
  
CFB L9H (dominant model) nc 
  
CFB L9H (recessive model) nc 
  
CFB R32W (additive model) 0.50 0.11-2.22 0.365 
CFB R32W (dominant model) 0.50 0.11-2.22 0.365 
CFB R32W (recessive model) nc 
  
CFB R32Q (additive model) 1.07 0.31-3.68 0.914 
CFB R32Q (dominant model) 1.09 0.31-3.85 0.890 
CFB R32Q (recessive model) nc 
  
CFB E566A (additive model) nc 
  
CFB E566A (dominant model) nc 
  
CFB E566A (recessive model) nc 
  
C3 P314L (additive model) 0.93 0.36-2.44 0.885 
C3 P314L (dominant model) 1.03 0.36-2.98 0.952 
C3 P314L (recessive model) nc 
  
C3 R102G (additive model) 1.17 0.51-2.68 0.713 
C3 R102G (dominant model) 1.49 0.55-3.99 0.433 
C3 R102G (recessive model) nc 
  
THBD A473V (additive model) 1.37 0.47-3.95 0.566 
THBD A473V (dominant model) 1.03 0.29-3.64 0.959 
THBD A473V (recessive model) nc     
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Table 3.7 Multivariate analysis of the association of long-term renal outcome with 
clinical, laboratory and genetic features. 
  All patients 
  HR 
HR 
95%CI 
p 
Absence of mutations or C3NeFs 7.1 1.9-26.3 0.004 
Sclerotic glomeruli (% of glomeruli) 69.3 3.1-1553 0.008 
Crescents (% of glomeruli) 39.7 3.3-481 0.004 
Nephrotic syndrome at onset 10.9 2.5-47 0.002 
HR:
 
Hazard ratio calculated by Multivariate Cox proportional-Hazards analysis. 
CI: Confidence Interval.
 
nc: not calculable. Nephrotic syndrome was defined as: 
24-hour proteinuria exceeding 3.5g in adults or 40mg/h/m2 in children together 
with albuminemia ≤3 g/dL. Intensified immunosuppression was also included in 
multivariate Cox Regression analysis but was not significantly associated with 
progress to ESRD (HR=3.9, 95%CI 0.65-23.9, p= 0.138). 
 
 
3.4.6 Treatment 
Seventy-two percent of patients received steroids, 74% angiotensin-converting enzyme 
inhibitors (ACEi) and/or angiotensin receptor blockers (ARB), and 40% intensified 
immunosuppression (cyclosporine A, mycophenolate and/or cyclophosphamide). 
Steroids, ACEi/ARB, or intensified immunosuppression did not correlate with renal 
outcome (Tables 3.6, 3.7 and 3.8). Eculizumab was administered for a mean (±S.D.) 
time of 14.9 (±10.1) months to 14 patients (4 Ig-MPGN, 4 DDD and 6 C3GN patients) 
who did not respond to other treatments. None of them have so far developed ESRD. 
However, with the exception of a previously published case,
318
 the follow-up is too 
short to draw any conclusions.  
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Table 3.8. Treatment received by Ig-MPGN and C3G patients. 
  Ig-MPGN C3G     
      DDD C3GN 
Steroids 85% 64% 55% 68% 
Intensified immunosuppression 45% 35% 39% 34% 
Eculizumab 6% 15% 22% 12% 
ACEi/ARB 80% 68% 83% 62% 
Ig-MPGN, n=67; DDD, n=21; C3GN, n=52. 
Intensified immunosuppression: cyclosporine A, mycophenolate and/or 
cyclophosphamide; ACEi: angiotensin-converting enzyme inhibitors; 
ARB: angiotensin receptor blockers. 
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3.5. Discussion 
In this study, we classified a large cohort of idiopathic Ig-MPGN and C3G patients 
following current criteria,
250, 253
 performed complement gene screening to disclose the 
genetic basis of these diseases, and correlated genetic, and biochemical data with 
clinical features to identify outcome predictors. We find genetic or acquired 
complement abnormalities in the majority of Ig-MPGN and C3G patients. We identify 
mutations in C3, CFB, CFH, CD46 and CFI, in accordance with previous studies,
253, 263
 
and we report a THBD mutation in C3G. Finally, we report that patients without 
complement gene mutations or C3NeFs are characterized by worse renal survival. 
A mutation in C3, leading to hyperfunctional C3 convertase, was reported in a family 
with DDD.
263
 Here, we observe that C3 mutations are also associated with Ig-MPGN 
and C3GN, and that they are the most frequent genetic abnormalities in these groups 
(Tables 3.3 and 3.4, and Figure 3.2). A mutation in the gene encoding FB was reported 
in a patient with C3GN.
311
 Another study described a C3GN patient carrying the E566A 
CFB variant,
261
 which however is present in about 2% of the control population, and in 
our cohort is not associated with either Ig-MPGN or C3G. In our cohort CFB mutations 
clustered in the Ig-MPGN histology group, supporting the association between 
alternative pathway dysregulation and Ig-MPGN. Altogether, mutations in the two 
components of the alternative pathway C3 convertase account for 63% of the identified 
genetic abnormalities. These findings are consistent with recent data showing a higher 
frequency of rare and novel C3 and CFB variants in C3G patients compared with 
controls.
262
 
Twenty-seven percent of mutations occur in genes encoding complement regulators and 
most of them affect CFH.
256
 Notably, we report genetic abnormalities in THBD, an 
anticoagulant endothelial glycoprotein that also regulates the complement alternative 
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pathway (Table 3.4). We describe a Proline to Serine substitution at position 495 of 
thrombomodulin in a DDD male patient with disease onset at age 12, showing non-
nephrotic range proteinuria and microhematuria at onset, low serum C3 levels, and 
C3NeF positivity. The THBD P495S mutation was previously reported in a patient 
affected by aHUS and leads to less efficient inactivation of C3b.
309
 Interestingly, 
another patient carries the THBD D486Y rare variant, which was previously found in 
two aHUS patients and is characterized by defective suppression of the complement 
alternative pathway through FI-mediated C3b inactivation.
309
 The D486Y carrier is a 
female with C3GN, disease onset at age 8, non-nephrotic range proteinuria at onset, low 
serum C3 levels and C3NeF positivity. Neither patient showed signs of TMA and/or 
aHUS. The allelic frequency of the D486Y variant is 0.7% in the general population, 
thus it cannot be considered causative of a rare disease such as C3G, but may instead be 
a disease risk factor. Indeed, C3G is considered a complex multifactorial disease.
264
 It is 
possible that in the two patients carrying P495S and D486Y, the presence of C3NeFs 
acted as a second hit, leading to the development of C3G. 
Thrombomodulin binds C3b and FH and enhances FI-mediated C3b inactivation, 
protecting the kidney from alternative pathway activation.
309
 Thrombomodulin 
expression on glomerular endothelial cells is increased in MPGN and lupus nephritis, 
but not in other glomerulonephritides, and this upregulation may be a protective 
response to counterbalance complement hyperactivation occurring in MPGN 
glomeruli.
319, 320
 Thrombomodulin also exists in soluble form in plasma that increases 
during inflammation and vascular injury, and regulates coagulation and 
inflammation.
321
 
Further evidence supporting the involvement of THBD in the pathogenesis of C3G is 
provided by our finding that the THBD A473 common variant is significantly associated 
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with the risk of developing the disease (Table 3.5). Functional studies on THBD A473V 
are lacking. Based on A473V proximity to D486Y and P495S, we hypothesize that the 
473 residue is relevant for C3b inactivation. Further evidence supporting the 
involvement of THBD in the pathogenesis of C3G is provided by our finding that the 
THBD A473 common variant is significantly associated with the risk of developing the 
disease, and that A473 inactivates C3b less efficiently than 473V. This hypothesis is 
supported by our observation that A473 homozygous C3G patients have lower serum 
C3 and higher SC5b-9 levels than 473V carriers. To identify the functional effects of 
A473V, additional studies are needed. 
We also identified an association between C3G risk and the homozygous CFH V62 
allele (Table 3.5). CFH V62 is less efficient than 62I at binding and inactivating C3b, 
and confers susceptibility to DDD, aHUS, and age-related macular degeneration.
264, 322, 
323
 Association studies highlighted the genetic complexity of both C3G and Ig-MPGN. 
Indeed, we show that the risk of developing C3G or Ig-MPGN strongly increases only 
when mutations are combined with common susceptibility variants (Figure 3.4). The 
combination of mutations with the homozygous CFH V62 and THBD A473 risk alleles 
strongly increases the probability of developing C3G. Conversely, in subjects carrying 
mutations but no susceptibility variants, the risk of C3G is comparable to subjects 
lacking both mutations and susceptibility variants.  
In addition, we observed an association between Ig-MPGN and the CD46 c.-366A and 
the CFB R32 alleles. Functional studies on the CD46 c.-366A>G polymorphism are not 
available, however its presence in the promoter of the gene suggests that it may impact 
gene expression. On the other hand, functional data show that the CFB R32 is 
characterized by an increased capability to form convertase and amplify complement 
activation compared to the 32Q and 32W alleles.
265, 324
   Similarly to C3G, the risk of 
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Ig-MPGN is higher when the mutations are combined with a susceptibility variant, 
CD46 c.-366A. Together, these observations may explain the incomplete penetrance of 
Ig-MPGN and C3G in mutation carriers. Analysis of both mutations and susceptibility 
variants may be useful for defining the risk of developing Ig-MPGN or C3G for 
patients’ relatives during genetic counseling. 
Interestingly, the complex pathogenesis of C3G and Ig-MPGN resembles that of 
another complement-related disorder, the atypical hemolytic uremic syndrome (aHUS), 
in which multiple hits are necessary for the disease to manifest. Such hits include 
triggers (infections, pregnancy or drugs), mutations in one or more complement genes, 
and common at-risk SNPs and haplotypes that act as susceptibility factors for the 
development of the disease.
293, 325, 326
 
Previous studies showed that the CFH Y402H common variant is associated with 
DDD.
264, 327
 In the present cohort, the prevalence of the 402H risk allele is also 
numerically higher in DDD patients compared to controls, however this difference is 
not statistically significant (Table 3.5). There is only a trend (p=0.063), when a 
recessive model of inheritance is considered for the risk allele. Notably, the CFH 402H 
allelic frequencies in the present cohort (0.45 in DDD vs. 0.37 in controls) were similar 
to those observed by Abrera-Abeleda et al. (0.48 in DDD vs. 0.37 in controls), therefore 
the fact that the statistical significance is not reached in this study is probably due to a 
low statistical power. Indeed, there were only 21 DDD patients included in the present 
study. 
Notably, the prevalence of alternative pathway abnormalities (mutations, C3NeFs, low 
C3 levels with normal C4) was comparable in Ig-MPGN and C3G (Table 3.2). In 
particular, 56% and 65% of Ig-MPGN and C3G patients, respectively, carried mutations 
and/or C3NeFs. This finding, which is consistent with a previous report,
256
 suggests that 
Complement gene variants in Ig-MPGN/C3G 
 
104 
 
Ig-MPGN and C3G have more commonalities than previously recognized, and that 
alternative pathway dysregulation plays a pathogenetic role in both. It is plausible that 
in some Ig-MPGN patients, immune-complex deposition may trigger the disease in 
predisposed subjects with genetic or acquired alternative complement pathway 
dysregulation.
253
 
In the present study, nephrotic syndrome at onset and a higher proportion of sclerotic 
glomeruli and crescents in kidney biopsies negatively impact on renal survival during 
follow-up (Table 3.7), in accordance with previous studies.
255, 328
 We also observe a 
higher risk of progressing to ESRD in patients without complement gene mutations or 
C3NeFs. Patients with gene mutations and/or C3NeFs are characterized by very low 
serum C3 levels and high plasma SC5b-9. In patients with Ig-MPGN or C3G carrying 
either complement gene mutations or C3NeFs, dysregulation of the alternative pathway 
in the fluid phase results in massive formation of complement products in blood, such as 
C3b and SC5b-9.
250
 The transfer of these complement products and debris through the 
fenestrated endothelium to subendothelial region and mesangium triggers glomerular 
inflammation and leads to disease.
1
 
The higher risk of ESRD in patients without mutations or C3NeFs might be explained 
by the presence of different underlying mechanisms of complement dysregulation 
resulting in renal damage. These mechanisms could involve solid-phase, kidney-
restricted complement activation, rather than fluid phase activation, as suggested by 
intense glomerular C3 deposits in the face of only modestly altered serum C3 and 
plasma SC5b-9 levels. This complement pattern resembles that of C3G patients with 
genomic rearrangements in FH-related genes (CFHR1-5).
329
 It has been suggested that 
there is continuous activation of C3 along the glomerular basement membrane, which 
under normal conditions is controlled by FH.
330
 Functional studies revealed that the 
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abnormal FH-related proteins compete with FH for binding to C3b and to cell 
surfaces,
330
 causing C3 activation products and C3G to accumulate.
85
 However, CFHR 
rearrangements are rare, and further studies are warranted to evaluate the mechanism 
leading to kidney-restricted activation of complement and the worse renal outcome in 
patients without identified mutations and/or C3NeFs. 
The present study has some limitations that must be taken into account. This is a 
multicenter and retrospective study that may be affected by heterogeneity in the 
diagnostic process and treatment. However, idiopathic Ig-MPGN and C3G are rare, and 
large prospective single center studies are extremely difficult. Moreover, multicenter 
studies have the advantage of increased result generalizability, and they allow more 
patients to be recruited, increasing statistical power.
331
 To reduce the impact of 
heterogeneity, we reviewed all kidney biopsy reports and clinical files centrally. Next-
generation sequencing is not sensitive for the detection of structural chromosomal 
rearrangements and/or insertions or deletions >10bp,
332
 thus we may have missed some 
genetic abnormalities in the studied genes. 
In conclusion, we identify alternative pathway abnormalities, i.e. mutations, C3NeFs, 
and low C3 levels with normal C4, similarly in Ig-MPGN and C3G. These findings do 
not support the current classification that restricts the definition of alternative pathway-
mediated glomerulopathies to patients with "dominant C3" glomerular staining,
253
 since 
the majority of cases classified as idiopathic Ig-MPGN are associated with 
abnormalities of the complement alternative pathway. Moreover, the presence of 
mutations alone does not significantly increase the risk of developing Ig-MPGN or 
C3G, but they do so when combined with common susceptibility variants, underlining 
that Ig-MPGN and C3G are complex diseases. Finally, we report that patients without 
complement gene mutations and/or C3NeFs have a higher risk of progressing to ESRD 
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than patients with identified mutations and/or C3NeFs. These results may also be 
interpreted as indicating the existence of at least two different pathogenic mechanisms 
leading to renal disease progression in Ig-MPGN/C3G. 
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4. CAN CLUSTER ANALYSIS HELP UNRAVEL 
THE PATHOGENESIS OF C3G/IC-MPGN AND 
PREDICT PROGRESSION TO ESRD? 
4.1 Introduction 
Membranoproliferative glomerulonephritis (MPGN) is a chronic nephropathy 
characterized by capillary wall thickening and mesangial expansion owing to increased 
matrix deposition and hypercellularity.
251
 Traditionally, MPGN was classified into types 
I to III based on the presence of subendothelial, highly electron-dense intramembranous 
or subepithelial deposits on electron microscopy (EM), respectively.
248
 Historically, 
many MPGN cases characterized by glomerular immune-complex deposits were shown 
to be secondary to infections, autoimmune diseases or malignancies.
248
 More recently, 
MPGN cases with isolated C3 deposits carrying abnormalities of the alternative 
pathway of complement were observed.
248
 To better reflect disease pathogenesis, a new 
classification based on immunofluorescence (IF) has been proposed that divides MPGN 
into immune-complex-associated MPGN (IC-MPGN), with significant glomerular 
immunoglobulin deposition, and C3 glomerulopathy (C3G), with dominant glomerular 
C3 deposition and little or no immunoglobulin deposition (C3 ≥2 grades of order of 
magnitude greater than any other immune-reactants).
248, 250, 253
 C3G is further divided 
into dense-deposit disease (DDD) and C3 glomerulonephritis (C3GN), the latter lacking 
the intramembranous highly electron-dense deposits.
253
 Notably, patients with 
predominant C3 glomerular staining on immunofluorescence and with proliferative 
patterns of injury other than MPGN are also included in C3G.
253
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The current classification is based on the assumption that IC-MPGN results from the 
deposition of immune complexes that trigger the complement system through the 
classical pathway, whereas C3G arises from abnormalities in the control of the 
complement alternative pathway.
248
 Consequently, evaluation for infections, 
autoimmune diseases or monoclonal gammopathy in IC-MPGN is recommended, and 
conversely genetic screening in complement genes and assays for C3NeF are 
recommended in C3G.
248
 It is believed that only few IC-MPGN patients remain 
idiopathic after extensive evaluation and that the disease may be initiated by 
immunoglobulin deposition and accelerated by complement alternative pathway 
abnormalities only in few IC-MPGN patients.
248, 253, 257
 
The introduction of IF-based classification is an advance to an etiology-based diagnostic 
approach, but some issues require further investigation. First, the widely accepted "C3 
dominant" criterion for the definition of C3G was established using DDD patients as a 
reference group and has not been validated using patients with known dysregulation of 
the complement alternative pathway.
300
 Second, up to 16% of patients shift from IC-
MPGN to C3G and vice versa when a kidney biopsy is repeated.
300, 333
 Third, the 
distinction between DDD and C3GN is not always clear-cut, but there are some 
borderline cases.
253
 Fourth, C3GN and DDD may not reflect different underlying 
causes, since both may affect different members of the same pedigree.
251, 329, 334, 335
 
Finally, complement alternative pathway dysregulation is common in idiopathic IC-
MPGN patients, since most carry C3NeF and/or mutations in complement alternative 
pathway genes.
256
 Additionally, about half of IC-MPGN patients have low serum C3 
with normal C4 levels, indicating activation of the alterative pathway of complement 
without significant activation of the classical pathway.
256
 Altogether, the assumption 
that immunoglobulin-positive MPGN is immune-complex-mediated and that 
immunoglobulin-negative MPGN is complement-mediated has yet to be validated. 
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Recently, unsupervised cluster analysis has been introduced as an objective data-driven 
grouping method to explore whether patients can be classified into relatively 
homogeneous groups.
336
 Simplistically, subjects with many aspects in common are 
placed close together and subjects with many dissimilarities are placed further apart. 
Therefore, the characteristics of the groups are not defined by the operator but arise 
from the data without a priori assumptions. This approach was successfully used to 
identify subtypes in different diseases.
336-338
 
In this study we evaluated whether the “C3-dominant” criterion, currently used to 
distinguish C3G from IC-MPGN patients, divides patients with genetic or acquired 
alternative complement pathway abnormalities from patients without. We show that the 
“C3 dominant” criterion does not effectively capture patients with alternative pathway 
abnormalities. We also explored whether cluster analysis based on histology findings, 
serum complement profile, genetic data and clinical features could be a tool for 
disclosing, in C3G and IC-MPGN patients, distinct disease entities characterized by 
specific pathophysiological mechanisms. Through cluster analysis, we identify four 
groups of patients with relatively homogeneous phenotypes. Patients with known 
alternative pathway abnormalities are separated from those without, the latter clustering 
into a unique group. Patients with alternative pathway abnormalities are further divided 
into three groups with distinct underlying disease pathogenetic mechanisms. These 
clusters are useful for better understanding the pathogenesis of the disease and 
predicting the risk of progression to ESRD. 
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4.2 Specific aims 
1. To evaluate whether the current IF-based C3G/IC-MPGN classification capture all 
patients with complement-mediated pathogenesis, studying a group of patients carefully 
characterized for genetic and biochemical parameters of complement alternative 
pathway dysregulation. 
2. To explore whether cluster analysis based on histologic findings, clinical features, 
serum complement profile and genetic data could be a tool for better understanding the 
disease etiology. 
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4.3 Methods 
4.3.1 Patients 
We analyzed a cohort of 163 patients recruited through the Italian Registry of MPGN 
affected by C3G or IC-MPGN. Patients with secondary MPGN, atypical hemolytic 
uremic syndrome preceding or concomitant to MPGN onset, and patients for whom IF, 
EM or DNA samples were not available were not included in this cohort. Of the 163 
patients, 137 had been described previously.
339
 All participants provided informed 
written consent. The study was approved by the Ethics Committee of the Azienda 
Sanitaria Locale of Bergamo (Italy). The patients were classified according to the recent 
C3G/IC-MPGN classification.
250, 253
 Briefly, patients with a MPGN pattern at light 
microscopy and with glomerular immunoglobulin and C3 deposits by IF were 
considered IC-MPGN, while patients with MPGN or mesangial proliferative patterns 
and “dominant C3” glomerular staining (intensity≥2 magnitude orders than other 
immune-reactants) were considered C3G. By EM, C3G was further classified as DDD 
or C3GN.
253
 
Clinical data were recorded using a standardized Case Report Form. Serum C3 and C4 
levels were assessed by kinetic nephelometry. Plasma SC5b-9 levels were measured 
using the MicroVue SC5b-9 Plus EIA commercial kit (SC5b-9 Plus, Quidel).
294
 C3NeF 
activity was determined by purifying IgG from plasma and assessing their ability to 
stabilize cell-bound C3bBb convertase as previously described.
298
 Targeted Next-
generation sequencing for the genetic screening of all exons and flanking regions of 
CFH, CD46, CFI, CFB, C3 and THBD genes was performed by highly multiplex PCR 
using the Ion AmpliSeq™ Library Kit 2.0 followed by template preparation and 
sequencing on an Ion PGM Sequencer as previously described.
339
 Variants fulfilling the 
following criteria were considered as mutations: 1. variants previously identified in 
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patients with complement disorders and with functional assays supporting variant 
pathogenicity; 2. variants with allele frequency ≤0.001 in any subpopulation of the 
ExAC database and CADD score ≥10. 
 
4.3.2 Variable reduction and Clustering 
We used 101 different variables (Table 4.1): 18 for clinical features at onset or during 
follow-up, 3 for treatment, 30 for pathologic findings (13 for light microscopy, 12 for IF 
and 5 for EM), 10 regarding the serum or plasma complement profile, 4 regarding 
genetic or acquired complement abnormalities and 36 regarding common SNPs of 
complement genes. 
To reduce redundancy, in the first step we performed principal component analysis 
(PCA) of the correlated variables (for example between the 'absolute serum C3 value' 
and the 'abnormally low serum C3' variables or between closely located SNPs with high 
linkage disequilibrium) as shown in Table 4.1. To remove noisy variables,
337
 we 
performed a second principal component analysis including all the independent 
variables and the components derived from the first step. In PCA only significant 
components (i.e. eigenvalue ≥1) were retained, since components with eigenvalue <1 
contribute little to explain the relationships between original variables.
337
 Finally, an 
unsupervised hierarchical clustering was performed based on significant components 
using the Ward's method with Euclidean distances. For the cluster analysis, imputation 
of the missing values was performed with the k-Nearest Neighbor method and iterative 
robust regression. Patients and variables with >20% of missing data were removed. 
  
Cluster analysis in C3G/IC-MPGN 
 
113 
 
Table 4.1. Variables included in the principal component analysis. The number of 
principal components with eigenvalue >1 in each step are also reported. 
Variable 
Principal 
components 
obtained in the 1
st
 
step 
Principal 
components 
obtained in the 2
nd
 
step 
Gender (male/female) 1 18 
Age at onset 1   
log2 Age at onset 
 
  
Age at onset ≥18 years     
Microhematuria at onset 1   
Gross hematuria at onset     
Proteinuria at onset 2   
Nephrotic syndrome at onset 
 
  
Nephrotic syndrome in overall disease course 
 
  
Renal impairment at onset 2   
ESRD at onset 
 
  
Chronic kidney disease in overall disease course 
 
  
ESRD in overall disease course     
Trigger event at onset 1   
High blood pressure at onset 1   
High blood pressure in overall disease course     
Thrombotic microangiopathy in overall disease course 1   
Familiarity for nephropathy 1   
Serum C3 (mg/dl) 2   
log2 Serum C3 (mg/dl) 
 
  
Pathologically low serum C3 (<90 mg/dl) 
 
  
Low serum C3 at 1st investigation and normal in later 
evaluations     
Serum C4 (mg/dl) 1   
log2 Serum C4 (mg/dl) 
 
  
Pathologically low serum C4 (<10 mg/dl)     
Plasma SC5b-9 (ng/ml) 1   
log2 plasma SC5b-9 
 
  
Pathologically high plasma SC5b-9 (>303 ng/ml)     
C3NeF positive 2   
N° of mutations 
 
  
Presence of mutations and/or C3NeF 
 
  
Mutations vs. C3NeF     
% Sclerotic glomeruli on LM 1   
% of crescents on LM 1   
Presence of crescents on LM     
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Table 4.1. Continue. 
Variable 
Principal 
components 
obtained in the 1
st
 
step 
Principal 
components 
obtained in the 2
nd
 
step 
Degree of mesangial proliferation on LM 1   
Presence of mesangial proliferation on LM   ... 
Degree of endocapillary proliferation on LM 1   
Presence of endocapillary proliferation on LM   
 
Degree of interstitial inflammation on LM 1   
Presence of interstitial inflammation on LM     
Degree of interstitial fibrosis on LM 1 
 
Presence of interstitial fibrosis on LM     
Degree of arteriolar sclerosis on LM 1   
Presence of arteriolar sclerosis on LM     
C3 on IF 1   
C3 ≥1+ on IF     
IgA on IF 1   
IgA ≥1+ on IF     
IgG on IF 1   
IgG ≥1+ on IF     
IgM on IF 1   
IgM ≥1+ on IF     
C1q on IF 1   
C1q ≥1+ on IF     
Fibrinogen on IF 1   
Fibrinogen ≥1+ on IF     
Mesangial deposits on EM 1   
Subepithelial deposits on EM 1   
Subendothelial deposits on EM 1   
Intramembranous granular deposits on EM 1   
Intramembranous highly electron-dense ribbon-like deposits 
on EM 1   
Corticosteroid treatment 1   
Massive immunosuppression treatment 
 
  
ACE-inhibitor/Renin-Angiotensin blocker treatment     
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Table 4.1. Continue. 
Variable 
Principal 
components 
obtained in the 1
st
 
step 
Principal 
components 
obtained in the 2
nd
 
step 
CFH c.-331C>T genotype 3 ...  
CFH c.-331C>T carrier C 
 
  
CFH c.-331C>T carrier T 
 
  
CFH V62I genotype 
 
  
CFH V62I carrier V 
 
  
CFH V62I carrier I 
 
  
CFH Y402H genotype 
 
  
CFH Y402H carrier Y 
 
  
CFH Y402H carrier H 
 
  
CFH E936D genotype 
 
  
CFH E936D carrier E 
 
  
CFH E936D carrier D     
CD46 c.-652G>A genotype 2   
CD46 c.-652G>A carrier G 
 
  
CD46 c.-652G>A carrier A 
 
  
CD46 c.-366A>G genotype 
 
  
CD46 c.-366A>G carrier A 
 
  
CD46 c.-366A>G carrier G 
 
  
CD46 c.*783T>C genotype 
 
  
CD46 c.*783T>C carrier T 
 
  
CD46 c.*783T>C carrier C     
CFB L9H genotype 3   
CFB R32W genotype 
 
  
CFB R32Q genotype 
 
  
CFB R32Q carrier R 
 
  
CFB R32Q carrier Q 
 
  
CFB E566A genotype 
 
  
C3 P314L genotype 2   
C3 P314L carrier P 
 
  
C3 P314L carrier L 
 
  
C3 R102G genotype 
 
  
C3 R102G carrier R 
 
  
C3 R102G carrier G     
THBD A473V genotype 1   
THBD A473V carrier A 
 
  
THBD A473V carrier V     
SNP carriers where no variability was observed (i.e. 100% vs. 0%) were removed. 
  
Cluster analysis in C3G/IC-MPGN 
 
116 
 
4.3.3 Identification of Classification Criteria 
For ease of use, quantitative variables were dichotomized by adopting cutoffs. The 
selection of features that could be used to identify clusters was performed in three 
phases as previously described.
340
 First, the odds ratio was calculated for each feature 
with the presence or absence of a cluster as dependent variable and the features with 
statistically significant odds ratios were included in the next phase. Second, logistic 
regression in a backward stepwise procedure was carried out for each cluster separately 
as dependent variable and the features that were significantly associated with one of the 
clusters were selected for the next phase. Third, multinomial logistic regression was 
performed with clusters as the dependent variable and the features from phase two as 
the independent variables and those non reaching significance were discarded. This 
model contained all the finally selected features together. 
In the first step of the algorithm that ascribes patients to clusters, we assigned one point 
to each feature and we summed the points for each patient to obtain a score. ROC curve 
was drawn for this score to determine the optimal cutoff to distinguish clusters. 
 
4.3.4 Statistical analyses 
We used the ANOVA test for continuous variables and the χ2 test (or Fisher Exact test, 
where appropriate) for categorical variables. Survival analyses considered as cumulative 
fractions of patients free of events were estimated using Kaplan-Meier survival curves. 
Multinomial logistic regression was performed with the mlogit package on the R 
platform. Only variables with a p-value <0.05 in the univariate analysis were considered 
in the multivariate analysis. P-values <0.05 were considered statistically significant. 
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4.4 Results 
4.4.1 Features according to the histologic classification 
The histological, biochemical, genetic and clinical features of the 163 patients, 
classified according to the recent C3G/IC-MPGN classification, are reported in Table 
4.2. Sixty-six patients (40%) had C3GN, 24 (15%) DDD and 73 (45%) IC-MPGN. A 
kidney biopsy was performed after a median of 0.4, 1.1 and 0.4 years from the onset for 
C3GN, DDD and IC-MPGN, respectively, without significant differences between 
histologic groups. Age of onset and sex distribution did not differ between histologic 
groups. Complement gene likely pathogenic variants (herein defined as mutations) were 
identified in 24%, 17% and 16% of patients with C3GN, DDD and IC-MPGN, 
respectively (Tables 4.2 and 4.3). C3NeF prevalence was higher in DDD patients (77%) 
compared to C3GN (40%, p=0.003) and IC-MPGN (42%, p=0.005). Overall, in all three 
histologic groups, the majority of the patients carried mutations and/or C3NeF with a 
higher prevalence in DDD (82%) compared to IC-MPGN (51%, p=0.012). 
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Table 4.2. Clinical features, complement assessment, genetic screening and histologic 
features in patients classified according to the recent histologic classification. 
Variable C3GN DDD IC-MPGN 
Overall 
p-value 
N 66 24 73 
 
Gender (% males) 61% 58% 49% 0.387 
Data at onset 
    
Age (yr) 17.7 (±15.5) 14.7 (±11.1) 20.3 (±15.7) 0.259 
Microhematuria 86% 92% 84% 0.743 
Gross hematuria 38% 46% 32% 0.449 
Proteinuria 92% 88% 89% 0.726 
Nephrotic syndrome 30% 25% 44% 0.126 
Renal impairment 20% 4% 25% 0.079 
Trigger event 34% 33% 26% 0.614 
Familiarity for nephropathy 18% 13% 14% 0.763 
     
Serum C3 (mg/dl)  51.5 (±41.9) 32 (±35.7) 50.5 (±39.5) 0.104 
Serum C4  (mg/dl)  21.5 (±8.8) 24.1 (±9.7) 21.1 (±11) 0.436 
Plasma SC5b-9 (ng/ml)  1171 (±1300) 558 (±531) 1029 (±1114) 0.090 
Low serum C3 and normal serum C4 75% 83% 67% 0.262 
     
C3NeF positive 40% 77%
a,c
 42% 0.007 
Mutation carriers 24% 21% 18% 0.648 
Mutation carriers and/or C3NeF 60% 82%
c
 51% 0.042 
     
Data during follow-up 
    
Nephrotic syndrome 47% 50% 70%
a
 0.017 
High blood pressure 35% 25%
c
 51% 0.041 
Chronic kidney disease 32% 29% 44% 0.239 
ESRD 11% 4% 10% 0.763 
Thrombotic microangiopathy 6% 0% 4% 0.587 
     
Histological features 
    
Time Onset to Biopsy (yr) 2.7 (±5.3) 2.8 (±4.1) 2.1 (±4.6) 0.733 
Light microscopy 
    
Sclerotic glomeruli 8% (±17%) 2% (±7%) 8% (±14%) 0.205 
Crescents 3% (±11%) 6% (±20%) 7% (±19%) 0.354 
Degree of mesangial proliferation* 1.7 (±1) 1.8 (±0.7) 2 (±0.9) 0.207 
Degree of endocapillary proliferation* 1 (±1.1) 0.9 (±1.1) 1.3 (±1) 0.244 
Degree of interstitial inflammation* 0.5 (±0.8) 0.6 (±0.8) 0.9 (±0.8)
a
 0.028 
Degree of interstitial fibrosis* 0.4 (±0.7) 0.1 (±0.4) 0.6 (±0.8) 0.059 
Degree of arteriolar sclerosis* 0.3 (±0.8) 0 (±0.1) 0.3 (±0.6) 0.209 
Immunofluorescence 
    
C3* 2.7 (±0.5) 2.8 (±0.3) 2.5 (±0.7) 0.070 
IgA* 0 (±0.1) 0.1 (±0.3) 0.5 (±0.8)
a,b
 2.3x10
-6
 
IgG* 0.2 (±0.4) 0.2 (±0.3) 1.6 (±1.2)
a,b
 4.6x10
-20
 
IgM* 0.3 (±0.5)
b
 0.7 (±0.7) 1.3 (±1)
a,b
 1.1x10
-12
 
C1q* 0.2 (±0.3) 0.1 (±0.3) 1.1 (±1)
a,b
 5.7x10
-13
 
Fibrinogen* 0.3 (±0.7) 0.3 (±0.8) 0.3 (±0.7) 0.990 
Electron microscopy 
    
Mesangial deps 73% 50% 56% 0.062 
Subepithelial deps 59%
b,c
 8%
c
 38% 8.1x10
-5
 
Subendothelial deps 70% 8%
a,c
 82% 2.8x10
-10
 
Intramembr. granular deps 54% 0%
a,c
 46% 2.1x10
-5
 
Intramembr. highly electron-dense 
ribbon-like deps 
0% 100%
a,c
 4% 6.7x10
-26
 
a
significantly different vs. C3GN; 
b
significantly different vs. DDD; 
c
significantly different vs. IC-
MPGN.*Degree of mesangial proliferation, endocapillary proliferation, interstitial inflammation, 
interstitial fibrosis, and arteriolar sclerosis, as well as IF findings were graded using a scale of 0 to 3, 
including 0, trace, 1+, 2+ and 3+. Continuous variables are reported as Mean (±S.D.). Intramembr.: 
intramembranous; deps: deposits. Serum C3: reference 90-180 mg/dl; serum C4: reference 10-40 mg/dl; 
plasma SC5b-9: reference ≤303 ng/ml.  
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Table 4.3. Patients with likely pathogenic variants present in the cohort. 
Likely pathogenic 
variant 
Zyg. Hist. 
Clust. 
/Gr. 
Global 
Freq. 
Max 
Freq. 
Funct. 
studies 
CADD C3NeF 
Serum 
C3 
(mg/dl) 
Plasma 
SC5-9 
(ng/ml) 
New/ 
known 
CFH:R2I 
(chr1:196621252G>T) 
Het DDD 3/3 0 0 No 11 Yes 54 286 (81) 
CFH:R78G 
(chr1:196642281A>G) 
Hom C3GN 1/1 0 0 No 16 No 15 1530 
(81, 306-
308) 
CFH:R78G 
(chr1:196642281A>G) 
Hom C3GN 1/1 0 0 No 16 No 14 4571 
(81, 306-
308) 
CFH:P88T 
(chr1:196643004C>A) 
Hom IC 1/1 0 0 No 29 No 48 2074 (81) 
CFH:P88T 
(chr1:196643004C>A) 
Hom IC 1/1 0 0 No 29 No 5 3596 (81) 
CFH:R127C 
(chr1:196645147C>T) 
Het C3GN 1/1 0 0 No 33 NA 72 2789 (81) 
CFH G133R 
(chr1:196645165G>A) 
Het C3GN 1/1 1.7x10-5 3.0x10-5 No 31 NA 55 355 New 
CFH:Y1008X 
(chr1:196711070delTA) 
Hom C3GN 1/1 0 0 No 32 No 18 NA (81) 
CFH:R1210C 
(chr1:196716375C>T) 
Het DDD 4/3 1.7x10-4 2.8x10-4 Yes 12 No 154 368 
(81, 256, 
294, 301) 
CD46:K66N 
(chr1:207930459A>T) 
Het IC 2/2 5.3x10-4 9.0x10-4 No 13 No 63 466 (81) 
CFI:c.1-4C>T 
(chr4:110723131G>A) 
Het C3GN 1/1 8.4x10-6 1.5x10-5 No 17 Yes 17 399 (81) 
CFI:G57D 
(chr4:110687868C>T) 
Het DDD 3/3 8.2x10-6 6.1x10-5 No 25 Yes 47 321 (81) 
CFI G119R 
(chr4:110685820C>T) 
Het C3GN 1/1 5.3x10-4 9.5x10-4 Yes 22 NA 79 310 (81, 294) 
CFB:G161R 
(chr6:31914966G>A) 
Het IC 2/1 6.9x10-5 3.0x10-4 No 27 Yes 36 1600 (81) 
CFB:H451R 
(chr6:31917278A>G) 
Het IC 2/2 0 0 No 25 Yes 40 1874 (81) 
CFB:R679W 
(chr6:31919196C>T) 
Hom IC 2/2 0 0 No 31 No 20 291 (81) 
CFI:R317W* 
(chr4:110670750G>A) 
Het C3GN 1/1 9.9x10-5 2.3x10-4 No 16 NA 18 NA (81, 310) 
Zyg.: zygosity; Hist.: Histologic group according to the current classification; Global Freq.: variant 
frequency in all subjects of the ExAC database (v0.3); Max Freq.: maximum frequency among the 
subpopulations of the ExAC database (v0.3). Funct. studies: Functional studies supporting pathogenicity 
are available. CADD: CADD Phred score (v1.3). In brackets the reference of the variants already 
described in MPGN, C3G or aHUS patients. Serum C3 in mg/dl; Plasma SC5-9 in ng/ml. IC: IC-MPGN. 
Serum C3: reference 90-180 mg/dl; plasma SC5b-9: reference ≤303 ng/ml. 
*found in the same patient. 
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Table 4.3. Continue. 
Likely pathogenic 
variant 
Zyg. Hist. 
Clust. 
/Gr. 
Global 
Freq. 
Max 
Freq. 
Funct. 
studies 
CADD C3NeF 
Serum 
C3 
Plasma 
SC5-9 
New/ 
known 
C3:R505C 
(chr19:6710823G>A) 
Het IC 2/1 8.3x10-6 1.5x10-5 No 25 Yes 18 495 (81) 
C3:V619M 
(chr19:6707931C>T) 
Het C3GN 1/1 2.9x10-4 0.001 No 22 No 57 561 (81) 
C3:G637R 
(chr19:6707877C>G) 
Het IC 1/2 2.2x10-4 3.8x10-4 No 24 Yes 12 1845 (81) 
C3:I761del 
(chr19:6702553delGAT) 
Het C3GN 1/1 0 0 No 14 No 33 845 New 
C3:I761del 
(chr19:6702553delGAT) 
Het C3GN 1/1 0 0 No 14 No 38 888 New 
C3:R1042Q* 
(chr19:6694471C>T) 
Het C3GN 1/1 0 0 No 32 NA 18 NA (81, 301) 
C3:K1051M 
(chr19:6694444T>A) 
Het IC 1/1 1.6x10-5 3.0x10-5 Yes 23 NA 41 348 (81, 304) 
C3:S1063N 
(chr19:6693465C>T) 
Het IC 1/2 1.1x10-4 8.1x10-4 Yes 10 No 70 235 (81) 
C3:R1303H 
(chr19:6685060C>T) 
Het C3GN 1/1 8.3x10-6 1.5x10-5 No 28 No 25 413 (81) 
C3:R1320Q 
(chr19:6685009C>T) 
Het C3GN 1/1 0 0 No 28 No 15 1087 (81) 
C3:D1362N 
(chr19:6684607C>T) 
Het IC 4/4 4.9x10-5 1.2x10-4 No 11 NA 112 337 (81) 
C3:C1518R 
(chr19:6679214A>G) 
Het C3GN 2/2 0 0 No 26 Yes 6 2520 (81) 
C3:D1625H 
(chr19:6678010G>C) 
Het C3GN 1/1 0 0 No 12 Yes 2 3750 (81) 
THBD:D486Y 
(chr20:23028686G>T) 
Het C3GN 1/1 0 0 Yes 12 Yes 40 1298 (81, 309) 
THBD:P495S 
(chr20:23028659G>A) 
Het DDD 3/3 5.8x10-4 0.001 Yes 6 Yes 18 137 (81, 309) 
Zyg.: zygosity; Hist.: Histologic group according to the current classification; Global Freq.: variant 
frequency in all subjects of the ExAC database (v0.3); Max Freq.: maximum frequency among the 
subpopulations of the ExAC database (v0.3). Funct. studies: Functional studies supporting pathogenicity 
are available. CADD: CADD Phred score (v1.3). In brackets the reference of the variants already 
described in MPGN, C3G or aHUS patients. Serum C3 in mg/dl; Plasma SC5-9 in ng/ml. IC: IC-MPGN. 
Serum C3: reference 90-180 mg/dl; plasma SC5b-9: reference ≤303 ng/ml. 
*found in the same patient. 
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4.4.2 Efficacy of the "C3 dominant" criterion for identifying DDD and alternative 
pathway dysregulation 
We evaluated whether the "C3 dominant" criterion, widely used to define C3G, 
efficiently identifies patients with intramembranous highly electron-dense deposits and 
patients with alternative pathway dysregulation. As shown in Table 4.4, “C3 dominant” 
staining captured 24 out of 27 patients with intramembranous highly electron-dense 
deposits (sensitivity=89%). On the other hand, “C3 dominant” staining had low 
sensitivity (57%) for identifying patients with complement gene mutations and/or 
C3NeF (Table 4.4). Consistently, the "C3 dominant" criterion had low sensitivity (56%) 
for identifying patients with low C3 and normal C4. In addition, compared to IC-
MPGN, C3G patients did not show a significantly higher prevalence of mutations 
and/or C3NeF (64% vs. 53%, p=0.154), or a prevalence of low C3 and normal C4 (76% 
vs. 68%, p=0.240). 
Variability in the interpretation of immune-reactant intensity may lead to 
misclassification of C3G and IC-MPGN.
329
 To overcome bias due to immune-reactant 
intensity misevaluation, we repeated the analyses, including only the extremes of the 
phenotypic continuum in the 163 patients: C3G patients with absent immunoglobulin or 
C1q staining (n=31) vs. IC-MPGN patients with 3+ staining in either at least one of the 
immunoglobulin classes or C1q (n=33) (Table 4.4). Even with this setting, the 
prevalence of mutations and/or C3NeF, as well as the prevalence of low C3 and normal 
C4, were not significantly higher in C3G compared to IC-MPGN (56% vs. 50%, 
p=0.670, and 77% vs. 66%, p=0.333, respectively). Accordingly, with the same setting, 
the sensitivity of IF for identifying patients with complement gene mutations and/or 
C3NeF or for identifying patients with low C3 but normal C4 did not improve (48% and 
50%, respectively).  
Cluster analysis in C3G/IC-MPGN 
 
122 
 
Table 4.4. Sensitivity and specificity of the C3-dominant criterion on IF to capture 
patients with intramembranous electron-dense deposits, mutations and/or C3NeF and 
low serum C3 and normal C4. 
  C3G 
IC-
MPGN 
p 
  "C3 dominant" criterion 
  Sensitivity Specificity 
All patients 
   
Intramembranous electron-dense 
deposits 
0.27 0.04 0.0001 
 
0.89 0.51 
Mutations and/or C3NeF 0.64 0.53 0.154 
 
0.57 0.55 
Low serum C3 and normal C4 0.76 0.68 0.240 
 
0.56 0.55 
       
Only C3G patients with isolated C3 and IC-MPGN 
patients with 3+ staining in any of Ig or C1q*    
Intramembranous electron-dense 
deposits 
0.23 0.03 0.025 
 
0.83 0.49 
Mutations and/or C3NeF 0.56 0.50 0.670 
 
0.48 0.57 
Low serum C3 and normal C4 0.77 0.66 0.333   0.50 0.63 
*C3G patients with no immunoglobulin or C1q staining on IF and IC-MPGN patients with 3+ staining in 
at least one of the immunoglobulins or C1q. C3G, n=90; IC-MPGN, n=73. 
 
 
4.4.3 Clustering analysis 
To investigate the presence of relatively homogeneous groups of patients based on 
histologic, biochemical, genetic and clinical features, we performed unsupervised 
hierarchical cluster analysis using 101 variables reduced to 18 principal components 
(Table 4.1). 
We identified 4 groups (clusters) as shown in Figure 4.1 and Table 4.5. Initially, cluster 
4 was separated from the others. It includes patients with a lower prevalence of 
mutations and/or C3NeF, normal or mildly altered serum C3 (s-C3) levels and later 
onset. Subsequently, cluster 3, which was characterized by a higher prevalence of 
intramembranous electron-dense deposits, was divided from clusters 1 and 2, which 
showed highly increased plasma SC5b-9 levels. Finally, compared to cluster 1, cluster 2 
included patients with stronger IgG and C1q staining. 
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Figure 4.1 
Figure 4.1. Dendrogram illustrating the results of the cluster analysis in 163 patients 
with C3G or IC-MPGN. Each vertical line at the extremity of the dendrogram (bottom) 
represents a patient and the length of the vertical lines represents the degree of 
dissimilarity between patients or groups of patients. The coloured boxes define the four 
clusters. 
 
 
Cluster 1 was composed of 71 patients with a high prevalence of mutations and/or 
C3NeF (70%), low s-C3 (38±30 mg/dl) and very high SC5b-9 levels (1315±1300 
ng/ml). The mean age of onset was 13.6 years. These patients were characterized by few 
crescents (1±4%, p=0.002) and low interstitial inflammation (0.4±0.5, p=2x10
-5
) in the 
kidney biopsy compared to the other clusters. On EM, subendothelial (82%) deposits 
were higher compared to clusters 3 and 4 (p=8x10
-10
). 
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Cluster 2 was composed of 26 patients characterized by a high prevalence of mutations 
and/or C3NeF (76%), low s-C3 levels (28±22 mg/dl) and high SC5b-9 levels 
(1681±1334 ng/ml). Compared to the other clusters, this cluster included patients with 
stronger staining of IgG (1.9±1.1, p=8x10
-8
) and C1q (1.4±1.0, p=5x10
-6
) in the kidney 
biopsy. On EM, subendothelial deposits were more frequent (88%) compared to clusters 
3 and 4 (p=8x10
-10
). Patients in this group had a higher prevalence of nephrotic 
syndrome at onset (65%, p=0.007) compared to the other groups. 
Patients in cluster 3 (n=29) showed a high prevalence of mutations and/or C3NeF (81%) 
and low s-C3 levels (33±29 mg/dl). This cluster was characterized by a higher 
prevalence of intra-membranous highly electron-dense deposits (83%, p=2x10
-20
), and 
lower subepithelial (7%, p=7x10
-4
) and subendothelial (14%, p=8x10
-10
) deposits 
compared to the other three clusters. 
Finally, cluster 4 was composed of 37 patients with a lower prevalence of mutations 
and/or C3NeF (9%, p=9x10
-10
), higher s-C3 (93±42 mg/dl, p=2x10
-16
) and later age of 
onset (31±19 years, p=5x10
-9
) compared to the other three clusters. Interestingly, cluster 
4 included all 7 patients in the present cohort that initially presented C3GN or IC-
MPGN with bright glomerular C3 staining and later developed thrombotic 
microangiopathy in a median time of 3.2 years (IQR, 2.3-5.9 years) from onset. 
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Table 4.5. Clinical features, complement assessment, genetic screening and histologic 
features in patients classified according to the clusters obtained through cluster analysis. 
Variable 1 2 3 4 
Overall 
p-value 
N 71 26 29 37 
 
Gender (% males) 55% 46% 52% 65% 0.493 
Data at onset 
     
Age (yr) 13.6 (±11.1) 20.5 (±13.2)
a,c
 12.6 (±8.1) 30.8 (±19.3)
a,b,c
 4.7x10
-9
 
Microhematuria 90% 83% 96% 72%
a,c
 0.026 
Gross hematuria 38% 27% 50% 30% 0.257 
Proteinuria 94% 92% 90% 81% 0.198 
Nephrotic syndrome 31% 65%
a,c,d
 28% 30% 0.007 
Renal impairment 14% 27% 3%
b
 38%
a,c
 0.002 
Trigger event 32% 24% 23% 36% 0.612 
Familiarity for nephropathy 24%
b,c
 4% 7% 14% 0.048 
      
Serum C3 (mg/dl) 38 (±30) 27.7 (±21.8) 33.1 (±29.2) 93.2 (±42.1)
a,b,c
 2.3x10
-16
 
Serum C4  (mg/dl) 21.3 (±10.2) 17.6 (±8.6)
c,d
 22.6 (±8.7) 24.9 (±10.6) 0.037 
Plasma SC5b-9 (ng/ml) 1315 (±1300)
c,d
 1681 (±1334)
c,d
 519 (±501) 385 (±270) 5.8x10
-7
 
Low serum C3 & normal C4 81% 81% 86% 39% 5.4x10
-5
 
      
C3NeF positive 48%
c
 68% 81% 0%
a,b,c
 1.0x10
-9
 
Mutation carriers 28% 27% 17% 5%
a,b
 0.037 
Mutation carriers and/or C3NeF 70% 76% 81% 9%
a,b,c
 8.5x10
-10
 
      
Data during follow-up 
     
Nephrotic syndrome 46% 85%
a,c
 52% 65% 0.006 
High blood pressure 35% 31% 28% 68%
a,b,c
 0.002 
Chronic kidney disease 23% 50%
a
 31% 59%
a,c
 8.0x10
-4
 
ESRD 3% 8% 7% 22% 0.013 
Thrombotic microangiopathy 0% 0% 0% 19%
a
 5.2x10
-5
 
      
Histological features 
     
Time Onset to Biopsy (yr) 2.6 (±5.1) 2.2 (±4.6) 2.2 (±3.7) 2.6 (±5.2) 0.977 
Light microscopy 
     
Sclerotic glomeruli 5% (±12%) 6% (±10%) 2% (±5%) 18% (±22%)
a,b,c
 1.3x10
-5
 
Crescents 1% (±4%)
b,c,d
 6% (±15%) 14% (±27%) 8% (±19%) 0.002 
Degree of mesangial proliferation* 2 (±0.8)
b,d
 1.5 (±1.2) 2.1 (±0.7)
b,d
 1.6 (±1) 0.020 
Degree of endocapillary 
proliferation* 
1 (±1.1) 1.6 (±1.1) 1.3 (±1.1) 0.9 (±1.1) 0.067 
Degree of interstitial inflammation* 0.4 (±0.5)
b,c,d
 0.8 (±0.7) 0.8 (±0.8) 1.2 (±1) 2.0x10
-5
 
Degree of interstitial fibrosis* 0.2 (±0.4) 0.7 (±0.9)
a,c
 0.2 (±0.5) 1 (±0.9)
a,c
 2.4x10
-7
 
Degree of arteriolar sclerosis* 0.1 (±0.4) 0.3 (±0.6)
c
 0.1 (±0.2) 0.6 (±1)
a,c
 8.0x10
-4
 
Immunofluorescence 
     
C3* 2.6 (±0.7) 2.8 (±0.3) 2.7 (±0.4) 2.6 (±0.5) 0.186 
IgA* 0.2 (±0.5) 0.6 (±0.7)
a,c
 0.1 (±0.3) 0.4 (±0.8) 0.009 
IgG* 0.6 (±0.9) 1.9 (±1.1)
a,c,d
 0.4 (±0.7)
d
 0.9 (±1.2) 7.8x10
-8
 
IgM* 0.8 (±0.9) 1.1 (±0.9) 0.7 (±0.7) 0.7 (±0.9) 0.272 
C1q* 0.5 (±0.8) 1.4 (±1)
a,c,d
 0.2 (±0.5) 0.6 (±1) 4.9x10
-6
 
Fibrinogen* 0.3 (±0.7) 0.8 (±1.1)
a,d
 0.3 (±0.7) 0.1 (±0.3) 0.001 
Electron microscopy 
     
Mesangial deps 73%
c,d
 68% 50% 44% 0.016 
Subepithelial deps 49% 52% 7%
a,b,d
 49% 7.0x10
-4
 
Subendothelial deps 82% 88% 14%
a,b,d
 63%
 a,b
 7.9x10
-10
 
Intramembr. granular deps 55%
c,d
 64%
c,d
 11% 29% 4.0x10
-5
 
Intramembr. highly electron-dense 
ribbon-like deps 
2% 0% 83%
a,b,d
 6% 1.9x10
-20
 
a
significantly different vs. Cluster 1; 
b
significantly different vs. Cluster 2; 
c
significantly different vs. Cluster 
3; significantly different vs. Cluster 4. *Degree of mesangial proliferation, endocapillary proliferation, 
interstitial inflammation, interstitial fibrosis, and arteriolar sclerosis, as well as IF findings were graded 
using a scale of 0 to 3, including 0, trace, 1+, 2+ and 3+. Continuous variables are reported as Mean (±S.D.). 
Intramembr.: intramembranous; deps: deposits. Serum C3: reference 90-180 mg/dl; serum C4: reference 10-
40 mg/dl; plasma SC5b-9: reference ≤303 ng/ml. 
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Clusters 1 and 4 were composed prevalently by C3GN and IC-MPGN patients (Table 
4.6). Cluster 2 included mostly IC-MPGN patients (77%), while cluster 3 was mainly 
composed of DDD patients. Interestingly, 21 out of 24 DDD patients and all 3 IC-
MPGN patients with intramembranous highly electron-dense deposits were included in 
cluster 3. 
 
Table 4.6. Overlapping between histologic groups and clusters. 
 Histologic diagnosis Cluster 1 Cluster 2 Cluster 3 Cluster 4 
Overall 
p-value 
C3GN 41 6 2 17 
 DDD 1 0 21 2 
 IC-MPGN 29 20 6 18 <2.2x10
-16
 
C3GN, n=66; DDD, n=24; IC-MPGN, n=73. 
 
4.4.4 A clinically applicable algorithm for cluster identification 
Then we selected the minimum set that could be used in clinical practice to ascribe 
patients to the new clusters from the histologic, biochemical, genetic and clinical 
features available at onset. The selection of the features that independently correlate 
with the clusters was performed in three phases using binomial and multinomial logistic 
regression (Tables 4.7 and 4.8). We observed that 11 different features associated with 
one or more clusters: mutations and/or C3NeF, serum C3 ≤70 mg/dl, mild-to-severe 
interstitial fibrosis, C1q glomerular staining ≥1+, fibrinogen glomerular staining ≥1+, 
mesangial deposits, intramembranous highly electron-dense deposits, adult-onset, the 
CFH H402Y, the C3 R102G and the THBD A473V variants. 
To finally make up a short, simple and more robust list of criteria, we repeated the 
above analyses, adopting a significance threshold of 0.001 (Tables 4.9 and 4.10). 
Multinomial logistic regression showed that mutations and/or C3NeF, and serum C3 
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≤70mg/dl reduced the probability of belonging to cluster 4 (Relative Risk, RR=0.05, 
p=5.7x10
-4
, and RR=0.03, p=1.3x10
-5
, respectively), while age of onset ≥18 years 
increased this probability (RR=15.9, p=5.5x10
-4
). The presence of C1q glomerular 
deposits (≥1+) increased the probability of belonging to cluster 2 (RR=8.7, p=1.5x10-4) 
and intramembranous electron-dense deposits highly increased the probability of 
belonging to cluster 3 (RR=861, p=1.5x10
-6
) (Table 4.10). 
We empirically combined the results of the above analysis in a 3 step algorithm (Figure 
4.2). Briefly, in the first step, we considered mutations and/or C3NeF, s-C3 ≤70mg/dl, 
age of onset <18 years and the intramembranous dense-deposits. Based on ROC curve 
analysis, patients fell into cluster 4 when they carried fewer than two of the above 
features. Second, patients with intramembranous dense-deposits were classified in 
cluster 3. Third, patients with ≥1+ C1q deposits were assigned to cluster 2 and the 
remaining in cluster 1. The characteristics of these algorithm-identified clusters are 
shown in Table 4.11. The concordance of the algorithm-based classification with the 
cluster analysis is 72% and with the multinomial logistic regression predictions is 88%. 
  
Cluster analysis in C3G/IC-MPGN 
 
128 
 
Table 4.7. Univariate and backward multivariate binomial logistic regression analysis 
to identify the criteria for patients’ classification adopting the 0.05 significance 
threshold. 
Cluster Feature 
Univariate analysis   Multivariate analysis 
OR p   OR p 
1 Age of onset ≥18 years 0.29 7.4E-04 
   
1 Familiarity for nephropathy 3.3 0.010 
   
1 Presence of sclerotic glomeruli on LM 0.36 0.004 
   
1 Serum C3 ≤70 mg/dl 2.8 0.008 
   
1 Plasma SC5b-9 >700 ng/ml 3.1 0.001 
   
1 Mutation carriers and/or C3NeF 2.3 0.013 
 
6.0 0.004 
1 Mutation carriers 2.2 0.046 
   
1 Presence of crescents on LM 0.10 0.000 
 
0.02 1.0x10
-4
 
1 Interstitial inflammation (≥+1) on LM 0.39 3.7E-03 
   
1 Interstitial fibrosis (≥+1) on LM 0.22 2.0E-04 
 
0.03 <0.0001 
1 Arteriolar sclerosis (≥+1) on LM 0.31 0.029 
   
1 Mesangial deposits on EM 2.3 0.020 
 
10.7 0.001 
1 Subendothelial deposits on EM 4.2 4.1E-04 
   
1 Intramembranous granular deposits on EM 2.8 0.005 
   
1 
Intramembranous highly electron-dense 
ribbon-like deposits on EM 
0.03 0.001 
 
3E-04 <0.0001 
1 CFH H402Y genotype 0.66 0.046 
   
1 CFH H402Y  HH & HY vs. YY 2.3 0.011 
 
8.5 0.002 
1 CD46 c.-652G>A  genotype 0.59 0.024 
   
1 CD46 c.-652G>A   GG & GA vs. AA  2.2 0.014 
 
9.7 0.001 
1 CFB R32Q genotype 0.34 0.022 
   
1 CFB R32Q  QQ & RQ vs. RR 0.31 0.018 
 
0.08 0.009 
1 C3 P314L genotype 0.42 0.008 
   
1 C3 R102G genotype 0.39 0.002 
   
1 C3 P314L  LL & PL vs. PP 0.42 0.018 
   
1 C3 R102G  GG & RG vs. RR 0.40 0.009 
 
0.07 2.0x10
-4
 
1 THBD A473V genotype 0.39 0.016 
   
1 THBD A473V  VV & AV vs. AA 0.39 0.024 
 
0.11 0.002 
       
2 Nephrotic syndrome at onset 4.4 0.001 
   
2 Serum C3 ≤70 mg/dl 11.8 0.017 
   
2 Sporadically low serum C3 3.1 0.022 
   
2 Plasma SC5b-9 >700 ng/ml 3.3 0.008 
 
7.6 0.005 
2 C3NeF positive 3.1 0.015 
   
2 Mesangial proliferation (≥+1) on LM 0.22 0.002 
   
2 Endocapillary proliferation (≥+1) on LM 3.7 0.013 
   
2 Interstitial fibrosis (≥+1) on LM 2.6 0.030 
   
2 IgA deposits (≥1+) on IF 4.0 0.005 
   
2 IgG deposits (≥1+) on IF 7.0 1.0E-04 
   
2 C1q deposits (≥1+) on IF  9.4 <0.0001 
 
76.0 2.0x10
-4
 
2 Fibrinogen* on IF 4.4 2.0E-03 
 
54.5 5.0x10
-4
 
2 Subendothelial deposits on EM 4.6 0.024 
   
2 Intramembranous granular deposits on EM 3.6 0.009 
   
2 CFH c.331C>T genotype 1.8 0.047 
   
2 CFH c.331C>T  CC & CT vs. TT 0.22 0.003 
   
2 CFH H402Y genotype 4.9 3.2E-04 
   
2 CFH H402Y  HH & HY vs. YY 0.13 1.0E-04 
   
2 CFH E936D genotype 3.2 3.2E-04 
   
2 CFH E936D  EE & ED vs. DD 0.05 3.5E-05 
 
0.01 4.0x10
-4
 
2 CFH E936D  DD & ED vs. EE 2.6 0.031 
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Table 4.7. Continue. 
Cluster Feature Univariate analysis 
 
Multivariate analysis 
  
OR p 
 
Cluster Feature 
2 CD46 c.-652G>A  genotype 4.9 0.001 
   
2 CD46 c.-652G>A   GG & GA vs. AA  0.13 4.1E-04 
 
0.01 5.0x10
-4
 
2 CD46 c.-366G>A genotype 3.1 0.007 
   
2 CD46 c.-366G>A  GG & GA vs. AA 0.31 0.014 
   
2 CD46 c.*783T>C  genotype 0.27 0.003 
   
2 CD46 c.*783T>C  CC & TC vs. TT 0.25 0.005 
   
       
3 Age of onset ≥18 years 0.25 0.015 
 
0.05 0.027 
3 Renal impairment at onset 0.12 0.040 
   
3 Serum C3 ≤70 mg/dl 4.0 0.031 
   
3 Plasma SC5b-9 >700 ng/ml 0.31 0.018 
   
3 Mutation carriers and/or C3NeF 3.1 0.021 
   
3 C3NeF positive 5.9 3.0E-04 
   
3 IgG deposits (≥1+) on IF 0.26 0.011 
   
3 C1q deposits (≥1+) on IF  0.25 0.015 
   
3 Subepithelial deposits on EM 0.06 6.2E-04 
 
0.06 0.032 
3 Subendothelial deposits on EM 0.06 1.1E-07 
   
3 
Intramembranous granular deposits on 
EM 
0.10 0.002 
   
3 
Intramembranous highly electron-
dense ribbon-like deposits on EM 
244 3.0E-12 
 
453.3 <0.0001 
3 CFH c.331C>T genotype 0.46 0.026 
   
3 CFH c.331C>T  TT & CT vs. CC 0.36 0.016 
   
3 CFH H402Y  YY & HY vs. HH 0.39 0.040 
   
3 CFH E936D genotype 0.42 0.050 
   
3 CFB R32Q genotype 3.0 0.015 
   
3 CFB R32Q  QQ & RQ vs. RR 2.9 0.025 
   
       
4 Age of onset ≥18 years 7.6 1.2E-06 
 
31.6 0.003 
4 Microhematuria at onset 0.28 0.009 
   
4 Proteinuria at onset 0.33 0.041 
   
4 Renal impairment at onset 3.7 0.002 
   
4 Serum C3 ≤70 mg/dl 0.04 <0.0001 
 
0.01 4.0x10
-4
 
4 Plasma SC5b-9 >700 ng/ml 0.12 2.0E-04 
   
4 Mutation carriers and/or C3NeF 0.04 2.8E-08 
 
5E-03 6.0x10
-4
 
4 C3NeF positive 0.02 1.0E-04 
   
4 Mutation carriers 0.17 0.018 
   
4 Presence of sclerotic glomeruli on LM 6.1 <0.0001 
   
4 Interstitial inflammation (≥+1) on LM 3.3 2.7E-03 
   
4 Interstitial fibrosis (≥+1) on LM 5.3 <0.0001 
 
52.7 0.004 
4 Arteriolar sclerosis (≥+1) on LM 3.2 0.013 
   
4 Mesangial deposits on EM 0.35 0.009 
 
0.06 0.011 
4 
Intramembranous granular deposits on 
EM 
0.31 0.017 
 
0.08 0.024 
4 CFB R32W genotype 0.27 0.043 
 
0.01 0.006 
4 C3 P314L genotype 2.3 0.007 
   
4 C3 P314L  PP & PL vs. LL 0.10 0.008 
   
4 C3 P314L  LL & PL vs. PP 2.2 0.039 
   
4 C3 R102G genotype 2.7 5.8E-04 
   
4 C3 R102G  RR & RG vs. GG 0.14 0.003 
   
4 C3 R102G  GG & RG vs. RR 3.1 0.004 
   
4 THBD A473V genotype 3.4 9.2E-04 
   
4 THBD A473V  VV & AV vs. AA 3.8 0.001   21.1 0.025 
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Table 4.8. Features that independently predict clusters obtained by multivariate 
multinomial logistic regression and adopting a 0.05 significance threshold. 
Feature Prevalence 
Group vs. 
reference 
β RR (e
β
) p 
Mutations and/or C3NeF 59% 4 -4.9 0.01 0.009 
Serum C3 ≤70 mg/dl 73% 4 -4.8 0.01 0.002 
Interstitial fibrosis (≥1+) on LM 29% 2 2.8 16 0.003 
  
4 4.1 58 0.008 
C1q deposits ( ≥1+) on IF 40% 2 2.3 10 0.004 
Fibrinogen deposits ( ≥1+) on IF 17% 2 2.8 16 0.006 
Mesangial deposits on EM 62% 4 -4.4 0.01 0.004 
Intramembranous highly 
electron dense deposits 
17% 3 7.1 1240 4.0x10
-6
 
Age of onset ≥18 years 34% 4 5.5 247 0.002 
CFH H402Y: HH & HY vs. YY 58% 2 -3.2 0.04 5.9x10
-4
 
C3 R102: GG & RG vs. RR 34% 4 3.6 35 0.004 
THBD A473V: VV & AV vs. AA 23% 4 3.0 19.8 0.046 
a
The group with the greatest number of patients (cluster 1) was taken as reference group. 
b
Relative 
risk. 
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Table 4.9. Univariate and backward multivariate binomial logistic regression analysis 
to identify the criteria for patients’ classification adopting the 0.001 significance 
threshold. 
Cluster Feature 
Univariate analysis   Multivariate analysis 
OR p   OR p 
1 Age of onset ≥18 years 0.29 7.4x10
-4
 
   
1 Plasma SC5b-9 >700 ng/ml 3.1 6.0x10
-4
 
   
1 Presence of crescents on LM 0.10 2.0x10
-4
 
   
1 Interstitial fibrosis (≥+1) on LM 0.22 2.0x10
-4
 
 
0.17 <0.0001 
1 Subendothelial deposits on EM 4.2 4.1x10
-4
 
 
4.93 1.0x10
-4
 
       
2 IgG deposits (≥1+) on IF 7.0 1.0x10
-4
 
   
2 C1q deposits (≥1+) on IF  9.4 <0.0001 
 
12.37 <0.0001 
2 CFH H402Y genotype 4.9 3.2x10
-4
 
   
2 CFH H402Y  HH & HY vs. YY 0.13 1.0x10
-4
 
   
2 CFH E936D genotype 3.2 3.2x10
-4
 
   
2 CFH E936D  EE & ED vs. DD 0.05 3.5x10
-5
 
 
0.07 0.001 
2 CD46 c.-652G>A   GG & GA vs. AA  0.13 4.1x10
-4
 
 
0.11 8.0x10
-4
 
       
3 C3NeF positive 5.9 3.0x10
-4
 
   
3 Subepithelial deposits on EM 0.06 6.2x10
-4
 
   
3 Subendothelial deposits on EM 0.06 1.1x10
-7
 
   
3 
Intramembranous highly electron-
dense ribbon-like deposits on EM 
244 3.0x10
-12
 
 
209.6 <0.0001 
       
4 Age of onset ≥18 years 7.6 1.2x10
-6
 
 
14.2 5.0x10
-4
 
4 Serum C3 ≤70 mg/dl 0.04 <0.0001 
 
0.02 <0.0001 
4 Plasma SC5b-9 >700 ng/ml 0.12 2.0x10
-4
 
   
4 Mutation carriers and/or C3NeF 0.04 2.8x10
-8
 
 
0.06 3.0x10
-4
 
4 C3NeF positive 0.02 1.0x10
-4
 
   
4 Presence of sclerotic glomeruli on LM 6.1 <0.0001 
   
4 Interstitial fibrosis (≥+1) on LM 5.3 <0.0001 
   
4 C3 R102G genotype 2.7 5.8x10
-4
 
   
4 THBD A473V genotype 3.4 9.2x10
-4
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Table 4.10. Features that independently predict clusters obtained by multivariate 
multinomial logistic regression and adopting a 0.001 significance threshold. 
Feature Prevalence 
Group vs. 
reference
a
 
β RRb (eβ) 
p 
Mutations and/or C3NeF 59% 4 -2.9 0.05 5.7x10
-4
 
Serum C3 ≤70 mg/dl 73% 4 -3.6 0.03 1.3x10
-5
 
Intramembranous highly electron 
dense deposits 
17% 3 6.8 861 1.5x10
-6
 
Presence of C1q deposits (≥1+) 40% 2 2.2 8.7 1.5x10
-4
 
Age of onset ≥18 years 34% 4 2.8 15.9 5.5x10
-4
 
 
a
The group with the greatest number of patients (cluster 1) was taken as reference group. 
b
Relative risk. 
A significance p-value threshold of 0.001 was adopted. 
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Figure 4.2 
Figure 4.2. Criteria for cluster definition. 
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Table 4.11. Clinical features, complement assessment, genetic screening and histologic 
features in patients classified according to the 3-step algorithm clusters. 
Variable 1 2 3 4 
Overall 
p-value 
N 53 32 26 52 
 
Gender (% males) 53% 44% 62% 62% 0.379 
Data at onset 
     
Age (yr) 11.1 (±7.6) 15.7 (±11.1) 14.3 (±10.8) 29.6 (±18.3)
a,b,c
 6.8x10
-11
 
Microhematuria 87% 93% 92% 78% 0.240 
Gross hematuria 42% 25% 46% 33% 0.266 
Proteinuria 92% 97% 85% 87% 0.333 
Nephrotic syndrome 30% 69%
a,c,d
 23% 27% 2.2x10
-4
 
Renal impairment 15% 19% 4% 33%
a,c
 0.015 
Trigger event 35% 16% 30% 34% 0.276 
Familiarity for nephropathy 21% 13% 12% 14% 0.705 
      
Serum C3 (mg/dl)  36.1 (±27.6)
b
 23.4 (±25.1) 32.2 (±34.6) 84.1 (±38)
a,b,c
 2.3x10
-16
 
Serum C4  (mg/dl)  22.3 (±9.5) 17.4 (±10.4)
a,c,d
 23.8 (±9.4) 22.8 (±10) 0.047 
Plasma SC5b-9 (ng/ml)  1284 (±1306)
c,d
 1834 (±1293)
c,d
 546 (±523) 486 (±613) 5.4x10
-8
 
Low serum C3 & normal C4 90% 69% 85% 51% 5.4x10
-5
 
      
C3NeF positive 60% 72% 78% 0%
a,b,c
 1.1x10
-12
 
Mutation carriers 38% 22% 23% 2%
a,b,c
 1.3x10
-4
 
Mutation carriers and/or C3NeF 85% 81% 83% 4%
a,b,c
 2.3x10
-17
 
      
Data during follow-up 
     
Nephrotic syndrome 47% 88%
a,c,d
 46% 56% 0.001 
High blood pressure 30% 41% 23% 60%
a,c
 0.004 
Chronic kidney disease 23% 34% 27% 58%
a,b,c
 0.001 
ESRD 4% 9% 4% 15% 0.177 
Thrombotic microangiopathy 0% 0% 0% 13%
a,b
 0.002 
      
Histological features 
     
Time Onset to Biopsy (yr) 2.6 (±4.6) 1.5 (±2.9) 2.7 (±4) 2.9 (±6.1) 0.600 
Light microscopy 
     
Sclerotic glomeruli 3% (±7%) 6% (±13%) 2% (±6%) 15% (±21%)
a,b,c
 9.1x10
-5
 
Crescents 5% (±17%) 1% (±4%) 6% (±20%) 8% (±18%) 0.378 
Degree of mesangial 
proliferation* 
1.9 (±0.9) 1.8 (±1.1) 1.9 (±0.7) 1.7 (±1) 0.564 
Degree of endocapillary 
proliferation* 
1.2 (±1.2) 1.5 (±1) 1 (±1.1) 0.9 (±1) 0.082 
Degree of interstitial 
inflammation* 
0.4 (±0.6)
b,d
 0.8 (±0.7) 0.7 (±0.8) 1 (±0.9) 0.005 
Degree of interstitial fibrosis* 0.2 (±0.5) 0.5 (±0.8)
a
 0.2 (±0.4) 0.8 (±0.9)
a,c
 1.8x10
-4
 
Degree of arteriolar sclerosis* 0.1 (±0.3) 0.2 (±0.5) 0 (±0.1) 0.6 (±1)
a,c
 1.8x10
-4
 
Immunofluorescence 
     
C3* 2.7 (±0.5) 2.8 (±0.5) 2.8 (±0.3) 2.5 (±0.7) 0.071 
IgA* 0.1 (±0.4) 0.5 (±0.6)
a,c
 0.1 (±0.3) 0.4 (±0.8)
a
 0.004 
IgG* 0.3 (±0.7) 1.6 (±1)
a,c,d
 0.3 (±0.7) 1.1 (±1.2)
a,c
 4.8x10
-9
 
IgM* 0.6 (±0.8) 1.3 (±0.9)
a,c,d
 0.7 (±0.7) 0.8 (±0.9) 0.004 
C1q* 0 (±0.1)
c,d
 1.7 (±0.7)
a,c,d
 0.2 (±0.5)
d
 0.6 (±0.9) 6.9x10
-21
 
Fibrinogen* 0.4 (±0.9) 0.5 (±0.8) 0.3 (±0.8) 0.1 (±0.3)
a,b
 0.037 
Electron microscopy 
     
Mesangial deps 68% 67% 54% 56% 0.473 
Subepithelial deps 48% 48% 12%
a,b,d
 48% 0.008 
Subendothelial deps 76% 89% 8%
a,b,d
 73% 1.2x10
-10
 
Intramembr. granular deps 56% 60% 0%
a,b,d
 40% 6.1x10
-6
 
Intramembr. highly electron-
dense ribbon-like deps 
0% 0% 100%
a,b,d
 2% 5.7x10
-29
 
a
significantly different vs. Cluster 1; 
b
significantly different vs. Cluster 2; 
c
significantly different vs. 
Cluster 3; 
d
significantly different vs. Cluster 4. *Degree of mesangial proliferation, endocapillary 
proliferation, interstitial inflammation, interstitial fibrosis, and arteriolar sclerosis, as well as IF findings 
were graded using a scale of 0 to 3, including 0, trace, 1+, 2+ and 3+. Continuous variables are reported as 
Mean (±S.D.). Intramembr.: intramembranous; deps: deposits. Serum C3: reference 90-180 mg/dl; serum 
C4: reference 10-40 mg/dl; plasma SC5b-9: reference ≤303 ng/ml. 
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4.4.5 Prognostic significance of the new cluster-based classification 
We evaluated whether the four clusters identified by the algorithm were characterized 
by a different renal outcome. Kaplan-Meier analyses showed that patients in the fourth 
cluster of the algorithm-based classification have a higher risk of ESRD during follow-
up (Figure 4.3A). Similar results were obtained with Kaplan-Meier analyses of renal 
outcome in the groups identified by the unsupervised hierarchical cluster analysis 
(Figure 4.3B), while there were no differences between histologic groups or between 
C3G and IC-MPGN (Figure 4.3). 
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Figure 4.3 
Figure 4.3. Kaplan-Meier renal survival analysis according to the clusters defined by 
the 3-step algorithm (panel A), the clusters obtained by the cluster analysis (panel B) 
and the histologic groups (panel C). 
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4.4.6 Differences in complement gene mutation distribution and C3NeF activity 
between clusters 
We evaluated the distribution of the mutations in the different algorithm-identified 
clusters. We observed that mutations affecting C3 and CFB, the two components of the 
alternative pathway C3 and C5 convertases, were more frequent in clusters 1 and 2 
(14% and 23% of patients, respectively) compared to cluster 3 (0%) (Figure 4.4A). At 
variance, no difference was observed between histologic groups or between C3G and 
IC-MPGN (Figure 4.4B). Interestingly, cluster 1 included all 5 patients with 
homozygous CFH mutations. 
To evaluate whether there are differences between C3NeFs characteristics in algorithm-
identified clusters, we analyzed the efficiency of C3NeF to stabilize C3 convertase in 
C3NeF-positive patients. C3NeFs of patients in cluster 1 showed lower C3 convertase 
stabilizing activity (57±34%) compared to cluster 3 (87±23%, p=0.008) (Figure 4.4C), 
while C3NeF activity did not differ between histologic groups or between C3G and IC-
MPGN (Figure 4.4D). 
Comparable results were obtained when we performed the above analyses using the 
groups identified by the unsupervised hierarchical cluster analysis (Figure 4.5). 
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Figure 4.4 
Figure 4.4. Panels A and B. Distribution of the mutations according to the algorithm-
based groups (panel A) and the current histologic classification (panel B). Mutations in 
C3 and CFB are significantly overrepresented in clusters 1 and 2 compared to clusters 3 
and 4 (panel A) but no statistically significant difference are observed between 
histologic groups (panel B) (**p<0.01, *p<0.05). Panels C and D. C3NeF residual 
activity evaluated by hemolytic assay in C3NeF positive patients mutations according to 
the algorithm-based groups (panel C) and the current histologic classification (panel D) 
(*p<0.05). Group 4 is not represented in panel C, since it included no C3NeF positive 
patients. The central box represents the values from 25° to 75° percentile. The blue lines 
represent the medians. A line extends from the minimum to the maximum value, 
excluding "outsiders" (circles) defined as a value that is smaller than the 25° percentile 
minus 1.5 times the interquartile range, or larger than the 75° percentile plus 1.5 times 
the interquartile range. 
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Figure 4.5 
Figure 4.5. A) Distribution according to the newly identified clusters of the mutations. 
Mutations in C3 (dark red) and CFB (light red) are significantly overrepresented in 
clusters 1 and 2 compared to clusters 3 and 4 (**p<0.01, *p<0.05, 
●
p=0.059). B) 
Distribution according to the newly identified clusters of the C3NeF residual activity 
evaluated by hemolytic assay in C3NeF positive patients (**p<0.01). The central box 
represents the values from 25° to 75° percentile. The blue lines represent the medians. A 
line extends from the minimum to the maximum value, excluding "outsiders" (circles) 
defined as a value that is smaller than the 25° percentile minus 1.5 times the 
interquartile range, or larger than the 75° percentile plus 1.5 times the interquartile 
range. 
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4.5 Discussion 
Here, in 163 patients with C3G or IC-MPGN, we first investigated whether the IF-based 
C3G/IC-MPGN classification fits with the underlying pathogenesis leading to different 
patterns of complement activation. We show that a significant number of IC-MPGN 
patients present alternative pathway dysregulation. To better understand the 
pathogenesis of the diseases, we explored the presence of relatively homogeneous 
subgroups through unsupervised cluster analysis based on histological, biochemical, 
genetic and clinical data. C3G/IC-MPGN patients could be divided into 4 clusters 
characterized by specific clinical phenotypes, IF and EM features and complement 
abnormalities. Finally we provide an easy-to-use algorithm to apply in clinical practice 
to ascribe patients into clusters. 
The current C3G/IC-MPGN classification is based on two assumptions. First, in 
idiopathic IC-MPGN, an unidentified antigen induces immunoglobulin production, with 
immune-complex formation, subsequent glomerular deposition and complement 
activation through the classical pathway.
258
 Second, in C3G, C3 deposits with scanty 
immunoglobulins implicate complement activation through the alternative (or the lectin) 
pathway.
248, 252
 Based on these assumptions, C3G patients should show a high 
prevalence of alternative pathway abnormalities, while IC-MPGN should show low 
prevalence.
258
 However, our study provides different evidence. The “C3-dominant” 
staining, which defines C3G, has low sensitivity for capturing patients with complement 
gene mutations and/or C3NeF, or patients with low serum C3 and normal C4 (Table 
4.4). There is no difference in alternative pathway dysregulation prevalence even when 
we compare patients with isolated C3 staining to those with strong 
immunoglobulin/C1q staining. 
Failure to observe a higher prevalence of alternative pathway abnormalities in C3G 
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compared to IC-MPGN could be attributed to the fact that a large number of idiopathic 
IC-MPGN cases carry alternative pathway abnormalities, which are not sufficient to 
cause the disease, but require the glomerular immunoglobulin deposition as a second 
"hit". Alternatively, some C3G cases without alternative pathway abnormalities may be 
secondary to “masked" immunoglobulin deposits, which are not detectable by standard 
immunofluorescence techniques.
341
 In addition, in some IC-MPGN cases carrying 
alternative pathway abnormalities, the presence of immunoglobulins may be a non-
specific finding caused by immunoglobulin entrapment secondary to proteinuria in 
areas of sclerosis or in podocytes.
85, 342
 Independently of the explanation, our findings 
and previous studies document that the presence of significant immunoglobulin/C1q 
staining alone cannot be used to exclude alternative pathway dysregulation.
256, 339
 
To investigate whether C3G/IC-MPGN patients can be subdivided in homogeneous 
groups, we used a statistical approach where the categorization criteria are not defined 
by the operator but arise from the data. Simplistically, patients who have many features 
in common are placed in the same group and those with many differences are placed 
further apart. The analyses show that patients without alternative pathway dysregulation 
(cluster 4) should be placed separately from those with such abnormalities (Table 4.5 
and Figure 4.1). Interestingly, the latter patients are further subdivided into 3 clusters. 
Clusters 1 and 2, with very high SC5b-9 levels and a high prevalence of subendothelial 
deposits, are distinguished from cluster 3, characterized by high prevalence of 
intramembranous electron-dense deposits. Then, cluster 1 is distinguished from cluster 
2, the latter presenting the strongest C1q and IgG staining, and the highest prevalence of 
nephrotic syndrome at onset. We show that these phenotypic-defined clusters can 
partially be explained by differences in mutation distribution in complement genes and 
in C3NeF efficiency to stabilize C3 convertase (Figures 4.4 and 4.5). Patients in clusters 
1 and 2 have higher prevalence of mutations in C3 and CFB, the two components of the 
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alternative pathway C3 and C5 convertases, compared to cluster 3. C3NeFs in cluster 3 
stabilize the C3 convertase more efficiently than those in cluster 1. Remarkably, neither 
the distribution of the mutations, nor the C3NeF efficiency to stabilize the C3 
convertase, were variables that were included in the cluster analysis. This further 
emphasizes the solidity of our findings. 
Zhang and colleagues proposed that C3GN and DDD can be differentiated on the basis 
of different degrees of complement activation at C3 or C5 levels; dysregulation of the 
C5 convertase is greater in C3GN, while dysregulation of the C3 convertase is greater in 
DDD.
343
 This model can be applied to clusters identified here. C5 convertase activity 
would be greater in clusters 1 and 2, as suggested by the higher SC5b-9 levels, leading 
to less electron-dense and more amorphous deposits all along the glomerular membrane 
layer, whereas C3 convertase activity would be greater in cluster 3, leading to denser 
midlayer deposits. This hypothesis is in line with findings here that C3 and CFB 
mutations, which likely affect both the C3 convertase (C3bBb) and the C5 convertase 
(C3bBbC3b), are prevalent in clusters 1 and 2, and that C3NeFs in cluster 3 strongly 
stabilize the C3 convertase. We hypothesize that C3NeFs in clusters 1 and 2 may 
stabilize the C5 convertase more effectively than C3NeFs in cluster 3, similarly to 
previously described C3NeFs
326
. However, further functional studies are needed to 
address this issue. Finally, the combination in cluster 2 of alternative pathway 
abnormalities with C1q deposits, which are always associated with IgG and/or IgM 
deposits, strongly suggests a concomitant activation of both classical and alternative 
pathways. 
At variance with clusters 1-3, cluster 4 is characterized by a low prevalence of 
complement gene mutations and/or C3NeF, and likely normal s-C3 and SC5b-9 (Table 
4.5). Patients present later onset, more advanced interstitial and arteriolar lesions, and a 
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higher risk of ESRD. The latter finding is in line with previous data from our group 
showing a higher risk of ESRD in C3G/IC-MPGN patients without mutations or 
C3NeF.
339
 The higher risk of ESRD in cluster 4 might be explained by the presence of 
peculiar underlying mechanisms of complement dysregulation resulting in renal 
damage. Bright C3 staining with a normal serum complement profile in this cluster 
implies local complement activation on glomerular cells or along the glomerular 
basement membrane,
85
 leading to direct injury of glomerular cells by complement 
effector molecules. The fact that all 7 patients who developed thrombotic 
microangiopathy, an event associated with local complement activation on endothelial 
glomerular cell surface, fall into cluster 4, would support the above hypothesis. On the 
other hand, we would speculate that in patients from clusters 1-3, massive fluid phase 
complement activation results in accumulation of degradation products in the 
glomerulus, but at the same time the associated systemic complement consumption 
prevents direct complement-mediated injury. Alternatively, in some patients from 
cluster 4 the C3 glomerular deposits may be due to a non-specific inflammatory process 
secondary to a glomerulopathy not directly related to complement, as suggested by the 
finding that some MPGN patients carry mutations in podocytopathy-associated 
genes.
152
 
Our approach has multiple advantages. We use a large cohort of C3G and IC-MPGN 
patients. We do not limit our observations to histologic features but integrate them with 
clinical features and markers of the underlying molecular mechanisms. We use a 
statistical approach, where the classification criteria are operator-independent. Patients 
within clusters share common phenotypes and underlying causes. The newly identified 
clusters are useful for predicting the risk of ESRD. Finally, clusters may also be useful 
for identifying the patients who would most benefit from anti-C5 treatment. In 
particular, patients with alternative pathway dysregulation and high SC5b-9, the main 
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features in clusters 1 and 2, may be more likely to respond to this therapy.
343, 344
 
We also provide a simple algorithm for patient assignment into clusters. It combines 
complement features, like complement gene mutations, C3NeFand s-C3 ≤70mg/dl, with 
histologic features, like intramembranous electron-dense deposits and C1q deposits, and 
with age of onset. This algorithm may be useful both in basic and clinical research to 
better define the pathogenesis of C3G/IC-MPGN, and to predict the progression to 
ESRD. 
Some limitations of the present study must be taken into account. Some abnormalities 
previously reported in association with IC-MPGN/C3G, such as DGKE and CFHR 
mutations and rearrangements, as well as autoantibodies against FH and FB, were not 
investigated. Other features relevant to C3G/IC-MPGN pathogenesis that could have 
increased the ability to identify clusters may have been missed. Additionally, this is a 
multicenter and retrospective study that may be affected by heterogeneity in the 
diagnostic process and treatment. Nonetheless, multicenter studies improve patient 
recruitment, increase statistical power and maximize the generalizability of results. 
Treatments might have modified disease presentation and course, affecting our results. 
Conversely, treatment responses may depend on clusters. Finally further future 
discovery of the disease causes will make the use of indirect evidence of alternative 
pathway dysregulation, such as low s-C3 levels, obsolete in the algorithm. 
In conclusion, we identify clusters of C3G/IC-MPGN patients with distinct underlying 
mechanisms and phenotypes. These clusters improve the ability to define the risk of 
ESRD and may be useful to basic and clinical researchers. Finally, we provide an easy-
to-use algorithm to identify clusters by integrating IF and EM features with the 
complement component profile and clinical features. 
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5. DESIGN OF A GENETIC TEST FOR 
IDIOPATHIC NEPHROTIC SYNDROME AND 
SEARCH FOR NOVEL GENES INVOLVED IN THE 
PATHOGENESIS OF SRNS 
5.1 Introduction 
Nephrotic syndrome (NS) is characterized by increased permeability of the glomerular 
barrier to plasma macromolecules resulting in heavy proteinuria that may lead to 
progressive renal function loss and exposes patients to the risk of life threatening 
infections, thromboembolic episodes, and dyslipidemia. NS affects 3-4 children every 
100,000 and accounts for about 30% of primary forms of glomerulonephritis in 
adults.
345
 
Glucocorticoids are first-line treatment and the rationale for immunosuppressive therapy 
relies on the evidence that immune alterations have been identified among affected 
patients.
107
 Specifically, it appears that in some patients T cells promote the production 
of a circulating factor that alters the glomerular permeability of the filtration barrier.
108
 
Most patients respond to corticosteroid therapy with remission of proteinuria (steroid 
sensitive NS, SSNS), while about 20% of them do not (steroid resistant NS, SRNS). 
More than 40% of steroid-resistant cases develop end stage renal disease (ESRD) within 
10 years from diagnosis.
345
 Some of these cases might benefit from other 
immunosuppressive treatments, such as alkylating agents, calcineurin inhibitors or 
Rituximab, which however have significant toxicity profiles.
110
 
Most SSNS patients show minimal change disease (MC) on renal biopsy, while among 
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patients with SRNS the more common histological findings are focal segmental 
glomerulosclerosis (FSGS), MC, and membranous nephropathy (MN) (Table 5.1). 
Other findings in SRNS may be membranoproliferative glomerulonephritis (MPGN), 
IgA nephropathy and amyloidosis. Recognition of the specific conditions underlying 
SRNS is important as they differ with regard to their treatment and outcome. 
SRNS is thought to be caused by a primary defect in the glomerular filtration barrier. 
Along the past 20 years, genetic studies of familial cases of SRNS and genetically 
modified animal models have shown the crucial role of genetic background in the 
pathogenesis of the disease. These studies have led to the identification of the podocyte 
and its interactions with the glomerular basement membrane as a central player in the 
pathogenesis of SRNS. Alterations in several podocyte proteins have been recognized 
as the cause of SRNS.
144
 Interestingly, defects in these proteins can cause isolated 
glomerulopathy, complex syndromes, where the nephropathy is associated with extra-
renal manifestations, or both. There is evidence that mutations affecting proteins that 
make part of the podocyte slit diaphragm, such as nephrin (NPHS1), podocin (NPHS2), 
calcium channel Transient Receptor Potential cation Channel 6 (TRPC6), phospholipase 
C-epsilon 1 (PLCE1) and CD2 Associated Protein (CD2AP), cause SRNS.
145, 146
 SRNS 
can also be caused by mutations in proteins involved in the organization of the podocyte 
cytoskeleton such as alpha-actinin-4 (ACTN4), inverted formin 2 (INF2), myosin 1E 
(MYO1E), Rho GDP dissociation inhibitor alpha (ARHGDIA), and RhoA-activated 
Rac1 GTPase-activating protein (ARHGAP24).
145, 146, 179, 180
 Another group of genes 
associated with SRNS are those encoding proteins involved in focal adhesions that 
tether basal surface of the podocytes to the underlying glomerular basement membrane 
including integrins ITGA3 and ITGB4, EMP2, LAMB2, and collagens COL4A3, 
COL4A4 and COL4A5.
346
 Mutations are also found in genes encoding transcription 
factors that regulate podocyte development and homeostasis including WT1, PAX2 and 
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LMX1B.
110
 The PTPRO gene encoding for the transmembrane podocyte protein Glepp1, 
which regulates the glomerular pressure/filtration rate, has also been associated to 
SRNS.
239
 Moreover, mutations in genes encoding for proteins involved in the 
biosynthesis of CoQ10, such as COQ2, COQ6, ADCK4 and PDSS2, have also been 
described.
214
 Recently, mutations of nucleoporin genes, such as NUP93, NUP107, 
NUP205 and XPO5, have been described to cause SRNS. Nucleoporins make part of the 
nuclear pore complex, a huge protein complex embedded in the nuclear envelope, which 
is involved in nucleocytoplasmic transport, nuclear framework, and gene regulation.
237, 
238
 
Noteworthy, PAX2 and LMX1B are also associated with congenital anomalies of the 
kidney and the urinary tract (CAKUT). CAKUT is the most frequent cause of chronic 
kidney disease in childhood. It comprise a spectrum of malformations that occur at the 
level of the kidney (small kidneys, renal dysplasia, multicystic kidneys, horseshoe 
kidney, renal agenesis), collecting system (megaureter, hydronephrosis, duplex ureter), 
bladder (e.g. ureterocele, vesicoureteral reflux), or urethra (e.g. posterior urethral 
valves).
219
 Proteinuria is also frequently observed.
219
 CAKUT are associated with genes 
involved in the kidney development from the ureteric bud induction stages (GDNF) to 
ureteric bud branching (PAX2, EYA1, SIX1, ROBO2) to glomerular and podocyte 
differentiation (PAX2, LMX1B).
219
 
Other molecular mechanisms have been identified in diseases characterized by 
nephrotic syndrome. As detailed in results of chapters 3 and 4 of this thesis, in patients 
affected by MPGN and C3 glomerulopathy mutations have been described in genes 
encoding proteins involved in the alternative pathway of complement system (CFH, 
CFHR5, CD46, CFI, CFB, C3 and THBD).
81
 Moreover, mutations in DGKE, the gene 
encoding for diacylglycerol kinase epsilon, have been found in MPGN, atypical 
Genetics of SRNS 
 
148 
 
hemolytic uremic syndrome and SRNS.
152, 347, 348
 
Membranous nephropathy (MN) is characterized by the deposition along the capillary 
walls of IgG auto-antibodies, commonly against the M-type phospholipase A2 receptor. 
Although it is an immune-mediated disease, a genetic background has been 
demonstrated. Indeed, a strong association between HLA-DQA1 and PLA2R1 gene 
variants and idiopathic MN has been shown.
273
 
IgA nephropathy (IgAN) is another disorder affecting kidney glomeruli. Its typical 
presentation is hypertension or mild oedema in young oligosymptomatic adults.
134
 
Hematuria and chronic kidney disease are the main characteristic, while NS is observed 
in 10% of patients.
278
 Among patients with NS 48% show complete remission, 32% 
partial remission and 20% no response to treatment.
278
 
IgAN is an immune-mediated disease caused by abnormal deposition of deficient O-
linked glycans IgA1 antibodies. Nonetheless, multiple susceptibility loci for IgAN have 
been identified implicating defects in adaptive immunity (HLA genes and), innate 
immunity (VAV3, DEFA, TNFSF, CARD9, ITGAM, ITGAX and HORMAD2) and the 
alternative pathway of complement (CFHR1).
279, 282
 Interestingly, the presence of 
components of the complement alternative pathway, but not of the classical pathway, in 
the kidney specimens and the increased susceptibility for IgAN in CFHR1 deleted 
subjects underline the role of the complement alternative pathway.
282
 This links IgAN to 
MPGN since the alternative pathway of complement is the milestone of the MPGN 
pathogenesis.
81, 349
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Table 5.1. Frequency of primary glomerulopathies. 
Type of Primary Glomerulopathy  
Frequency (%) No 
remission 
(%) 
ESRD (%) 
Childhood Adults 
Minimal change nephropathy 80-95 10-30 10-35 <5 
Focal segmental glomerulosclerosis  4-10 10-30 40-89 0-55 
Membranoproliferative glomerulonephritis  4-7 4-15 95 40-90 
Membranous nephropathy  2-4 23-30 50-67 30-50 
Other (mesangioproliferative 
glomerulonephritis, IgA nephropathy etc.) 
4-5 15-47 <90 20 
Modified from Rugarli (MASSON, 1997),
350
 McGrogan (NDT, 2011)
135
 and eMedicine 
(emedicine.medscape.com). 
 
 
Recurrence of proteinuria after renal transplantation is observed in approximately 30 to 
50% of patients with NS and negatively impacts graft survival. Genetic forms rarely 
recur after transplantation,
351
 providing further evidence that the disease originates from 
a primary glomerular injury. So far, abnormalities in known genes account for about 
40% of familial and about 20% of sporadic cases with primary SRNS. Hence, other 
genes are probably involved in the pathogenesis of SRNS. Other loci have been linked 
to familial SRNS, even if the corresponding genes have not been identified yet, further 
supporting a highly genetic heterogeneity of this disease.
352
 
Genetics have been recently experienced a dramatic change with the introduction of 
next generation sequencing (NGS), which allows rapid and low cost sequencing of 
genomic regions, which would require months of work with classic Sanger sequencing. 
NGS has been recently applied to the discovery of new causal variants and candidate 
genes for various Mendelian disorders including SRNS.
179
 In addition, de novo variants 
were also identified for sporadic cases, which would have not been possible without 
NGS.
353
 However its application to clinical diagnosis is still in its infancy, since the 
accuracy of mutation detection should be improved in order to become a viable 
option.
354-356
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Understanding of the genetic factors that contribute to the development of SRNS would 
provide invaluable information that could be used for early diagnosis, more precise 
treatment decisions and genetic counselling in patients and families. Creating a NGS 
panel that comprises genes associated with different glomerulonephritides could be 
helpful to reach diagnosis in a part of NS patients, in whom renal biopsy is often 
contraindicated (e.g. due to coagulation disorders). It may also improve the accuracy of 
histologic diagnosis and contribute to more targeted therapies. Here is presented the 
design and the set-up of a NGS panel for glomerular disorders and nephrotic syndrome. 
Its application in a SRNS cohort resolved a significant percentage of cases and suggests 
a role of the CAKUT-associated genes in the pathogenesis of SRNS. Finally, research 
of novel SRNS-genes identified EPB41L5 as a candidate gene for SRNS. 
 
 
  
Genetics of SRNS 
 
151 
 
5.2 Specific aims 
 
1. To create a NGS based genetic test containing genes associated with the most 
common primary proteinuric glomerular disorders. 
2. To search for mutations in known SRNS-associated genes in patients with the 
sporadic and the familial form of SRNS, in order to evaluate the prevalence of 
mutations in patients. 
3. To evaluate whether SRNS patients carry mutations in genes associated with other 
primary proteinuric glomerular disorders. 
4. To search for new gene/s involved in the pathogenesis of SRNS by screening selected 
candidate genes in the entire cohort. 
5. To search for new gene/s involved in the pathogenesis of SRNS in familial cases 
without mutations in the known genes using autozygosity and linkage studies all along 
the genome and whole exome studies. 
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5.2 Methods 
5.2.1 Patients 
Patients have been recruited by the Registry of Steroid Resistant Nephrotic Syndrome 
established at the Clinical Research Centre for Rare Diseases Aldo e Cele Daccò 
(CRCRD). Clinical data for all patients have been collected either by direct interview or 
by examining the clinical files sent by external nephrology units. All participants 
provided informed written consent. The study was approved by the Ethics Committee of 
the Azienda Sanitaria Locale of Bergamo (Italy). 
 
5.2.2 Search strategy and selection criteria to identify genes associated with kidney 
glomerular disorders and nephrotic syndrome 
We searched PubMed, Google Scholar and the OMIM database between April, 2015, 
and July 31, 2015, for the following search terms: 
“nephrotic syndrome”, “steroid resistant nephrotic syndrome”, “focal segmental 
glomerulosclerosis”, “FSGS”, “minimal change disease”, “minimal change nephrotic 
syndrome”, “congenital anomalies of the kidney and the urinary tract”, “CAKUT”, 
“membranoproliferative glomerulonephritis”, “mesangiocapillary glomerulonephritis”, 
“mesangioproliferative glomerulonephritis”, “dense deposit disease”, “C3 
nephropathy”, “C3 glomerulonephritis”, “C3 glomerulopathy”, “IgA-nephropathy”, 
“IgA glomerulonephritis”, “IgA nephritis”, “membranous nephropathy”, “membranous 
glomerulonephritis”, “C1q nephropathy”, and “fibrillary glomerulonephritis”. 
The above terms were searched at the OMIM database as is. At PubMed each one was 
combined with the following terms: “... AND (gene OR genet* OR mutat*)”, while at 
Google Scholar was combined with: “... AND (gene OR genetic OR mutation)” 
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Restriction for English language was applied. 
Original research and reviews on the genetic causes of the above disorders were 
selected. The references of the reviews were also evaluated to identify more genes. Only 
genes causing glomerular disorders and/or nephropathy in human beings were selected. 
Among the CAKUT-associated genes, only those associated with proteinuria were 
selected. 
 
5.2.3 Selection of the candidate genes 
To select the candidate genes different databases and software were used: 
Gene expression profiling by next generation sequencing (RNA-seq) in normal tissues 
were obtained from the RNA Seq Atlas (http://medicalgenomics.org/rna_seq_atlas).
357
 
To evaluate a prevalent expression in kidney, for each gene the median tissue 
expression was subtracted from the kidney expression value. 
The Mouse Genome Informatics (MGI) database that enables access to spontaneous, 
induced, and genetically-engineered gene mutations and their strain-specific phenotypes 
and link them to the human homologues. Phenotypic terms present in MGI were 
obtained for all available genes (http://www.informatics.jax.org/) using the Batch query 
search engine. The phenotypic terms present in the Mouse Genome Informatics (MGI) 
database were divided in 3 subgroups: terms related to glomerulopathy and nephrotic 
syndrome (n=99, Table 5.2), terms related to other kidney and urinary tract 
abnormalities (n=263) and terms not related to kidney (n=7,796). 
Disease-causing genes are not expected to tolerate mutations. Two indexes gene 
mutation tolerance were used: the Gene-level Integrated Metric of negative Selection, 
GIMS (data were obtained from http://glom.sph.umich.edu/GIMS/),
358
 and the Residual 
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Variation Intolerance Score, RVIS (data were obtained from http://genic-
intolerance.org/).
359
 For GIMS a lower number indicates stronger negative selection. 
For RVIS a gene with a score close to 0 has less functional variants and is defined as 
“intolerant”. 
The Podocyte Prediction Score, a score for defining the importance of a gene for the 
podocyte, was obtained through Support Vector Machine learning using genome-wide 
expression data of normal murine podocytes, mesangial, and endothelial cells.
359, 360
 
Prioritization was performed using 3 different tools (Endeavour, ToppGene e 
GeneDistiller). For technical limitations during the analyses with ToppGene and 
GeneDistiller, the Test gene set was divided in 3 parts. The following SRNS, MPGN 
and MN associated genes were used as training set. 
- SRNS: NPHS2, NPHS1, PLCE1, LAMB2, PTPRO, MYO1E, WT1, TRPC6, CD2AP, 
INF2, ARHGDIA, ARHGAP24, ACTN4, PAX2, ADCK4, EMP2, TTC21B, CRB2, 
CUBN, SMARCAL1, COQ2, COQ6, LMX1B, COL4A4, COL4A3, COL4A5, MYH9, 
ANLN 
- MPGN: CFB, CFH, C3, CFI, CD46, THBD, DGKE, CFHR5 
- MN: PLA2R1 
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Table 5.2. Phenotypic terms present in the Mouse Genome Informatics database that were 
considered as related to glomerulopathy and nephrotic syndrome. 
glomerulonephritis delayed kidney development 
abnormal renal glomerulus basement membrane morphology abnormal kidney cortex morphology 
increased renal glomerulus basement membrane thickness abnormal kidney development 
abnormal renal glomerulus morphology kidney failure 
increased renal glomerulus apoptosis abnormal basement membrane morphology 
renal glomerulus hypertrophy impaired basement membrane formation 
abnormal renal filtration rate albuminuria 
cortical renal glomerulopathies erythruria 
renal fibrosis hemoglobinuria 
renal glomerulus atrophy erythrocyturia 
renal necrosis decreased circulating serum albumin level 
decreased renal plasma flow rate albuminuria 
abnormal renal glomerular filtration rate abnormal circulating serum albumin level 
decreased renal glomerular filtration rate increased glomerular capsule space 
renal glomerulus fibrosis glomerular crescent 
absent renal glomerulus glomerulosclerosis 
renal glomerular synechia abnormal glomerular mesangium morphology 
increased renal glomerulus lobularity abnormal glomerular capillary endothelium morphology 
abnormal renal corpuscle morphology abnormal glomerular capillary morphology 
abnormal renal glomerulus basement membrane thickness abnormal glomerular endothelium fenestra morphology 
abnormal renal plasma flow rate dilated glomerular capillary 
renal glomerulus lipidosis absent tubuloglomerular feedback response 
decreased renal glomerulus basement membrane thickness abnormal juxtaglomerular apparatus morphology 
abnormal renal protein reabsorption abnormal juxtaglomerular cell morphology 
abnormal podocyte morphology absent glomerular endothelium fenestra 
podocyte foot process effacement abnormal glomerular filtration barrier function 
abnormal podocyte foot process morphology abnormal glomerular capsule parietal layer morphology 
fused podocyte foot processes decreased glomerular capsule space 
absent podocytes juxtaglomerular cell hyperplasia 
absent podocyte slit diaphragm decreased tubuloglomerular feedback response 
podocyte hypertrophy decreased glomerular capillary number 
podocyte microvillus transformation abnormal tubuloglomerular feedback response 
increased podocyte apoptosis glomerulus hemorrhage 
absent podocyte foot process glomerular capillary congestion 
decreased podocyte number glomerular capillary thrombosis 
abnormal podocyte slit diaphragm morphology abnormal glomerular capsule space morphology 
detached podocyte abnormal extraglomerular mesangial cell morphology 
abnormal podocyte slit junction morphology abnormal glomerular filtration barrier morphology 
abnormal podocyte adhesion expanded mesangial matrix 
abnormal podocyte motility mesangial cell hyperplasia 
abnormal podocyte polarity mesangial cell interposition 
decreased urine urea nitrogen level absent mesangial cell 
increased urine protein level mesangiolysis 
decreased urine creatinine level abnormal mesangial cell morphology 
abnormal urine protein level abnormal mesangial matrix morphology 
increased urine microalbumin level mesangial cell hypoplasia 
increased urine major urinary protein level increased circulating creatinine level 
increased urine microglobulin level decreased creatinine clearance 
increased urine beta2-microglobulin level increased blood urea nitrogen level 
hematuria  
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Manual evaluation of the genes emerged from the above databases and software was 
performed based on the scientific literature obtained through PubMed and Google 
Scholar using the following search terms: 
(‘gene name’ OR ‘alternative gene name 1’ OR ... OR ‘alternative gene name n’ OR 
‘gene symbol’ OR ‘alternative gene symbol 1’ OR ... OR ‘alternative symbol n’) 
AND (nephrotic OR proteinuria OR albuminuria OR glomerular OR glomerulopathy 
OR podocyte OR “slit diaphragm” OR “focal segmental glomerulosclerosis” OR 
“minimal change disease” OR “membranoproliferative glomerulonephritis” OR 
“membranous nephropathy”) 
 
5.2.4 Ion Torrent PGM DNA Sequencing 
Genomic DNA was extracted from peripheral blood using the NucleoSpin® Blood kit 
(Macherey-Nagel). Analysis of DNA regions from 112 genes was performed by highly 
multiplex PCR using the Ion AmpliSeq™ Library Kit 2.0 and the Ion AmpliSeq Custom 
WG_IAD76560 panel (subdivided into two pools), designed by the White-Glove 
service of Life Technologies. After clonal amplification using the Ion PGM™ Template 
HiQ Kit, sequencing was performed on Ion PGM Sequencer (Life Technologies) using 
a Ion 318 chip v2. Variants were identified using TorrentSuite Software 5.2 which 
includes the alignment plugin, coverage plugin, and variantCaller plugin. In addition, 
for coverage analysis a home-made R script was created and used to manage the 
Samtools and Bedtools software. Regions with a depth of amplicon coverage ≥10x 
reads were considered appropriately analyzed. 
Likely pathogenic variants were confirmed with Sanger sequencing. 
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5.2.5 Whole Exome Sequencing 
Whole Exome Sequencing (WES) with the Illumina platform for the pedigrees of 
SN091 and SN140 was outsourced at the Department of Biotechnology, University of 
Verona, Italy. The library was enriched for exonic regions in the human genome using 
the TruSeq Exome Enrichment Kit (Illumina) and subsequently sequenced on a HiSeq 
2000 Illumina sequencer. 
Whole Exome Sequencing (WES) with the SOLiD platform for patient IR35 was 
outsourced at the Genomnia laboratories (Italy). The library was enriched for exonic 
regions in the human genome using the SureSelect Human All Exon kit (Agilent). Then 
it was analyzed on a SOLiD Sequencer (Applied Biosystems). 
 
5.2.6 Variant annotation 
Functional annotation of the variants was performed using the ANNOVAR software 
(June 17th 2015 release). 
The allele frequencies of the variants were obtained from the following public 
databases: "1000 Genomes Project" (v5a.20130502 release), "NHLBI GO Exome 
Sequencing Project" (v.0.0.30, Nov. 3, 2014, release) and Exome Aggregate 
Consortium (ExAC v0.3). 
To perform the comparisons between patients and controls, 404 unphenotyped subjects 
of European non-Finnish origin from the 1000 Genomes Project (CEU, TSI, GBR and 
IBS subpopulations) for whom individual genotypes were available was used as a 
control group. To avoid bias in assessing allele frequency, the independent 6500 Exome 
Sequencing Project (ESP) was considered as reference to assess allelic frequencies for 
case-control comparison. Missense variants, insertions/deletions in the coding regions, 
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splicing variants affecting the first two nucleotides flanking exons, or variants lying 
within the Kozak consensus sequence, were considered functional. Common variants 
that exceeding an allelic frequency of 0.01 in any subpopulation from all databases were 
filtered out. 
The neutral or damaging effect of a variant on the protein function was predicted using 
the following software and algorithms available through the Annovar software: SIFT, 
Polyphen2, Mutation Taster, Mutation Assessor, LRT, FATHMM, CADD v1.3 
(damaging if ≥10), GERP (damaging if ≥2) e SiPhy (damaging if ≥10). Since the 
CADD score of insertion and deletions is not precomputed in Annovar, it was calculated 
directly at CADD website (http://cadd.gs.washington.edu/score). 
Likely pathogenic variants in known genes were defined on the basis of inheritance, 
type of mutation, allele frequency and CADD pathogenic score. The presence of at least 
one allele was required for genes with autosomal dominant or X-linked inheritance, and 
the presence of one homozygous or two heterozygous alleles for genes with autosomal 
recessive inheritance. Nonsense variants (due to stop codons) and frameshift variants, 
which lead to truncated protein products and thereby impair protein function, were 
considered pathogenic, if the inheritance criterion was fulfilled. Missense and in frame 
insertions or deletions were evaluated as follows: 1) allelic frequency ≤0.0001 for genes 
with autosomal dominant or X-linked inheritance, and ≤0.001 for genes with autosomal 
recessive inheritance; 2) CADD pathogenicity score ≥15 (a more stringent CADD score 
cut-off was used compared to the one in the 10 algorithm prediction). 
In the candidate genes, the variants with allelic frequency ≤0.001 and CADD score ≥15 
were defined as possibly pathogenic variants. 
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5.2.7 Genome-wide SNP genotyping 
Genotyping of about 1 million SNPs all along the genome was performed using the 
Genome-Wide Human SNP Array 6.0 (Affymetrix) in collaboration with the 
Department of Biomedical Sciences, University of Brescia. 
 
5.2.8 Autozygosity mapping software 
A way to identify regions where both alleles are inherited by a common ancestor of the 
parents (identity by descent) is the autozygosity mapping. For this purpose, based on the 
Broman and Weber approach,
361
 the autozygosity LOD score is calculated for a 
genomic variant i using the following formula: 
                
                       
                           
 
 
   
 
 
where the probabilities of the observed genotype at a marker, given the autozygosity 
status of the surrounding segment, are obtained through the formulas in the following 
table: 
Observed 
Genotype 
Probability that the 
segment is  
Ratio 
Autozygous 
Not 
Autozygous 
AA 
(1-ε)pA + 
εpA
2 
pA
2 (1-ε)/pA + ε 
AB 2εpApB
2 2pApB
2 ε 
ε denotes the combined rate of genotyping errors and mutations. 
 
The autozygosity strength of a region is given by the sum of the single variant 
autozygosity LOD scores for the given region. In order to evaluate the autozygosity 
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score for all the SNPs along the whole genome (1 million SNPs), script in Python 2.6 
was written. Since the SNP distribution is not homogeneous all over the genome and 
there is an inflation of the autozygosity score in the regions with high SNP density, a 
second algorithm was created where I take only 1 SNP (the most informative, in the 
mean of less probable to occur) for each region of 0.1 cM (Density Adjusted 
Algorithm). 
 
5.2.9 Linkage studies 
Furthermore, genotypes emerged from the Human SNP Array 6.0 (Affymetrix) were 
used to perform classic whole-genome linkage analysis with the Merlin software. The 
parametric analysis was performed using an autosomal recessive model for rare disease 
(allele frequency 0.001) for pedigrees with consanguinity of parents and autosomal 
dominant model for rare disease (allele frequency 0.00001) for the pedigree with 
suspected autosomal dominant inheritance. 
 
5.2.10 Statistical analyses 
χ2-test and Fisher exact test were used for categorical variables when appropriate. 
Statistical analyses were performed with the R software (https://cran.r-project.org/). P-
values <0.05 were considered statistically significant.  
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5.3 Results 
5.3.1 To create a diagnostic NGS-based panel for SRNS 
5.3.1.1 Panel design 
The first aim of this study was to create a genetic test based on next-generation 
sequencing approach that could allow the detection of SNV and indel mutations, as well 
as susceptibility SNPs, known to be associated with kidney glomerular disorders and 
nephrotic syndrome. To achieve this goal, the English-language literature was reviewed. 
There were 79 genes with mutations repeatedly found in glomerular proteinuria and 
nephrotic syndrome (Table 5.3). There were also 28 non-coding SNPs in 19 genes that 
predispose to SRNS (n=7), MPGN (n=2), MN (n=2), IgAN (n=15) and SSNS (n=1). 
Overall, mutations or polymorphic risk alleles in 92 different genes were identified to be 
associated with proteinuric nephropathy. 
Altogether the genes included were associated to SRNS, CAKUT, MPGN, MN and 
IgAN. Furthermore, there were genes, which genetic abnormalities cause 
glomerulopathy with extra-renal manifestations including amyloidosis, Alport 
syndrome, Nail-patella syndrome, Renal-coloboma syndrome, Fabry disease, Denys-
Drash syndrome, Epstein/Fechtner syndrome, Branchio-oto-renal syndrome, coenzyme 
Q10 deficiency, immune-osseous dysplasia of Schimke, glycosylation disorder type Ik, 
nephropathy-epidermolysis bullosa-deafness syndrome, nephropathy-epidermolysis 
bullosa-pneumopathy syndrome, Townes-Brocks syndrome, Kallman syndrome, and 
hypoparathyroidism-deafness-renal dysplasia syndrome. 
Two hundred forty four genes were obtained by interrogating different databases and 
software. After manual evaluation 21 genes were selected as candidates to cause 
nephrotic syndrome based on high expression in human kidney, kidney glomerular 
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abnormalities in animal models, protein-protein interaction with genes associated with 
SRNS, MPGN or MN, and low tolerance to functional genetic variation (Table 5.3). 
 
Table 5.3. List of genes included in the proteinuric glomerulopathy panel. 
Disease Gene/SNP name 
Gene 
n° 
ncSNP 
n° 
SRNS ACTN4, ADCK4, ARHGAP24, ARHGDIA, CD2AP, CRB2, 
CUBN, EMP2, INF2, MYO1E (gene, rs113915226), NPHS1 
(gene, rs73928332), NPHS2, PLCE1, PTPRO, TRPC6 (gene, 
rs41302375), DGKE, TTC21B, APOL1 (rs73885319, rs60910145, 
rs71785313), GPC5 (rs16946160) 
17 7 
    
SRNS 
syndromic 
WT1, COL4A3, COL4A4, COL4A5, MYH9, LMX1B, ALG1, 
CD151, COL4A6, ITGB4, SCARB2, ZMPSTE24, ANLN, COQ2, 
COQ6, ITGA3, LAMB2, PDSS2, SMARCAL1 
19 0 
    
CAKUT PAX2 (gene, rs4523631), EYA1, GATA3, KAL1, SALL1, SIX1, 
SIX5, SOX17, BMP7, CHD1L, DLX5, FREM2, HPSE2, RET, 
ROBO2, SIX2, UPK3A, HNF1B, BMP4, FOXC2 
20 1 
    
MPGN/C3G C3, CD46 (gene, rs2796268), CFB, CFH (gene, rs3753394), 
CFHR5, CFI, THBD, C1QA, CFP 
9 2 
    
MN PLA2R1 (gene, rs4664308), PRKCD, HLA-DQA1 (rs2187668) 2 2 
    
IgAN VAV3 (rs17019602), HLA-DR/HLA-DQ (rs7763262, rs9275224, 
rs2856717, rs9275596), PSMB8 (rs9357155), TAP2-PSMB9 
(rs2071543), HLA-DP (rs1883414), DEFA (rs2738048, 
rs10086568), CARD9 (rs4077515), ITGAM-ITGAX (rs11150612, 
rs11574637), TNFSF3 (rs3803800), HORMAD2 (rs2412971), 
CFHR1 
1 15 
    
Amyloidosis FGA, LYZ, APOA1, APOA2, APOE, GSN 6 0 
    
Metabol. dis. FN1, GLA, CTNS, LCAT 4 0 
    
SSNS HLA-DQA1 (rs1129740) 0 1 
    
 
    
Candidates KIRREL, APCS, ILK, MIR192, MIR193A, DDN, TJP1, CRIM1, 
NCK1, NCK2, TCF21, IQGAP1, EPB41L5, FAT1, PDLIM2, 
CTGF, PODXL, FYN, TRIM3, TINAG, CD59 
21 0 
ncSNP: non-coding Single Nucleotide Polymorphism; SRNS: Steroid-resistant nephrotic syndrome; 
CAKUT: Congenital Abnormalities of the Kidney and Urinary Tract; MN: Membranous nephropathy; 
IgAN: IgA nephropathy; MPGN: Membranoproliferative glomerulonephritis; C3G: C3 glomerulopathy; 
SSNS: Steroid-sensitive nephrotic syndrome. Metabol. dis.: metabolic disorders. 
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A custom library with 1881 primer pairs divided in two pools was designed to sequence 
the 1314 coding exons, their flanking regions, and the 29 non-coding SNPs. Altogether, 
the design covered 315,783 out of 316,167 bp (99.88%) of all genes (coding exons ± 5 
bp of flanking intronic regions) and SNPs. The theoretical coverage was 99.94% 
(274,738 out of 274,559 bp) for the known genes and 99.51% (41,429 out of 41,224 bp) 
for candidate genes. 
The performances of the panel were evaluated in 32 patients analyzed in 4 runs (8 
patients/run) on Ion 318 Chips v2 using the Hi-Q chemistry both for template 
preparation and sequencing. A mean depth of 181x (±42) was obtained (Table 5.4). A 
coverage of ≥10x and ≥20x was reached in 98.8% and 98.4% of coding bases (±2bp of 
intronic regions), respectively. There were 1845 (98.1%) and 1823 (96.9%) amplicons 
showing a coverage of at least 10x and 20x all along the coding regions, respectively. 
 
 
Table 5.4. Performance of the sequencing. 
  Mean (±SD) 
Mapped Reads 610,613 ± 114,768 
On Target (%) 65.2 ± 6.5 
Uniformity (%) 94.5 ± 1.6 
Mean Depth 181.0 ± 42.4 
% bases Cov≥10x 98.8 ± 0.2 
% bases Cov≥20x 98.4 ± 0.2 
N amplicons with coding region Cov≥10x 1845.2 ± 7.4 
N amplicons with coding region Cov≥20x 1823.4 ± 19.5 
% amplicons with coding region Cov≥10x 98.1 ± 0.4 
% amplicons with coding region Cov≥20x 96.9 ± 1.0 
Cov: coverage. 
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The variant identification using the Torrent Suite Variant Caller with the standard 
parameters showed a sensitivity of 98.2% and a false positive error rate of 5.8%. A new 
strategy was set up that increased the sensitivity (99.6%) without compromising the 
false positive error rate (5.4%). The strategy is extensively described in chapter 6. 
 
5.3.1.2 Clinical and epidemiological features of the patients 
One hundred sixty-eight patients affected by Steroid-Resistant Nephrotic Syndrome 
(SRNS) were recruited through the SRNS Registry of the CRCRD. Patients of 14 
families that were previously found to carry mutations by Sanger sequencing (5 in WT1, 
4 in PAX2, 2 in CD2AP, 2 in MYO1E and 1 in PLCE1) were not included. Seventy-nine 
out of 168 were sporadic cases, with no other family members affected by SRNS or 
other type of nephropathy, whereas 89 were familial cases belonging to 34 different 
families. The median age of onset of the patients in this cohort was 20.5 years 
(interquartile range 8-33 years). The distribution of the age of onset ranged from 0 to 71 
years and showed a mode between 16 and 20 years of age (Figure 5.1). 
Kidney biopsy showed a focal segmental glomerulosclerosis (FSGS) pattern of injury in 
71% of the patients, minimal change disease (MC) in 20%, shifting from MC at the first 
biopsy to FSGS at a following biopsy in 3%, diffuse mesangial sclerosis in 1% and not 
conclusive findings in 4%, while biopsy was not available in 3% of SRNS patients. 
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Figure 5.1 
Figure 5.1. Distribution of the patient age of onset in the SRNS cohort. 
 
 
About 27% of patients, who initially received the diagnosis of isolated SRNS, presented 
one or more extra-renal manifestations on in-depth evaluation of clinical records. 
Despite there was no statistically significant difference between familial and sporadic 
cases, familial cases had more likely ear and eye involvement suggesting, that Alport or 
Alport-like syndrome could be underdiagnosed (Figure 5.2). 
 
 
Figure 5.2 
Figure 5.2. Panel A: Description of the different extra-renal manifestations observed in 
the SRNS patients recruited in the study. Panel B: Comparison of the extra-renal 
manifestation distribution between sporadic and familial cases (Pearson chi-squared test 
was performed). 
  
A B 
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5.3.1.3 Screening of a SRNS cohort with the new NGS panel 
The presence of likely pathogenic (LP) variants in glomerulopathy-associated genes was 
investigated through the NGS panel in 111 unrelated SRNS patients. We considered 
only missense or in frame indel variants with Minor Allelic Frequency (MAF) ≤0.0001 
and Combined Annotation Dependent Depletion (CADD) pathogenic score ≥15, as well 
as all nonsense and frameshift variants, since they lead to truncated proteins. For genes 
with autosomal dominant or X-linked inheritance, patients were considered carrying LP 
variants in case of at least one variant. For genes with autosomal recessive inheritance, 
patients were considered carriers of LP variants in case of one homozygous variant or 
two heterozygous variants. 
LP variants in SRNS-associated genes were detected in 26 (23%) out of 111 unrelated 
patients (Table 5.5). The most frequently involved genes were those encoding for the 
collagen IV chains α3 (6 heterozygous patients), α4 (4 heterozygous patients) and α5 (2 
hemizygous patients and 2 heterozygous patients). LP variants were also found in INF2 
(3 heterozygous patients), NPHS1 (2 compound heterozygous patients), PAX2 (2 
heterozygous patients), ARHGAP24 (1 heterozygous patient), COL4A6 (1 heterozygous 
patient), FAT1 (1 compound heterozygous patient), MYH9 (1 heterozygous patient) and 
TRPC6 (1 heterozygous patient). 
Among the different LP variants in COL4A3, COL4A4 and COL4A5, 10 are located in 
the corresponding triple helix domains (4 in COL4A3, 2 in COL4A4 and 4 in COL4A5). 
Six of these variants cause the replacement of one Glycine in the (Gly-X-Y)n repeat of 
the corresponding collagen triple helixes (3 in COL4A3, 1 in COL4A4 and 2 in 
COL4A5). Four LP variants are located in the corresponding globular NC1 domains (2 
in COL4A3 and 2 in COL4A4). In COL4A4 the C1683Y variant affect the Cysteine at 
position 1683, which forms a disulfide bond with Cys-1588 or with Cys-1622 residues. 
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The COL4A4 R1682W is placed next to the previous Cys-1683 residue. Also the 
COL4A3 Q1663E is placed next to a disulfide bond site, the Cys-1662 that forms a 
disulfide bond with the Cys-1570 or with the Cys-1604 residues. 
The G73S, R218Q and E220K variants affect evolutionary conserved residues of the 
GBD/FH3 domain of INF2. These mutations have been previously described in SRNS 
patients.
186, 188
 
Regarding the LP variants found in the NPHS1 gene, all of them are located at the extra-
cellular C2-type Ig-like domains that allow nephrin-nephrin interactions at the slit 
diaphragm. The S350P, a previously described SRNS-causing mutation, lies in the Ig-
like C2-type domain 4.
362
 The NPHS1 T172del, leading to the deletion of a Threonine, 
the S510Y, leading to a Serine to Proline substitution, and the S937N, leading to a 
Serine to Asparagine substitution, have not been previously described in SRNS patients 
and lie in the Ig-like C2-type domains 1, 5 and 8, respectively. 
The PAX2 Y185* variant leads to the formation of a truncated protein lacking the last 
212 amino acids, including the octapeptide domain, the homeodomain and the 
transactivation domain. The PAX2 F10S variant leads to the substitution of a highly 
conserved Phenylalanine by a Serine, whose effect on protein function is unknown. 
The ARHGAP24 A704fs variant results in the formation of a truncated protein lacking 
the last 45 amino acids and thus loosing part of the coiled-coil domain. 
The MYH9 V1837G is a novel variant that affects a highly conserved amino acid 
located in a putative coiled-coil domain at the C-terminal of the protein. 
The TRPC6 R895C affects a residue located at a putative coiled-coil sequence in the C-
terminal cytoplasmic domain. It is a known SRNS causing mutation leading to channel 
over-activation.
162
 The COL4A6 N1448D is a located at the triple helix domain and was 
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not previously reported. 
A compound heterozygous patient was identified carrying the A131E and the C4113Y 
variants in the FAT1 gene. The A131E leads to the substitution of an Alanine by a 
Glutamate at position 131, in the first Cadherin domain (Figure 5.3). This variant is not 
present in public databases; it has a CADD score of 15 and is predicted as damaging by 
6 out of the 10 used algorithms. The C4113Y is a Cysteine to Tyrosine substitution at 
amino acid 4113, located in the fourth EGF-like domain. Also this variant is not present 
in public databases; it has a CADD score of 27 and is predicted as damaging by all 10 
algorithms. 
Altogether the prevalence of mutations in the above SRNS-associated genes was higher 
in patients compared to controls (0.108 vs.0.015, OR=8.04, p=3.4x10
-5
; Table 5.8). 
 
 
Figure 5.3 
Figure 5.3. Graphical representation of the FAT1 protein. In its extracellular region 
contains 33 cadherin domains (CA), a laminin G domain (LamG) and 5 epidermal 
growth factor (EGF)-like repeat domains (E). It also contains a transmembrane region 
(TM) and a C-terminal cytoplasmic domain containing a PTB-like motif (PTB-like) 
with a PDZ-binding motif. Vertical lines represent the two LP variants identified in 
patient SN098. 
 
 
Interestingly, I found SRNS patients carrying LP variants in genes that were previously 
associated with other disorders including CAKUT and amyloidois/metabolic disorders 
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(Tables 5.6 and 5.7). Nine patients carried LP variants in CAKUT-associated genes. The 
LP variants were found in CHD1L (3 heterozygous patients), RET (2 heterozygous 
patients), FREM2 (1 compound heterozygous patient), FOXC2 (1 heterozygous patient), 
HNF1B (heterozygous patient), ROBO2 (1 heterozygous patient) and SALL1 (1 
heterozygous patient). All but FREM2 were characterized by autosomal dominant 
inheritance. 
The most frequently affected CAKUT-associated gene was CHD1L. Three LP variant 
were found, all of them leading to formation of truncated proteins (Q51*, K365fs and 
R410*). Notably, Q51* and R410* were already reported in public databases with an 
allele frequency of 0.0016 and 0.0002 in at least one subpopulation, respectively. The 
prevalence of LP variants in CHD1L did not differ significantly between the patients 
and 404 ethnically matched controls of the 1000 Genomes Project (Table 5.8); however, 
if the more stringent criterion of nonsense/frameshift mutations was adopted, the 
difference became statistically significant (3/111 vs. 0/404, p=0.0098). 
There were two patients carrying LP variants in the RET gene. Both affect a highly 
conserved Lysine (K994N and K1003E) within the protein kinase domain. 
In the HNF1B gene a novel A503V LP variant was identified that lies within the QSP-
rich domain required for the HNF1B transactivation.
363
 
The ROBO2 M189K is a novel LP variant that occurs in the C2-type Ig-like domain 2 of 
the protein. 
Two additional novel LP variants were found in SALL1 (N1090S) and in FOXC2 
(Y25H). These substitutions affect amino acid whose function is unknown. 
 Finally, a compound heterozygous patient was identified carrying the FREM2 R217C 
and A337S variants, both located at the chondroitin sulfate proteoglycan repeat 1. 
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The overall prevalence of mutations in the above CAKUT genes was also higher in 
patients compared to controls (0.081 vs. 0.022, R=3.87, p=0.006; Table 5.8). 
Four patients carried LP variants in the amyloidois/metabolic disorder group. One 
patient carried the FGA L673P and another the Y821C novel variants, both located at 
Fibrinogen C-terminal domain. The prevalence of FGA LP variant was higher in 
patients compared to controls (0.018 vs. 0, p=0.046, Table 5.8). 
One patient had two heterozygous FN1 LP variants (S727A and V728E). Both are novel 
and lie within the Fibronectin type-III 2 domain. Finally one patient carried the G1026E 
variant, which is located within the Fibronectin type-III 5 domain of FN1. Mutations in 
FN1 gene cause glomerulopathy with fibronectin deposits. Both patients with FN1 LP 
variants described here had pathologic diagnosis of FSGS but the deposits of fibronectin 
were not investigated. 
Altogether, LP variants were detected in 33 (30%) out of 111 index patients (Tables 5.5 
and 5.7). There were 26 patients that carried LP variants in a single gene. Interestingly 7 
patients carried LP variants in more than one gene. Patient SN121 carried the 
heterozygous G213E variant in COL4A3 gene and the heterozygous C1683Y variant in 
COL4A4 gene. Similarly to previous described patients with digenic COL4A3/COL4A4 
inheritance, patient SN121 had an earlier disease onset and a more severe disease 
course. In three patients one of the combined LP variants fell into the CHD1L gene. In 
patient SN021, the heterozygous PAX2 Y185* is combined with the heterozygous 
CHD1L R410*. Patient SN114 carries the compound heterozygous variants S350P and 
S510Y in NPHS1 together with the K365fs variant in CHD1L. In patients SN148 the 
heterozygous SALL1 N1090S variant is combined with the heterozygous CHD1L Q51* 
variant. LP variant in RET were combined with SRNS gene LP variants in two patients. 
Patient SN133 carries the hemizygous c.321+1G>C variant in COL4A5 together with 
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the heterozygous K994N variant in RET. Patient SN150 carries the heterozygous MYH9 
V1837G variant combined with the heterozygous RET K1003E variant. Finally, in 
patient SN059, the heterozygous INF2 R218Q is combined with the heterozygous 
ROBO2 M189K. 
To disclose whether the combination of LP variants in CAKUT-associated genes with 
SRNS-associated genes is a random finding or it may reflect an underlying mechanism, 
the prevalence of CAKUT LP variants in patients carrying or not carrying LP variants in 
SRNS-associated genes was compared. The prevalence of CAKUT LP variants was 
higher in patients carrying SRNS LP variants compared to those patients without SRNS 
LP variants (0.20 vs. 0.05, p=0.026). Moreover, the rate of patients with one CAKUT-
associated gene LP variant combined to a SRNS-associated gene LP variant was higher 
compared to 404 ethnically matched controls (0.045 vs. 0.007, p=0.014). If the 
combinations of LP variants in two different CAKUT genes were also considered 
together with the CAKUT-SRSNS combinations, the significance became stronger 
(0.054 vs. 0.010, p=0.0089). 
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Table 5.5. Likely pathogenic variants identified in SRNS-associated genes. 
ID Genomic coordinates Gene 
AA/cDNA 
Change 
GT Inher. 
All DB 
Max Freq 
ESP Max 
Freq 
CADD PPr 
SN025 chr4:86921740delCGAG ARHGAP24 p.A704fs Het AD 0 0 35 1 / 1 
SN094 chr2:228155553G>A COL4A3 G1054E Het AD 0 0 17 9 / 10 
SN121 chr2:228116080G>A COL4A3 G213E Het AD 0 0 22 10 / 10 
SN143 chr2:228175562G>A COL4A3 R1609Q Het AD 0 0 24 10 / 10 
SN173 chr2:228176560C>G COL4A3 Q1663E Het AD 0 0 19 7 / 10 
SN208 chr2:228168752G>A COL4A3 G1349S Het AD 0 0 20 9 / 10 
SN319 chr2:228159248A>G COL4A3 K1127R Het AD 0 0 15 3 / 10 
1862 chr2:227983416C>G COL4A4 R145T Het AD 0 0 17 8 / 9 
SN121 chr2:227872066C>T COL4A4 C1683Y Het AD 0 0 20 9 / 9 
SN163 chr2:227872070G>A COL4A4 R1682W Hom AD 1.5E-05 0 16 9 / 9 
SN248 chr2:227976420C>T COL4A4 G190R Het AD 1.50E-05 0 20 9 / 9 
QUGI249 chrX:107846253G>T COL4A5 E736* Het XL 0 0 40 4 / 6 
SN041 chrX:107846265G>T COL4A5 G740W Hem XL 0 0 16 10 / 10 
SN133 chrX:107811904G>C COL4A5 c.321+1G>C Hem XL 0 0 24 4 / 4 
SN152 chrX:107823772G>C COL4A5 G264R Het XL 0 0 20 10 / 10 
2089 chrX:107403705T>C COL4A6 N1448D Het XL 0 0 17 9 / 10 
SN098 chr4:187518866C>T FAT1 p.C4113Y Het AR 0 0 27 10 / 10 
SN098 chr4:187630590G>T FAT1 p.A131E Het AR 0 0 15 6 / 10 
SN003 chr14:105169782G>A INF2 E220K Het AD 0 0 18 9 / 10 
SN059 chr14:105169777G>A INF2 R218Q Het AD 0 0 21 8 / 10 
SN138 chr14:105167919G>A INF2 G73S Het AD 0 0 36 9 / 10 
SN150 chr22:36680531A>C MYH9 V1837G Het AD 0 0 19 9 / 10 
SN112 chr19:36332622C>T NPHS1 S937N Het AR 5.00E-04 0.0005 23 9 / 10 
SN112 chr19:36341872delTGG NPHS1 p.Thr172del Het AR 6.07E-05 0 18 2 / 2 
SN114 chr19:36337008G>T NPHS1 S510Y Het AR 0 0 20 9 / 10 
SN114 chr19:36339661A>G NPHS1 S350P Het AR 8.65E-05 0 15 5 / 10 
SN021 chr10:102541061C>G PAX2 Y185* Het AD 0 0 41 5 / 6 
SN086 chr10:102506046T>C PAX2 F10S Het AD 0 0 22 8 / 9 
SN272 chr11:101323799G>A TRPC6 R895C Het AD 0 0 24 10 / 10 
Hom: homozygous; Het: heterozygous; Hem: hemizygous; Inher.: inheritance; AD: autosomal dominant; 
AR: autosomal recessive; XL: X-linked. AA/cDNA Change: Amino acid or cDNA change. PPr: 
Pathogenic prediction; number of pathogenic predictions on the number of total predictions obtained with 
10 different algorithms. 
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Table 5.6. Likely pathogenic variants identified in CAKUT-associated genes (PAX2 
was not included). 
ID 
Genomic 
coordinates 
Gene 
AA/cDNA 
Change 
GT Inher. 
All DB 
Max 
Freq 
ESP 
Max 
Freq 
CADD PPr 
SN114 chr1:146747775ins 
AAGTTATT 
CHD1L p.K365fs Het AD 0 0 33 1 / 1 
SN021 chr1:146756158C>T CHD1L p.R410* Het AD 0.0002 0 38 5 / 6 
SN148 chr1:146737614C>T CHD1L p.Q51* Het AD 0.0016 0 25 4 / 6 
SN170 chr16:86601014T>C FOXC2 p.Y25H Het AD 1.6E-05 0 18 9 / 9 
2087 chr13:39262130C>T FREM2 p.R217C Het AR 1.0E-04 0 17 9 / 10 
2087 chr13:39262490G>T FREM2 p.A337S Het AR 1.0E-04 0 23 8 / 10 
SN151 chr17:36061014G>A HNF1B p.A503V Het AD 0 0 23 8 / 10 
SN133 chr10:43620373A>C RET p.K994N Het AD 1.5E-05 0 17 8 / 10 
SN150 chr10:43620398A>G RET p.K1003E Het AD 0 0 21 8 / 10 
SN059 chr3:77530269T>A ROBO2 p.M189K Het AD 0 0 25 6 / 10 
SN148 chr16:51172864T>C SALL1 p.N1090S Het AD 1.0E-04 
1.00E-
04 
24 6 / 10 
Hom: homozygous; Het: heterozygous; Hem: hemizygous; Inher.: inheritance; AD: autosomal 
dominant; AR: autosomal recessive; XL: X-linked. AA/cDNA Change: Amino acid or cDNA 
change. PPr: Pathogenic prediction; number of pathogenic predictions on the number of total 
predictions obtained with 10 different algorithms. 
 
 
 
Table 5.7. Likely pathogenic variants identified in amyloidosis and metabolic disorder 
associated genes. 
ID 
Genomic 
coordinates 
Gene 
AA/cDNA 
Change 
GT Inher. 
All DB 
Max 
Freq 
ESP 
Max 
Freq 
CADD PPr 
SN128 chr4:155505415T>C FGA p.Y821C Het AD 0 0 16 10 / 10 
SN177 chr4:155505859A>G FGA p.L673P Het AD 1.0E-04 1.0E-04 18 10 / 10 
SN016 chr2:216274402A>T FN1 p.V728E Het AD 0 0 25 9 / 10 
SN016 chr2:216274406A>C FN1 p.S727A Het AD 0 0 17 9 / 10 
SN048 chr2:216269288C>T FN1 p.G1026E Het AD 0 0 30 9 / 10 
Hom: homozygous; Het: heterozygous; Hem: hemizygous; Inher.: inheritance; AD: autosomal 
dominant; AR: autosomal recessive; XL: X-linked. AA/cDNA Change: Amino acid or cDNA 
change. PPr: Pathogenic prediction; number of pathogenic predictions on the number of total 
predictions obtained with 10 different algorithms. 
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Table 5.8. Frequency of subjects carrying likely pathogenic variants in known 
glomerulopathy-associated genes. 
Gene 
Frequency of LP 
variant carriers OR p 
Patients Controls 
SRNS 0.234 0.032 8.04 1.0x10
-12
 
ARHGAP24 0.009 0.007 1.22 1.000 
COL4A3 0.054 0.010 5.71 0.009 
COL4A4 0.036 0.010 3.74 0.070 
COL4A5 0.036 0.005 7.51 0.022 
COL4A6 0.009 0.000 11.0 0.216 
FAT1 0.001 0.000 3.63 1.000 
INF2 0.027 0.007 3.71 0.118 
MYH9 0.009 0.010 0.91 1.000 
NPHS1 0.009 0.000 11.0 0.216 
PAX2 0.018 0.002 7.39 0.119 
TRPC6 0.009 0.005 1.83 0.518 
     
CAKUT 0.081 0.022 3.87 0.006 
CHD1L 0.027 0.012 2.22 0.378 
FOXC2 0.009 0.002 3.66 0.385 
FREM2 0.009 0.000 11.0 0.216 
HNF1B 0.009 0.000 11.0 0.216 
RET 0.027 0.010 2.78 0.174 
ROBO2 0.018 0.015 1.22 0.684 
SALL1 0.009 0.005 1.83 0.518 
     
Amyl./Metab. dis. 0.018 0.007 2.45 0.295 
FGA 0.018 0.000 18.5 0.046 
FN1 0.018 0.017 1.04 1.000 
OR: odds-ratio. Amyl./Metab. dis.: amyloidosis or metabolic disorders. 
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5.3.1.4 Analysis of the candidate genes 
Since information on inheritance was not available for candidate genes, all variants with 
a frequency ≤0.001 and a CADD score ≥15 were considered as possibly pathogenic 
(PP) variants. As shown in Table 5.9, there were 10 patients carrying PP variants in 6 
different candidate genes (EPB41L5 n=3, TINAG n=3, KIRREL n=1, PDLIM2 n=1, 
TJP1 n=1, and TRIM3 n=1). 
To disclose whether these variants are incidental findings, the prevalence of PP variants 
as defined above was evaluated in 404 ethnically matched controls (Table 5.10). The 
prevalence of PP variants in EPB41L5 was higher in patients compared to controls 
(0.027 vs. 0.002, p=0.033). No differences were observed in the prevalence of the PP 
variants in the remaining candidate genes between patients and controls. 
A deeper analysis of the EPB41L5 variants showed that they were all carried in 
heterozygous state by three patients (1 familial and 2 sporadic cases). The affected 
relatives of the familial cases were not available for segregation studies. All three 
variants affect highly conserved amino acids (Figure 5.4). Two of them (Q168E and 
E287D) are located at the FERM domain of EPB41L5 (Figure 5.5). Through the FERM 
domain, EPB41L5 interacts with other partners of the Crumbs complex regulating the 
formation of the slit diaphragm and the maintenance of podocyte cell polarity.
364
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Table 5.9. Possibly pathogenic variants in candidate genes included in the NGS panel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hom: homozygous; Het: heterozygous; Hem: hemizygous. Inher.: inheritance. PPr: Pathogenic 
prediction; number of pathogenic predictions on the number of total predictions obtained with 10 
different algorithms. na: not applicable. 
 
 
Table 5.10. Frequency of subjects carrying possibly pathogenic variants in candidate 
genes included in the NGS panel. 
Gene 
Frequency of PP 
variant carriers 
OR p 
Patients Controls 
EPB41L5 0.027 0.002 11.2 0.033 
TINAG 0.027 0.010 2.78 0.174 
TRIM3 0.009 0.005 1.83 0.518 
KIRREL 0.009 0.005 1.83 0.518 
PDLIM2 0.009 0.005 1.83 0.518 
TJP1 0.018 0.035 0.51 0.541 
 
  
ID 
Genomic 
coordinates 
Gene 
AA/cDNA 
Change 
GT Inher. 
All DB 
Max 
Freq 
ESP Max 
Freq 
CADD PPr 
SN031 chr2:120844804A>T EPB41L5 p.E287D Het na 1.00E-04 0 17 8 / 10 
SN037 chr2:120833326C>G EPB41L5 p.Q168E Het na 3.01E-05 0 25 9 / 10 
SN296 chr2:120925069C>T EPB41L5 p.R664W Het na 1.00E-03 0 20 10 / 10 
SN248 chr1:158064158C>A KIRREL p.T592N Het na 4.00E-04 0 19 8 / 10 
SN161 chr8:22451386G>A PDLIM2 p.R591H Het na 0 0 28 7 / 10 
SN133 chr6:54173572A>G TINAG p.Y75C Het na 0 0 15 6 / 10 
SN138 chr6:54186175G>A TINAG p.G167E Het na 0 0 18 8 / 10 
SN205 chr6:54173549T>A TINAG p.D67E Het na 0 0 18 6 / 10 
SN168 chr15:30009035C>G TJP1 p.E1395Q Het na 0 0 28 9 / 10 
SN071 chr11:6477659G>A TRIM3 p.R433C Het na 1.62E-05 0 20 7 / 10 
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Figure 5.4 
Figure 5.4. Alignment of the EPB41L5 homologues from different species around the 
Q168E, E287D and R664W variants of EPB41L5 obtained by the Polyphen-2 software. 
The residue affected by each variant is shown in the black frame.  
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Figure 5.5 
Figure 5.5. Graphical representation of the protein encoded by the candidate EPB41L5 
gene. It contains a FERM domain at the N-terminus of the protein and a PDZ-binding 
motif (PDB) at the C-terminal. Vertical lines represent the possibly pathogenic variants 
found in 3 SRNS patients. 
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5.3.2 To search for novel genes involved in the pathogenesis of the familial form of 
SRNS. 
Two families with SRNS patients and unknown etiology have been enrolled for genome 
wide analyses. For both, consanguinity of the patients' parents was hypothesized. 
 
5.3.2.1 Novel gene hunting in patient MEBO291 
Patient MEBO291 is a 24 years-old female of Italian origin. She developed SRNS at 
age 17 years. Proteinuria at onset was 12 g/24h. She presented no extra-renal 
manifestations. She underwent kidney biopsy with pathological features showing 
minimal change disease. Sanger sequencing revealed no mutations in INF2, NPHS2, 
WT1 (exons 8 and 9) and TRPC6. Screening with the NGS panel revealed no mutations. 
The patient pedigree is shown in Figure 5.6. She had no familial history for 
nephropathy, except from traces of proteins and blood in the urine in the younger 
brother. Consanguinity of the parents was referred. 
 
Figure 5.6 
Figure 5.6. Pedigree of patient MEBO291; the asterisk denotes the subjects for whom 
DNA sample is available. 
 
Autozygosity mapping using the results of Genotyping of about 1 million SNPs with the 
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Genome-Wide Human SNP array, showed the presence of different autozygosity 
regions (in chromosomes 2, 6, 13, 14 and 20) where the two alleles had high probability 
to be identical by descent (Figure 5.7, panels A and B). Parametric whole-genome 
linkage analysis assuming a autosomal recessive inheritance showed four candidate 
regions (in chromosomes 2, 6, 13 and 20) reaching a maximum LOD score of 1.85 
(Figure 5.7, panel C). 
 
 
Figure 5.7 
Figure 5.7. Autozygosity and linkage analysis in patient MEBO291. Panel A: classic 
autozygosity LOD score for regions of 2 cM (overlapped by 0.1 cM). Panel B: 
autozygosity LOD score for regions of 2 cM (overlapped by 0.1 cM) using the Density 
Adjusted Algorithm. Panel C: LOD score of parametric linkage analysis assuming an 
autosomal recessive inheritance. 
 
 
Whole exome sequencing (WES) was performed in patient MEBO291 on an Illumina 
platform obtaining 101,849 variants. After filtering out common variants (minor allele 
frequency, MAF, >0.01), non functional variants, 355 variants survived. Considering an 
autosomal recessive inheritance due to consanguinity, I kept only the homozygous 
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variants, thus reducing the disease-associated candidates to 10. Among these, only the 
chr13:g.28,626,716C>T, that leads to amino acid change V194M in the FLT3 gene, fell 
into one of the candidate regions identified by the autozygosity and linkage studies 
(Table 5.11). This variant has a MAF of 0.005, a CADD score of 10 and is predicted 
damaging by 4 out of 10 used algorithms. Evaluation of FLT3 with the String software 
showed that FLT3 is linked to WT1 and indirectly through RAC1 with ACTN4, MYO1E 
and ARHGDIA (Figure 5.8). 
Prioritization of all variants identified by the WES, independently from the inheritance, 
was performed using the Exomiser software (Table 5.12). This analysis highlighted the 
heterozygous P494S in the DDR1 gene as the most probable disease-causing variant. 
This variant has a CADD score of 15, it is predicted damaging by 5 algorithms and is 
not present in the public databases. 
Finally, variants in known kidney disorders were investigated. The R93W variant was 
identified in the CAKUT-associated GDNF gene. This variant has a MAF of 0.04, a 
CADD score of 16 and is predicted damaging by all the algorithms. The R93W has been 
previously described in CAKUT patients and it is considered of uncertain significance. 
The presence of these three variants was evaluated in the family members of SN140 
(Figure 5.9). The parents of SN140 were heterozygous for FLT3 V194M; however, 
there were two unaffected siblings carrying V194M in homozygous state. The DDR1 
P494S was inherited from the mother and was present in the first sister. Finally GDNF 
was inherited from the father and was also present in the second sister. 
The genes FLT3, GDNF and DDR1 were sequenced in 67 SRNS patients carrying no 
mutations in known SRNS genes. No LP variants were identified in FLT3 and in 
GDNF. A heterozygous G413A variant was found in the DDR1 gene. This variant was 
not present in the public databases, has a CADD score of 14 and is predicted damaging 
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by 4 algorithms. However, the comparison with 404 controls using the LP definition for 
autosomal dominant inheritance showed no statistically significant difference (0.015 vs. 
0.012, p=1.00). 
 
Table 5.11. Number of variants that have been identified in MEBO291 during exome 
sequencing analysis and that have survived after the application of different filters. 
 
Total N° 
variants 
… functional variants 
with MAF <0.01 
… predicted 
damaging 
… homozygous 
… within linkage 
regions 
N° variants 101,849 814 355 10 1 
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Table 5.12. Genes that ranked in the first ten positions during prioritization of the 
SN140 variants with the Exomiser software. 
Rank Gene 
Exomiser 
Score  
Phenotype 
Score 
Variant 
Score 
Phenotypic similarity 
Phenotypic 
similarity to 
mouse mutant 
Proximity in 
interactome 
1 DDR1 0.977 0.754 1.000 . 0.754 to mouse 
mutant involving 
DDR1 
FN1 
2 IFT122 0.929 0.642 1.000 0.642 to 
Cranioectodermal 
dysplasia 1 associated 
with IFT122. 
. LMX1B 
3 NOS1 0.91 0.618 1.000 . 0.618 to mouse 
mutant involving 
NOS1 
ASL 
4 SLC22A5 0.904 0.611 1.000 . 0.611 to mouse 
mutant involving 
SLC22A5 
SLC26A6 
5 SLC6A19 0.904 0.611 1.000 0.393 to Pseudomonas 
aeruginosa, susceptibility 
to chronic infection by, in 
cystic fibrosis associated 
with FCGR2A 
. SLC6A18 
6 FCGR2A 0.901 0.740 0.850 . 0.740 to mouse 
mutant involving 
FCGR2A 
APCS 
7 AGER 0.886 0.725 0.850 . 0.725 to mouse 
mutant involving 
AGER 
THBD 
8 STARD8 0.876 0.587 0.996 . . TNS1 
9 REEP1 0.874 0.581 1.000 . . IFT122 
10 SF3A2 0.865 0.574 1.000 to Prader-Willi syndrome 
associated with SNRPN 
. SNRPN 
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Figure 5.8 
Figure 5.8. Output of the direct (physical) and indirect (functional) protein-protein 
interaction analysis using the String v9.05 software. These interactions may be both 
known or predicted and they derive from four sources: genomic context, high-
throughput experiments, (conserved) coexpression, and previous knowledge (data 
mining). The already known podocytopathy-associated genes and the 10 exome derived 
candidate disease-associated genes were used as input. In the red circle is shown the 
candidate FLT3 gene that is integrated in the network. In the yellow circles the other 
genes with homozygous variants identified in the WES. 
 
 
 
Figure 5.9 
Figure 5.9. Segregation of the candidate variants in the SN140 pedigree.  
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5.3.2.2 Novel gene hunting in patients IR35 and IR40 
Patients IR35 and IR40 are two male brothers of Iranian origin (Figure 5.10). Patient 
IR40 is the first born of the family. He is 46 years-old and is affected by SRNS since 
age 41 years-old. The proteinuria at onset was 3.8g/24h. He had no extra-renal 
manifestations. Kidney biopsy showed minimal change nephropathy with mild 
mesangial proliferation and mild segmental thickness of glomerular basement 
membrane. 
IR35 is the second born of the family. He is a 40 years-old male affected by SRNS with 
onset at age 30 years. Proteinuria at onset was 3.4 g/24h. He had no extra-renal 
manifestations. Kidney biopsy showed minimal change nephropathy. He developed 
ESRD requiring dialysis at the age of 33 years and received a kidney transplantation at 
the age of 35 years. No recurrence or rejection of the graft were observed at 5 years of 
follow-up. 
Parents consanguinity was referred and suggested by the common geographical origin 
of parents (parents are both from a small village), but the common ancestor was not 
identified. Both patients had no mutations in SRNS genes. 
 
Figure 5.10 
Figure 5.10. Pedigree of patients IR35 and IR40; the asterisk denotes the subjects for 
whom DNA sample was available. 
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Autozygosity mapping showed the presence a single 3.5 Mb long region in chromosome 
1 where the two alleles have high probability to be identical by descent and that was 
shared by both affected brothers (Figure 5.11). WES was performed in patient IR35 and 
showed the presence of 53 homozygous variants with MAF <0.01 and predicted 
damaging (Table 5.13). Among these 53 variants only the chr1:g.12,836,101C>A, 
leading to the amino acid change L235I in the PRAMEF12 gene, fell in the candidate 
region identified by the autozygosity analysis (Table 6). This variant has a CADD score 
of 24 and is predicted as damaging by 5 out of 10 algorithms. However, its allele 
frequency is rather high (MAF=0.009). Furthermore, gene PRAMEF12 did not show 
any link to the podocytopathy-associated genes when evaluated with String (Figure 
5.12). 
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Figure 5.11 
Figure 5.11. Autozygosity and linkage analysis in patients IR35 and IR40. Panel A: 
autozygosity LOD score for regions of 2 cM (overlapped by 0.1 cM) in patient IR35. 
Panel B: autozygosity LOD score for regions of 2 cM (overlapped by 0.1 cM) using the 
Density Adjusted Algorithm in patient IR35. Panel C: classic autozygosity LOD score 
for regions of 2 cM (overlapped by 0.1 cM) in patient IR40. Panel D: autozygosity LOD 
score for regions of 2 cM (overlapped by 0.1 cM) using the Density Adjusted Algorithm 
in patient IR40. 
 
 
Table 5.13. Number of variants that have been identified in IR35 during exome 
sequencing analysis and that have survived after the application of different filters. 
 
Total N° 
variants 
… functional 
variants with MAF 
<0.01 
… predicted 
damaging 
… homozygous 
… in 
autozygosity 
region 
N° variants  62113 572 359 53 1 
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Figure 5.12 
Figure 5.12. Output of the direct (physical) and indirect (functional) protein-protein 
interaction analysis using the String v9.05 software. The already known podocytopathy-
associated genes and the 53 exome derived candidate disease-associated genes were 
used as input. In the dark blue circles the candidate that are integrated in the network are 
shown. In the red circle the only gene lying in the autozygosity region is shown. 
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5.3 Discussion 
In this study, a next-generation sequencing panel was designed and developed, which 
analyses whole coding exons and SNPs in 93 different genes known to be associated 
with glomerulopathies including the disorders that commonly cause nephrotic 
syndrome. The panel was used to screen 111 index cases from a SRNS cohort and 
resolved 30% of overall SRNS cases. The majority of the mutations are found in already 
known SRNS-associated genes. Interestingly, likely pathogenic variants are also found 
in genes previously associated with CAKUT, as well as with amyloidosis and 
glomerulopathy with fibronectin deposits. Finally, through candidate screening and 
exome studies, the EPB41L5 is identified as candidate SRNS-associated genes. 
In this cohort, likely pathogenic variants in SRNS-associated genes are found in 23% of 
patients (Tables 5.5-5.8). The most frequently affected genes are COL4A3, COL4A4 and 
COL4A5. Thirteen (12%) out of 111 index patients carry likely pathogenic variants in 
one of these three genes. Contrary to a previous large study,
152
 a high prevalence of 
mutations in NPHS2, NPHS1, WT1, PLCE1 and LAMB2 was not observed. Regarding 
WT1, its low prevalence was probably biased by the fact that 5 patients carrying WT1 
mutations identified in a previous Sanger sequencing study, were not included in the 
study cohort. As for the other genes, discrepancy with literature may be due to the 
higher age of SRNS onset of the patients included in this study (median age 20.5 years) 
as compared to published studies that mainly focused on pediatric cohorts. Indeed 
NPHS2, NPHS1, PLCE1 and LAMB2 mutations mostly affect infants or small children 
with congenital nephrotic syndrome or early onset SRNS, while their prevalence drop 
with age.
152
 Conversely, the data presented here are in line with previous findings that 
COL4A4 mutations are the most frequent mutations in adult focal segmental 
glomerulosclerosis.
210
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Interestingly, likely pathogenic variants are also found in genes other that those already 
known to be associated with SRNS. In particular, 8% of patients carry LP variants in 
CAKUT-associated genes. This may reflect the fact that the molecular pathways 
underlying CAKUT and SRNS partially overlap. CAKUT genes are involved in the 
kidney development from the early stages to the glomerulus and podocyte formation.
219
 
The PAX2 gene, which was considered as a SRNS-associated gene in this study because 
it is associated with adult onset FSGS, was first identified as a CAKUT-causing 
gene.
221, 365
 Furthermore, transcription factors involved in podocyte development 
include proteins encoded by genes associated both with FSGS (WT1 and PAX2) and 
CAKUT (LMX1B and FOXC2). Interestingly, in the present cohort the CAKUT LP 
variants are frequently combined with SRNS variants and these associations do not 
seem incidental. It is possible that these variants concur to the development of the 
disease or act as genetic modifiers resulting in more severe disease presentation. 
This study also aimed to identify novel SRNS-causing variants. Two different strategies 
have been adopted. The first was to identify candidate genes on the basis of their 
expression in the human kidney and glomerulus, their association with glomerular 
abnormalities in animal models, their interaction with proteins associated with SRNS, 
MPGN and MN, and their tolerance to functional genetic variation. Software and 
algorithms that prioritize genes on the basis of multiple features, such as ToppGene, 
Endeavour and GeneDistiller, or on the low tolerance to functional genetic variation, 
were also used. All these data were used to obtain a list of top genes followed by 
manual evaluation based on the literature. On September 2015, 21 candidates were 
selected and included in the NGS panel. Since then, five new SRNS-causing genes have 
been reported. One of these, FAT1, which encodes an atypical cadherin present at the 
podocyte slit diaphragm, was included among the candidates of the panel here 
presented. On the other hand, the four nucleoporin genes (NUP93, NUP107, NUP205 
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and XPO5), which have been involved in a new SRNS-associated pathway, were not 
included. Therefore, candidate gene analysis may be a viable approach for genes 
involved in known pathways, but would probably fail to catch those belonging to 
unknown mechanisms. 
Among the other candidate genes analyzed here, the EPB41L5 is the most promising to 
be involved in SRNS pathogenesis (Tables 5.9 and 5.10). The EPB41L5 encodes for the 
Erythrocyte Membrane Protein Band 4.1 Like 5, a protein involved in the formation of 
slit diaphragm and in the maintenance of podocyte cell polarity.
366
 It is a component of 
the mammalian Crumbs complex and antagonizes its signaling.
366
 Studies in zebrafish 
show that moe, the zebrafish EPB41L5 ortholog, is expressed in podocytes and it is 
required for proper formation and maintenance of slit-diaphragms. Podocytes of moe -/- 
mutants lack slit-diaphragms on basement membrane-associated foot processes.
364
 In 
the mutant embryos, it is possible that slit-diaphragms may form at sites distant from the 
basement membrane, since some double cross-strand structures spanning the space 
between processes extending into Bowman’s space are observed.364 Absence of moe 
expression results in loss of glomerular barrier permselectivity and aberrant passage of 
high molecular weight molecules.
364
 In addition, through its FERM domain, EPB41L5 
directly binds CRB2 that is a known SRNS-causing gene.
235, 236, 367, 368
 Zebrafish crb2b 
is required for podocyte foot process arborization, slit diaphragm formation, and proper 
nephrin trafficking.
235
 In the present SRNS cohort, three possibly pathogenic variants of 
EPB41L5 are present. All the three variants affect evolutionary conserved amino acids 
(Figures 5.4 and 5.5) and two of them are located in the FERM domain, through which 
EPB41L5 interacts with other proteins of the Crumb complex.
366
 Notably, these two 
variants fulfill the criteria of likely pathogenic variants adopted in this study. Finally, 
the prevalence of possibly pathogenic variants was significantly higher in patients 
compared to controls. However, the significance level is not robust and the effect of the 
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identified variant was evaluated only in silico. Analysis of further SRNS cohorts and 
functional studies on the role of the identified variants are necessary. 
A second strategy, based on whole genome autozygosity mapping and whole exome 
sequencing allowed the identification of DDR1 as a potential SRNS candidate gene 
(Table 5.12). This gene encodes for the Epithelial discoidin domain-containing receptor 
1, which is a collagen receptor that bind collagen IV in podocytes.
369
 It also interacts 
with myosin IIA (MYH9), another SRNS-associated protein, thus regulating cell 
spreading and motility.
370, 371
 DDR1-deficient mice show localized thickening of the 
glomerular basement membrane, focal loss of slit diaphragms and proteinuria.
369
 
Through the exome study a heterozygous missense variant of DDR1 was identified 
(P494S). Further screening of 67 patients disclosed the presence of a second variant 
(G413A). These variants are located at the second and first Glycine/Proline-rich 
domains of DDR1, respectively, and both affect evolutionary conserved residues. 
However, the variant was found in two unaffected relatives and the prevalence of likely 
pathogenic variants is not significantly higher in patients compared to controls. 
Altogether, the data available here do not support a role in the pathogenesis of SRNS, 
although such a role cannot be excluded. Further screening of patients and functional 
studies are warranted to define the role of DDR1. 
Some limitations of the present study have to be considered. The number of patients 
included in this cohort is low. Moreover, the control subjects were obtained from a 
public database. They were not recruited from the same territory of the patients and they 
were not analyzed with the same technique. Finally, the pathogenicity of many variants 
is based on prediction software and algorithms, and functional studies are not available. 
Therefore, a cautious interpretation of the results is necessary. This is a pilot study to 
evaluate the performance of the NGS panel. Recruitment and analysis of further SRNS 
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patients, as well as screening of control subjects, is in the future perspectives. However, 
some elements enforce the findings presented here. The high rate of combined CAKUT 
LP variants support these are not incidental findings. Moreover, the absence of LP 
variants in genes that present a different pathogenesis, such as the MPGN-associated 
genes, provide further support. 
In conclusion, this study shows that next-generation sequencing can be successfully 
applied in the screening of SRNS. It also suggests that CAKUT genes may be involved 
on the pathogenesis of SRNS. Finally, EPB41L45 is proposed as a candidate gene for 
SRNS. 
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6. OPTIMIZATION OF VARIANT 
IDENTIFICATION IN THE ION TORRENT 
PGM PLATFORM 
6.1 Introduction 
Next Generation Sequencing (NGS) has been a revolutionary tool for discovering causal 
variants in human diseases and unraveling new disease mechanisms.
372
 Compared to 
classical Sanger sequencing, NGS can detect genetic abnormalities from a significantly 
larger number of genes or samples in parallel, in a more rapid and cost effective 
manner.
373
 Based on the platforms and kits, the sequencing may yield hundreds to 
millions of variants compared to a human reference sequence. In these large data sets, 
the identification of causal variants may be arduous because of the presence of many 
false positive variants. 
Distinguishing true variants from false positive variants is an outstanding challenge in 
variant discovery. High sensitivity and specificity are essential for clinical genetic tests, 
since high error rates may compromise confirmation of diagnosis, treatment strategies, 
genetic counseling and carrier screening.
374
 Inaccurate genetic tests have significant 
impact on validation time and costs.
375
 Nonetheless, several studies on currently 
available NGS sequencers have highlighted that the accuracy of mutation detection 
should be improved to ensure that NGS become a viable option for clinical genetic 
testing.
354-356, 373, 375
 
Several NGS sequencers are available and they are characterized by distinct error 
profiles, which are related to the respective sequencing technology.
376
 The overall error 
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rate ranges from 0.3 per 100 sequenced bases for the Illumina platform to 16.2% of the 
Pacific biosciences platform (Table 6.1). The Ion Torrent platform that emerged as a 
viable alternative to Illumina in the last years showed 1.6% of error rate.
376, 377
 
Regarding the type of error, Illumina and Complete Genomics show more substitution 
than indel errors, while indel errors are predominant in all other platforms.
376
 
 
Table 6.1. Error rates (per 100 sequenced bases) of high-throughput sequencing 
platforms. 
Platform Subs (±SD)   Indels (±SD)   All (±SD)
a
 
Illumina HiSeq 0.26 (±0.11) 
 
0.03 (±0.02) 
 
0.28 (±0.12) 
Illumina MiSeq 0.25 (±0.11) 
 
0.01 (±0.01) 
 
0.30 (±0.19) 
Ion Torrent PGM 0.17 (±0.17) 
 
1.46 (±1.22)
b
 
 
1.63 (±c 1.24)
b
 
454 GS FLX 0.09 (NA
c
) 
 
0.90 (NA
c
) 
 
0.99 (NA
c
) 
454 GS Junior 0.05 (NA
c
) 
 
0.39 (NA
c
) 
 
0.46 (NA
c
) 
Complete Genomics 2.30 (NA
c
) 
 
0.02 (NA
c
) 
 
2.32 (NA
c
) 
Pacific Biosciences RS 1.10 (±0.45)   15.57 (±3.29)   16.19 (±3.17) 
Modified from Laehnemann, 2016.
376
 Subs: substitution errors per 100 bases; Indels: insertion 
and deletion errors per 100 bases; SD: standard deviation. 
a
Some studies contain only aggregated measures for Indels and/or total error; therefore, the 
value of All is not necessarily the sum of Subs and Indels. 
b
One study with three samples used indel-tolerant mapping, resulting in almost 100% of reads 
being mapped, but also producing much higher indel error rates and high SD. 
c
Only one sample was analyzed, thus SDs are not available. 
 
 
The false positive variants are commonly machine artifacts or alignment errors.
378-380
 
The artifacts are introduced during sample preparation, clonal amplification, sequencing 
cycles, and data collection.
381, 382
 Amplification bias during PCR can result in 
underrepresentation of one of the two alleles in heterozygous variants.
383
 Polymerase 
errors, such as base misincorporations and rearrangements secondary to template 
switching, may also result in incorrect variant calls. 
Although the overall error rates are relatively low, some properties of nucleic acid 
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sequences are known to raise the error rates.
372, 376, 384, 385
 These sequence-specific error 
sources include homopolymers and regions with high GC content. Homopolymers are 
stretches of identical bases, which are frequently associated with errors at the bases next 
to the homopolymer. As short as two nucleotide homopolymers may increase the 
sequencing error at the base following the homopolymer.
385
 Moreover, certain DNA 
sequence motifs, such as GGA or GGT, are more susceptible to sequencing errors.
372, 385
 
High GC content regions are another source of error in NGS because they negatively 
affect read coverage and because of their low complexity leads to polymerase errors.
376, 
386
 Furthermore, single nucleotides show different behavior. In the Illumina platform the 
A↔C and the G↔T transversions are much more common than other false 
substitutions.
376
 Finally, a source of error common in many platforms is the decay of 
base signal along each read.
376
 Toward the end of the read, the frequency of erroneous 
calls significantly increase.
376
 
Alignment errors are a further source of false positive variants. They are typically 
associated with repetitive or homologous sequence regions, and they can lead to 
substitution, insertion and/or deletion errors involving one or more bases.
372, 387
 Since 
both sequencing and alignment errors can be associated with particular DNA sequence 
motifs, these errors can be consistent between samples analyzed using the same 
sequencing chemistry, run on the same instrument and analyzed with the same 
bioinformatic pipeline, as shown in multiple studies.
384, 388-390
 
In the last years, new biochemical protocols and bioinformatic solutions have been 
introduced to improve sequencing accuracy.
382
 Since the large majority of the studies 
have used Illumina sequencers, most technical optimization efforts have been focused 
on this platform.
377, 391-393
 Accordingly, most bioinformatic methods are optimized for 
Illumina-derived data.
376, 377, 394-398
 Several basic parameters on variant calling and 
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alignment have been developed within the different variant calling softwares to identify 
false positive variants. These parameters, such as the probabilistic base quality score, 
the alignment mapping quality score, the aligned read coverage for possible alleles and 
the base alignment quality score, can be used to apply hard filters for variants to discard 
putative false positives.
372, 380, 399, 400
 They can also be used in a statistical model to 
generate the variant quality score (QUAL), an estimated Phred-scaled probability that 
the variant exists given sequencing data. However, this score underperforms at DNA 
regions prone to sequencing and/or alignment errors. To address QUAL score 
limitations, further parameters have been developed, including several bias values that 
compare variant containing reads versus reference containing reads for systematic 
differences in base quality, mapping quality, mapping position, and mapping direction. 
A more sophisticated implementation of the above parameters in Illumina-derived data 
is the variant quality score recalibration (VQSR), a quality score that is supposed to be 
better calibrated compared to QUAL. To obtain VQSR, machine learning algorithms are 
employed under a multidimensional Gaussian mixture model to learn from each dataset 
what is the parameter profile of true variants vs. the profile of false positive variants.
380
 
However, VQSR does not fully capture site specific issues, because it evaluates variants 
from many different regions simultaneously and the site-specific characteristics are 
difficult to codify.
372
 
Other methods incorporate additional information to more accurately identify sites with 
higher variant calling error rate, such as methods that utilize cross-sample error 
information. This approach assesses the characteristics of the errors by pooling 
information across samples and positions, since specific region likely contain similar 
errors in different samples.
388, 389, 401, 402
 
Recently, VarBin has been proposed as a novel analytical method to distinguish true 
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from false positive variants in Illumina NGS data. VarBin is a variant likelihood binning 
method that uses Genotype likelihood scores (PL) to generate the variant likelihood 
ratio over coverage depth (PLRD), a value affected by alignment and sequencing error. 
Then it compares the PLRD calculated for the variant of interest to those calculated for 
multiple background samples for each variant change and position. Similarly to other 
cross-sample methods, it is based on the fact that error characteristics show similar 
trends between samples sequenced with the same chemistry on the same platform and 
with the same bioinformatic data pipeline. Its advantage is that it evaluates each variant 
site individually. 
While there are numerous scientific publications aiming to address false positive 
variation on Illumina platform, only few studies are available for the Ion Torrent 
platform. This may be due to the fact that it is a young technology launched in 2011. 
The Ion Torrent NGS platforms generate DNA sequencing reads by detecting pH 
changes caused by ion release during incorporation of deoxyribonucleotide 
triphosphates into a growing DNA chain on a semiconductor device.
403
 In general, Ion 
Torrent NGS platform is characterized by high accuracy at single nucleotide variant 
(SNV) discovery, but has a high false positive rate for the identification of small 
indels.
355, 377, 404
 This is particularly pronounced in homopolymer regions.
403
 
Several improvements have been delivered by Life Technologies for the Ion Torrent 
platform. In 2015, the HiQ sequencing chemistry was released to improve accuracy of 
indel detection. According to the manufacturer, indel error rates decrease up to 90% 
compared to previous Ion Torrent sequencing chemistries.
405
 Moreover, to overcome the 
problem of high indel false positive rates, multiple upgrades of the Torrent Suite, the 
proprietary analytical workflow for the Ion Torrent platform, have been released.
403
 
More recent versions of the Torrent Suite Variant Caller (TSVC) include flow signal 
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information during variant calling, which is expected to improve the accuracy. 
In the scientific literature, a first solution was proposed within a workflow for clinical 
genetic testing of the BRCA1 and BRCA2 genes on Ion Torrent PGM.
406
 The workflow 
used a filter of 'presence of variants in <15% of samples' thus discarding frequently 
recurring errors and achieving a sensitivity ≥98.6% and a specificity of 96.9%. 
However, such approach may result in low sensitivity for samples derived from the 
same family or that contain highly conserved functional mutations. 
A study on improving the indel detection specificity of BRCA1 and BRCA2 genes using 
PGM implemented two simple filtering criteria: B-allele frequency (BAF), that is the 
non-reference allele frequency, and variation of the width of deletions and insertions 
(VARW), which is the variance of the width of the inserted/deleted sequences.
375
 After 
optimizing the filtering thresholds, the authors succeeded to achieve ≥99.99% 
specificity retaining 100% sensitivity.
375
 
In a follow-up study the same group adopted the Quality by Depth (QD) parameter, 
which is the ratio of QUAL score on read depth, as an alternative to the BAF threshold, 
since BAF estimation is unreliable in regions of low read depth.
403, 407
 They showed that 
the combination of QD with the VARW can substantially improve variant detection 
specificity without compromising sensitivity. 
A more sophisticated strategy was developed by Damiati and coauthors for data from 
whole exome sequencing on Ion Proton sequencer.
377
 For SNV and indel calls 
separately, they identified five parameters calculated by the TSVC that could better 
discriminate erroneous calls. Both for SNVs and indels these parameters are: QUAL, 
GQ (the genotype quality score), FDP (the flow-space corrected read depth) and FAO 
(the flow-space corrected alternate allele observations). The fifth parameter is STB, the 
strand bias ratio, for SNVs and HRUN, the length of homopolymer, for indels. Three 
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sets of thresholds for these parameters are provided, corresponding to low, medium and 
high-stringency levels of filtering, which filter out 20-68% of false SNVs and 10-40% 
of false indels retaining 99%, 95% and 90% of true positive calls, respectively. 
Interestingly, manual inspection of NGS data in the Integrative Genomics Viewer (IGV) 
browser allows to differentiate likely true variants from false positive variants. 
372
 
Comparison of the reads from different samples allow the visual identification of 
common false positive variant features such as the low variant allele percentage, the 
presence of the variant in reads from only one direction, the sequence context, and the 
presence of the variant in many background samples even if it may not have passed the 
variant calling filters.
372
 Ideally, visual inspection allows the simultaneous evaluation of 
multiple error features thus gaining further information compared to hard filtering. For 
these reasons, prediction of true variants from more likely false positive variants has 
been already used in scientific literature and has been included in the guidelines of the 
Italian Society of Human Genetics.
372, 375, 408
 
Contrary to Illumina platform, more sophisticated metrics that implement basic 
parameters on variant calling and alignment have not been developed for the Ion 
Torrent platform. Such metrics could allow a more robust identification of true variants 
over false positive variants. This would increase confidence in the results of variant 
discovery and decreases analysis efforts.
372
 Here, a score that combines multiple variant 
calling parameters is presented that allow increased sensitivity and low false positive 
detection rate with the Ion Torrent PGM. 
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6.2 Specific aims 
1. To create a strategy that allows to increase the sensitivity of the Ion Torrent PGM 
platform. 
2. To create a score that combines multiple variant calling parameters in order to 
increase sensitivity and reduce false positive detection rate with the Ion Torrent PGM 
platform. 
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6.3 Methods 
6.3.1 Patients 
We analyzed 26 patients recruited through the Registry of Steroid Resistant Nephrotic 
Syndrome, the Registry of Membranoproliferative Glomerulonephritis and the 
International Registry of atypical Hemolytic Uremic Syndrome. All participants 
provided informed written consent. The study was approved by the Ethics Committee of 
the Azienda Sanitaria Locale of Bergamo (Italy). 
 
6.3.2 Ion Torrent PGM DNA Sequencing 
Genomic DNA was extracted from peripheral blood using the NucleoSpin® Blood kit 
(Macherey-Nagel). Analysis of DNA regions from 112 genes was performed by highly 
multiplex PCR using the Ion AmpliSeq™ Library Kit 2.0 and the Ion AmpliSeq Custom 
WG_IAD76560 panel (subdivided into two pools), designed by the White-Glove 
service of Life Technologies. After clonal amplification using the Ion PGM™ Template 
HiQ Kit, sequencing was performed on Ion PGM Sequencer (Life Technologies). 
Variants were identified using TorrentSuite Software 5.2. Regions with a depth of 
amplicon coverage ≥10x reads were considered appropriately analyzed. Genetic variants 
were functionally annotated using the ANNOVAR software (June 17th 2015 release). 
The 1000 Genomes Project, the Exome Sequencing Project and the ExAC databases 
were adopted as reference to assess allelic frequencies. 
 
6.3.3 Sequencing with other techniques 
For the sequencing by the Sanger method, DNA regions were amplified by PCR 
amplification followed by purification using ExoSAP-IT® (GE Healthcare, Little 
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Chalfont, UK). The direct sequencing was performed through sequence reaction using a 
BigDye® terminator kit v.3.1 (Applied Biosystems, Foster City, CA, USA) followed by 
purification of the sequencing reaction products using the BigDye XTerminator® 
Purification Kit (ThermoFisher Scientific) and then run on an ABIPRISM® 3130xl 
Genetic Analyzer (Applied Biosystems, Foster City, CA). 
Sequencing with the Illumina platform was outsourced. Exome sequencing was 
performed using the TruSeq Exome Enrichment Kit (Illumina) and sequenced on a 
HiSeq 2000 sequencer (Illumina). Target sequencing of 32 SRNS-associated genes was 
performed using a custom MASTR kit (Multiplicom) and sequenced on HiSeq 
sequencer (Illumina). 
 
6.3.4 Statistical analyses 
One-way ANOVA, Kruskal-Wallis and multivariate regression tests were used for 
continuous variables. Multivariate analyses included all the covariates that reached 
statistical significance at the univariate analysis. Statistical analyses were performed 
with the R software (https://cran.r-project.org/) using the glm, ggplot2 and givitiR 
packages. P-values <0.05 were considered statistically significant. 
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6.4 Results 
6.4.1 Performance of the proteinuric glomerulopathy NGS panel 
This study was performed in the context of a wider project that aimed to create a NGS 
based test that would allow the detection of SNV and indel mutations known to occur in 
glomerular proteinuria and nephrotic syndrome, as well as SNP alleles known to 
predispose to disorders associated with glomerular proteinuria and nephrotic syndrome, 
as detailed in Chapter 5. 
 
6.4.2 Performance of the panel 
The performance of this panel was evaluated in 11 patients with proteinuric 
nephropathy (6 patients with SRNS, 3 patients with MPGN and 2 patients with atypical 
Hemolytic Uremic Syndrome, aHUS). These patients have been previously analyzed by 
whole exome sequencing (n=4), Sanger sequencing of six SRNS-associated genes (n=4) 
or by a previously described and validated NGS genetic panel for MPGN/aHUS (n=3) 
(ref and chapters 3 and 4 of this thesis). Overall, the previous sequencing in the above 
patients identified 2664 true variants suitable for the comparison with the new 
proteinuric glomerulopathy NGS panel. 
Using the default parameters for variant calling on the TSVC, 605±22 variants were 
identified in each sample for a total of 6655 different variants 
These parameters showed an overall sensitivity of 98.2% (Table 6.2). The performance 
was better for SNVs, for which 98.7% of true variants were captured, compared to indel 
variants, for which only 91.7% of true variants were captured. Altogether, there were 47 
variants (31 SNVs and 16 indels) that were not identified by TSVC. On the other hand, 
5.8% of the identified variants were false positives (Table 6.2). When SNVs and indels 
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were analyzed independently, the false positive detection rate was 3.3% and 30.2%, 
respectively. 
 
Table 6.2. Sensitivity and false positive detection rate. 
Parameter profile 
All   SNV   Indel 
Sens FDR   Sens FDR   Sens FDR 
Default* 0.982 0.058 
 
0.987 0.033 
 
0.917 0.302 
Custom 0.997 0.109 
 
0.999 0.037 
 
0.969 0.551 
Combined Default & Custom 0.9996 0.139   0.9996 0.061   1.000 0.580 
SNV: single nucleotide variant; indel: insertion/deletion variant; All: both SNV and indel; 
Sens: Sensitivity (= true positive / [ true positive + false negative ]); FDR: False detection 
rate (false positive / [ true positive + false positive ]) 
*default parameter profile provided by the TSVC 5.2 version. 
 
 
To increase sensitivity, the causes leading to false negatives were investigated using the 
hotspot option of the TSVC and by manual inspection on IGV browser. Most of the 
missed variants were filtered out during hard filtering, therefore a new set of thresholds 
for the TSVC parameters was used to filter out false positive calls without 
compromising sensitivity, as reported in Table 6.3. 
 
 
  
Optimization of variant identification 
 
207 
 
Table 6.3. Optimized thresholds of the TSVC parameters to increase sensitivity. 
Parameter Default Custom 
relative_strand_bias 0.7 0.85 
snp_strand_bias 0.98 1.00 
filter_insertion_predictions 0.30 0.40 
data_quality_stringency 5.00 4.50 
filter_unusual_predictions 0.30 0.70 
indel_min_cov_each_strand 4.00 3.00 
   
hotspot_strand_bias 0.98 1 
hotspot_min_variant_score 10 6 
 
 
With the new custom thresholds for variant calling, a mean of 646 (±26) variants were 
identified for each sample. The overall sensitivity improved compared to the analysis 
with the default parameters (99.7% vs. 98.2%) at the cost of more false positive variants 
(FDR 10.9% vs. 5.8%) (Table 6.2). Such performance was observed both for SNVs and 
indels, when they were analyzed separately. The sensitivity was 99.9% and 96.9% for 
SNVs and indels, respectively. The FDR was 3.7% and 55.1% for SNVs and indels, 
respectively. 
Altogether, there were 9 variants (3 SNVs and 6 indels) that were not identified by 
TSVC using the custom setting. Interestingly, 8 out of these 9 false negative were 
correctly called with the default settings. Therefore, the two analyses are combined 
achieving to reduce the false positives to 1 and obtaining a sensitivity of 99.96%. 
However, this procedure further increased the FDR (13.9%, 6.1% and 58.0% for 
overall, SNV and indel, respectively) (Table 6.2). 
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6.4.3 Strategy to reduce false positive variants 
In order to reduce the high false positive detection rate of the above analyses, it was 
investigated whether the combination of TSVC parameters in a probabilistic model 
could outperform hard filtering. At this purpose, we used the above dataset containing 
2664 true variants and 441 false positive variants. Since this dataset was enriched for 
variants from a subgroup of genes (i.e. SRNS-associated for Sanger sequencing variants 
and complement disorder-associated genes for the NGS complement panel), to avoid a 
possible bias, all the variants with no information by an alternative technique were 
manually evaluated on IGV. In this way, 3576 likely true variants and 415 likely false 
positive variants were identified. For 73 variants, it was not possible to reach a high 
confidence prediction. The sensitivity and the FDR of this enlarged dataset (overall 
6240 true variants and 856 false positive variant) were comparable to the above more 
restrict dataset (Tables 6.2 and 6.4). 
 
Table 6.4. Sensitivity and false positive detection rate in the larger dataset containing 
likely true and likely false variants. 
Parameter profile 
All   SNV   Indel 
Sens FDR   Sens FDR   Sens FDR 
Default* 0.985 0.044 
 
0.992 0.021 
 
0.904 0.278 
Custom 0.997 0.098 
 
0.999 0.035 
 
0.970 0.506 
Combined Default & Custom 0.9998 0.116   0.9998 0.049   1.000 0.530 
SNV: single nucleotide variant; indel: insertion/deletion variant; All: both SNV and indel; 
Sens: Sensitivity (= true positive / [true positive + false negative ]); FDR: False detection 
rate (false positive / [ true positive + false positive ]) 
*default parameter profile provided by the TSVC 5.2 version. 
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To implement the TSVC parameters in a probabilistic model, the linear or non-linear 
relationship between true variants and all parameters (as is and in the logit) were 
evaluated. Some examples are reported in Figure 6.1. Interestingly, several parameters 
showed linear (n=6), logarithmic (n=12) or polynomial (n=2) rather than categorical 
relationship (n=15). Then univariate analysis was performed. As expected, all the 
parameters were significantly associated with true variants separately (Table 6.5). 
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Figure 6.1. Linearity of the prevalence of true variants in correlation with the 
parameters of Torrent Suite Variant Caller that reached significance in the multivariate 
logistic regression. AO: Alternate allele observations; AF: Allele frequency based on 
Flow Evaluator observation counts; MLLD: Mean log-likelihood delta per read; SSSB: 
Strand-specific strand bias for allele; VARB: Variant Hypothesis bias in prediction; 
REVB: Reverse strand bias in prediction; RBI: Distance of bias parameters from zero; 
FXX: Flow Evaluator failed read ratio; STB: Strand bias in variant relative to reference; 
LEN: allele length; HRUN: Run length: the number of consecutive repeats of the 
alternate allele in the reference genome; QD: QualityByDepth as 4*QUAL/FDP 
(analogous to GATK). 
Figure 6.1 
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Figure 6.1. Continue. 
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Figure 6.1. Continue. 
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Figure 6.1. Continue. 
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Table 6.5. Univariate analysis showing the correlation of the TSVC parameters with the 
true variants. 
Parameters OR (95% CI) Coeff. p-value 
log10(DP) 6.0 (5.1-7.0) 1.79 2.8E-114 
log10(FDP) 6.5 (5.6-7.6) 1.87 5.8E-122 
RO > 2 0.24 (0.19-0.30) -1.43 1.2E-38 
FRO > 68 2.0 (1.7-2.3) 0.70 6.4E-19 
log10(AO) 18.2 (15.3-21.7) 2.90 4.4E-228 
log10(FAO) 11.4 (9.8-13.4) 2.44 2.6E-204 
SRF > 1 0.43 (0.36-0.51) -0.85 9.3E-22 
SRR > 55 2.0 (1.7-2.4) 0.71 4.8E-17 
AF 168 (114-247) 5.12 5.04E-148 
log10(SAF) 5.1 (4.7-5.7) 1.64 4.4E-250 
log10(SAR) 4.8 (4.4-5.3) 1.57 2.4E-230 
FSRF > 36 1.9 (1.6-2.2) 0.65 4.3E-16 
log10(FSAF) 5.5 (5.0-6.0) 1.70 1.2E-273 
FSRR > 38 1.3 (1.2-1.4) 0.27 2.4E-15 
log10(FSAR) 4.8 (4.4-5.3) 1.57 2.5E-246 
log10(QUAL) 7.2 (6.3-8.2) 1.97 5.0E-190 
log10(GQ) 10.1 (8.8-11.8) 2.32 7.2E-207 
REFB > -0.0536 3.4 (2.8-4.2) 1.23 1.4E-30 
VARB > 0.044 0.06 (0.05-0.08) -2.78 9.9E-160 
FWDB > 0.1013 0.12 (0.09-0.15) -2.14 4.7E-80 
REVB 8x10
-3
 (4x10
-3
-0.016) -4.86 1.8E-40 
FXX 4x10
-12
 (2x10-13
-1
x10
-10
) -26.17 2.3E-54 
RBI 3x10
-5
 (1x10
-5
-7x10
-5
) -10.38 1.1E-110 
log10(MLLD) 26.1 (20.9-32.7) 3.26 1.7E-177 
SSEN > 0 0.07 (0.03-0.14) -2.69 6.9E-13 
SSEP > 0 0.09 (0.06-0.15) -2.37 1.7E-22 
SSSB > -0.2083 14.7 (12.1-17.9) 2.69 9.3E-160 
STB 2x10
-3
 (2x10
-3
-4x10
-3
) -6.04 6.4E-154 
log10(STBP) 1.9 (1.3-2.8) 0.64 0.0016 
LEN 0.91 (0.88-0.95) -0.09 5.6E-07 
HRUN 0.78 (0.75-0.81) -0.25 7.3E-34 
QD:  QD < 5.1804 0.023 (0.019-0.029) -3.74 3.4E-240 
          14 < QD ≤ 36 0.038 (0.031-0.048) -3.25 6.5E-194 
VARW > 0 0.06 (0.05-0.07) -2.79 8.2E-217 
GT 7.3 (6.1-8.8) 1.99 6.0E-102 
Variant type:  TYPE = "ins" 0.057 (0.045-0.072) -2.86 4.1E-124 
                            TYPE = "del" 0.024 (0.019-0.029) -3.75 1.5E-259 
                            TYPE = "mnp" 0.009 (0.005-0.016) -4.74 3.0E-55 
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Since it is possible that there is a correlation between the different parameters, 
multivariate analysis in a backward stepwise procedure was performed, to identify the 
parameters that independently dissected true from false variants (Table 6.6). The 
variants included in the multivariate model were the number of reads containing the 
alternate allele (AO), the alternate allele frequency (AF), the mean Log-Likelihood 
Difference between predictions under the reference and the alternate allele hypothesis 
(MLLD), strand-specific strand bias (SSSB), the Euclidean distance between ideal 
predictions for the alternate alleles and the average measured values for the alternate 
alleles (VARB), the Euclidean distance between ideal predictions for the locus and the 
average measured values for the locus on the reverse strand (REVB), the Euclidean 
distance between ideal predictions for the locus and the average measured values for the 
locus (RBI), the proportion of reads that fail to fit any candidate variant (FXX), the 
strand bias measured in proportion of variant on each strand using flow evaluated allele 
counts (STB), the length of the alternate allele (LEN), the length of the first 
homopolymer in the reference that changes in length (HRUN), QUAL on DP ration 
(QD), variation of the width of deletions and insertions (VARW) and the type of variant 
(insertion, deletion or multiple nucleotide variation). 
The parameters AO, MLLD, STB and LEN were associated with higher probability of 
the variants to be true. The parameters REVB, RBI, FXX, HRUN, VARW, QD <5.2 or 
within 14-36, and being a deletion, insertion or Multi Nucleotide Polymorphism (mnp) 
were associated with lower probability of the variants to be true. The AF showed the 
maximum probability of true variant for the 0.5 and 1 values and the lowest for the 0 
value. Finally, variants with SSSB and VARB values around 0 had the maximum 
probability to be true.  
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Table 6.6. Multivariate analysis. 
Parameter OR (95% CI) p-value β 
log10(AO) 8.5 (6-12) 1.2E-33 2.1 
Polynomial AF:  AF
1
 1x10
21
 (1x10
11
-2x10
31
) 4.3E-05 48.7 
                            AF
2
 3x10
-27
 (4x10
-34
-3x10
-20
) 5.0E-14 -61.0 
                            AF
3
 5x10
8
 (1900-2x10
14
) 0.002 20.1 
log10(MLLD) 3.3 (1.8-6.1) 1.5E-04 1.2 
Polynomial SSSB:  SSSB
1
 2x10
5
 (58.0-6x10
8
) 0.003 12.1 
                                SSSB
2
 7x10
-44
 (8x10
-54
-6x10
-34
) 1.6E-17 -99.4 
Polynomial VARB:  VARB
1
 3x10
-16
 (6x10
-22
-2x10
-10
) 1.3E-07 -35.7 
                                  VARB
2
 4x10
-15
 (5x10
-25
-4x10
-5
) 0.005 -33.0 
REVB 4x10
-16
 (2x10
-21
-6x10
-11
) 5.9E-09 -35.6 
RBI 0.089 (0.011-0.725) 0.024 -2.4 
FXX 0.010 (2x10
-4
-0.419) 0.016 -4.6 
STB 23.3 (2.4-223) 0.006 3.1 
LEN 1.6 (1.4-1.9) 3.1E-08 0.5 
HRUN 0.905 (0.836-0.979) 0.013 -0.1 
QD:  QD < 5.1804 0.470 (0.248-0.888) 0.020 -0.8 
         14 < QD ≤ 36 0.497 (0.287-0.86) 0.012 -0.7 
VARW 0.952 (0.913-0.992) 0.020 -0.05 
Variant type:  TYPE = "ins" 0.269 (0.156-0.463) 2.2E-06 -1.3 
                       TYPE = "del" 0.020 (0.012-0.034) 7.9E-48 -3.9 
                       TYPE = "mnp" 0.023 (0.004-0.121) 9.2E-06 -3.8 
Constant 0.024 (0.003-0.198) 5.4E-04 -3.7 
 
 
 
The β coefficients of the logistic regression model were used to calculate the probability 
of being a true variant (pTRUE) for each one of the 2664 true and the 441 false positive 
variants in the first dataset. This probability was used to identify and discard likely false 
positive calls. Adopting a pTRUE >0.50 cut-off to accept a variant as true, the sensitivity 
slightly improved compared to the Default analysis (0.986 vs. 0.982) and the false 
positive variant error rare was reduced by almost 3-fold (0.022 vs. 0.058) (Tables 6.2 
and 6.7). When a pTRUE >0.10 cut-off was adopted, FDR was comparable to the Default 
analysis (0.054 vs. 0.058), while sensitivity was increased (0.996 vs. 0.982). 
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Table 6.7. Sensitivity and false positive detection rate in the combined Default and 
Custom dataset using the pTRUE. 
Analysis 
All   SNV   indel 
Sens FDR   Sens FDR   Sens FDR 
pTRUE > 0.80 0.970 0.009  
0.981 0.006 
 
0.818 0.048 
pTRUE > 0.50 0.986 0.022  
0.992 0.016 
 
0.911 0.107 
pTRUE > 0.20 0.994 0.037  
0.998 0.024 
 
0.943 0.188 
pTRUE > 0.10 0.996 0.054  
0.998 0.029 
 
0.969 0.293 
pTRUE > 0.01 0.999 0.090  
0.999 0.044 
 
0.990 0.440 
pTRUE > 0.001 0.9996 0.117   0.9996 0.052   1.000 0.533 
 
 
6.3.4 Frequency-based validation of pTRUE 
Since false positives often occur randomly, they are enriched for novel variants.
409
 On 
the other hand, variants already reported in public databases should be enriched for true 
positives, since false positives are not commonly expected in these databases.
372
 Based 
on these facts, it would be expected that pTRUE is higher in common variants. To verify 
this hypothesis, fifteen new samples were sequenced and analyzed with the default and 
the custom settings. A total of 9536 variants were obtained. The pTRUE was compared 
between novel variants and common variants that show an allelic frequency >1% in the 
1000 Genome Project, Exome Sequencing project and the ExAC databases. The mean 
pTRUE was significantly lower in novel variants compared to common variants 
(0.440±0.48 vs. 0.967±0.18, p<2x10
-16
) (Figure 6.2). 
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Figure 6.2 
Figure 6.2. Distribution of pTRUE for novel and common variants. 
 
 
6.3.5 Validation of pTRUE in rare variants 
To further validate the strategy, 140 variants with allelic frequency <1% were selected 
and analyzed with another technique. The frequency criterion was adopted in order to 
reproduce the mutational screening setting, which is one of the most frequent 
applications of the target NGS panels on Ion Torrent PGM. The selected variants 
contained both SNV (n=100) and indels (n=40), to ensure that the approach presented 
here could accurately detect a spectrum of mutations. There were 86 likely true variants 
and 54 likely false positive variants defined on the basis of the pTRUE score. Sanger 
sequencing and Illumina NGS, which were used as validation techniques, showed that 
83 out of 86 likely true variants were really true. On the other hand, all the likely false 
positive variants were confirmed as false. In this confirmation dataset the sensitivity 
was 100% and the FDR 3.5%.  
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6.4 Discussion 
In this study, the sensitivity and the false positive detection rate of the Ion Torrent PGM 
platform were evaluated. Altogether relatively low error rates are observed that, 
however, may affect its clinical application. Here, it is shown that the performances of 
the platform can be improved by replacing the hard-filtering strategy with a unique 
score, pTRUE, that combines multiple variant calling and alignment parameters. 
Using the standard protocol with the default Torrent Suite Variant Caller parameters, 
variants are detected with a sensitivity of 98.2% and a false detection rate of 5.8% 
(Table 6.2). Since accurate mutation identification is of paramount importance for 
confirmation of the diagnosis, risk assessment, genetic counseling, and carrier screening 
in patients and families affected by genetic disorders,
374
 an effort was made to increase 
sensitivity. A higher sensitivity was obtained at the expense of more false positive 
variants by adopting more relaxed thresholds for the parameters of the variant calling 
process. Currently, the TSVC, the proprietary software commonly used to identify 
variants in the Ion Torrent platform, calculates a set of parameters that correlate with the 
variant quality.
375, 377
 A set of thresholds for these parameters is defined and then, by a 
hard-filtering approach, variants that do not pass all the thresholds are discarded as 
putative false positive calls.
377
 However, many of these parameters are quantitative 
variables and, as shown here, different values may be characterized by a different 
prevalence of true variants. Reducing these variants in dichotomous results in loss of 
valuable information. Moreover, it is possible that variants that do not fulfill multiple 
parameter thresholds have higher probability to be false positive callings compared to 
variants that do not fulfill just one. 
To overcome these issues, the variant caller parameters were combined in a logistic 
regression probabilistic model (Tables 6.5 and 6.6). There are 14 parameters that 
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independently predict whether a variant is true or false. The probability derived from 
this model, pTRUE, was used to distinguish true variants from erroneous calls, thus 
increasing sensitivity and reducing the error rate. In addition, since different 
applications may require different levels of sensitivity and error rate, it is possible to 
tailor the analysis by adopting different thresholds for pTRUE. The score was validated 
with two different datasets. Firstly, the validity of pTRUE is suggested by the fact that it is 
significantly higher in common variants compared to novel variants, since novel 
variants are enriched for false positives, while common variants already reported in 
public databases are enriched for true positives
372, 409
. Secondly, 140 true and false 
variants were selected and verified by an independent technique showing 100% of 
sensitivity and 3.5% of false detection rate. 
Some limitations of the present study must be taken into account. First, the pTRUE was 
obtained in a limited panel of genes, therefore it may not be able to separate true and 
false positive variants in other genes. However, the probabilistic model was trained with 
1564 different types of variants derived from 112 different genes, therefore it is likely 
that this dataset may represent most of the variants in other genes. Moreover, the 
validity of the variant caller parameters used in the model is widely tested singularly 
both by Life Technologies and in the literature.
377, 403
 Another criticism of this study is 
that a part of the variants included in the training dataset were obtained by 
distinguishing likely true from false positive variants by manual inspection of reads in 
the IGV. This may have introduced a bias, however, a high confidence of such 
predictions has been previously shown.
372, 375, 408
 The good performances in the two 
validation datasets suggest that the introduction of few errors may be balanced by the 
advantage of including more variants in different genes. 
In conclusion, a new score and a new approach are proposed in this study that increase 
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the sensitivity and reduce the false positive callings in the Ion Torrent platform. Such an 
approach may allow a more accurate application of the NGS in the clinical practice for 
the benefit of patients and researchers. 
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7. CONCLUSIONS 
In the present thesis two groups of kidney disorders characterized by the presence of 
nephrotic syndrome are studied: the immune complex-mediated membranoproliferative 
glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), and the steroid-resistant 
nephrotic syndrome (SRNS). Genetic screening was performed and genetic data were 
combined with clinical, histopathologic and biochemical features to improve the 
knowledge in the pathogenesis of the diseases. 
The main technique used to study these diseases was next-generation sequencing. In 
particular, the Ion Torrent PGM platform was employed. Altogether relatively low error 
rates are observed with this platform. However, optimization is required, since high 
sensitivity and low false positive detection rate are essential for clinical application of 
genetic tests. To improve the performances of the platform, it was created a new score 
that through a probabilistic model combines 14 different parameters among those 
currently used to identify true variants. By relaxing the thresholds in the hard-filtering 
strategy and using the new score to exclude putative false positives, it was possible to 
increase the sensitivity and reduce the false positive callings. This may allow a more 
accurate application of the Ion Torrent PGM platform in the clinical practice for the 
benefit of patients and researchers. Of note, this approach was adopted for the genetic 
assay used to analyze the SRNS cohort, an assay interrogating 112 different genes. In 
the MPGN cohort, a genetic assay of only six genes was used with relaxed filtering 
criteria and all the rare variants that could be involved in the pathogenesis of the disease 
were verified by Sanger sequencing. 
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In the first part of this thesis focused on IC-MPGN/C3G, it is shown that mutations in 
the complement alternative pathway genes C3, CFB, CFH, CD46 and CFI account for a 
significant part of IC-MPGN/C3G patients in accordance with previous studies.
256, 262
 In 
addition, two rare variants in the THBD gene in two unrelated C3G patients are reported 
in this study. These variants are already described as mutations in patients affected by 
atypical hemolytic uremic syndrome, an allelic disorder of IC-MPGN/C3G.
309
 
Moreover, functional studies in vitro have previously shown that these two THBD 
variants cause impaired FI-mediated C3b inactivation leading to defective suppression 
of the complement alternative pathway.
309
 Altogether these data support that pathogenic 
variants in THBD are involved in the pathogenesis of C3G. 
Another interesting finding from the study of the IC-MPGN/C3G cohort is that the 
presence of mutations alone does not significantly increase the risk of developing IC-
MPGN or C3G. Indeed, the risk of developing IC-MPGN or C3G strongly increases 
only when mutations are combined with common susceptibility variants, while the risk 
of developing the disease is comparable between subjects carrying mutations but no 
susceptibility variants and subjects lacking both mutations and susceptibility variants. 
These data underline that IC-MPGN and C3G are complex genetic diseases. 
Remarkably, the majority of IC-MPGN patients present alternative pathway 
dysregulation in this study. The prevalence of alternative pathway abnormalities 
(mutations, C3NeFs, low C3 levels with normal C4) was comparable in IC-MPGN and 
C3G. In particular, 56% and 65% of IC-MPGN and C3G patients, respectively, carried 
mutations and/or C3NeFs. These findings, which are consistent with a previous 
report,
256
 suggest that IC-MPGN and C3G have more commonalities than previously 
recognized, and do not support the current classification that restricts the definition of 
alternative pathway-mediated glomerulopathies to patients with "dominant C3" 
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glomerular staining.
253
 Moreover, in accordance with previous findings,
255, 256
 in this 
study the different histologic groups have similar risk of developing ESRD. On the 
other hand, it is shown here that patients without complement gene mutations in the six 
analyzed genes and without C3NeFs have a higher risk of developing ESRD than 
patients carrying mutations and/or C3NeFs. This observation may indicate the existence 
of at least two different pathogenic mechanisms of renal disease progression in IC-
MPGN/C3G. 
To better understand the pathogenesis of the diseases, the presence of more 
homogeneous subgroups within IC-MPGN/C3G was investigated through unsupervised 
hierarchical clustering. This is a statistical approach where the classification criteria are 
not defined by the operator based on a priori hypotheses but arise from the data. Both 
etiologic features, such as presence of C3NeF or complement alternative pathway gene 
mutations, and phenotypic features, such as histologic findings, serum complement 
profile and clinical features, were included in the analysis. Four relatively homogeneous 
subgroups (clusters) were identified. The first 3 clusters were characterized by high 
prevalence of mutations and/or C3NeF contrary to cluster 4. Clusters 1 and 2 both 
showed the highest prevalence of subendothelial deposits and the highest SC5b-9 levels, 
whereas cluster 2 was distinguished from cluster 1 for the stronger C1q and IgG 
staining, and for the higher prevalence of nephrotic syndrome at onset. Cluster 3 
showed the highest prevalence of intramembranous electron-dense deposits. Cluster 4 
had the highest serum C3 levels and the highest risk of developing ESRD. Altogether, 
these clusters of IC-MPGN/C3G patients seem to reflect the underlying molecular 
mechanisms and are useful to predict the risk of developing ESRD. 
In the second part of this thesis, the genetic causes of SRNS were investigated. The 
major role of COL4A3-5 mutations in the pathogenesis of adult-onset SRNS and/or 
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FSGS, which was reported in a previous study,
210
 is confirmed. Moreover, this study 
shows that mutations in CAKUT-associated genes are enriched in SRNS patients. In 
particular, for the first time to the best of my knowledge, likely pathogenic (LP) variants 
in CHD1L, RET, FREM2, FOXC2, ROBO2 and SALL1 in patients with isolated SRNS 
are reported. This finding is not surprising, if it is considered that mutations in PAX2 
and LMX1B cause both CAKUT and isolated SRNS.
221, 410
 In addition, LP variants in 
CAKUT-associated genes combine with LP variants in SRNS-associated genes more 
frequently than would be expected by chance. These data suggest that the molecular 
pathways underlying CAKUT and SRNS partially overlap and that a complex genetic 
pathogenesis should be considered at least in some patients. 
Finally, a new candidate gene for SRNS is proposed, namely EPB41L5. They protein 
encoded by this gene is a component of the mammalian Crumbs complex, which drives 
the apical-basal cell polarity.
366
 EPB41L5 physically interacts with CRB2, a core 
protein of the Crumbs complex that is a known SRNS-causing gene.
235, 236, 367
 
Moreover, EPB41L5 is expressed in zebrafish podocytes and it is required for proper 
formation and maintenance of slit-diaphragms, since EPB41L5 deficient zebrafishes 
present absence of slit-diaphragms and loss of glomerular barrier permselectivity.
364
 In 
three unrelated patients of the present SRNS cohort, three possibly pathogenic variants 
of EPB41L5 affecting evolutionary conserved amino acids were identified and at least 
two them affect the FERM domain, which is crucial for the protein function.
366
 Analysis 
of further SRNS patients and functional studies on the identified variants are necessary 
to disclose the role of EPB41L5. 
In conclusion, this thesis provides new insights in IC-MPGN/C3G and SRNS. It 
introduces new players in the pathogenesis of these diseases. Moreover, in IC-
MPGN/C3G provides evidence of the presence of subgroups of patients with common 
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underlying mechanisms as well as common clinical and histopathologic features. 
Therefore, the present thesis may be a contribution to better understand the pathogenesis 
of IC-MPGN/C3G and SRNS, and may be useful in future basic and clinical research. 
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